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In the United Kingdom 1 in 6 - 8000 children are born missing one or both of 
their ears. The surgical technique most commonly used to reconstruct ears 
requires surgeons to remove ribs from the patient, and the cartilage from the 
ribs is used to carve a new ear. This procedure involves many risks including 
significant pain, punctured lung and chest deformity. Therefore the ability to 
‘grow’ an ear would be a major advancement.  
 
Stem cells show huge promise in tissue engineering and regenerative 
medicine. Approved stem cell technology must be evaluated with regards to 
safety, purity, identity, potency and efficacy prior to biologic licensing and 
clinical use. Therefore, access to ethically sourced tissue for research is 
fundamental to the successful delivery of novel therapies. Adipose tissue 
provides an abundant and accessible source of stem cells for clinical 
translation. Within the first section of this thesis, the perceptions and attitudes 
of patients towards the donation and use of adipose tissue for research are 
sought. Based on this information, a tissue bank with all appropriate ethical 
approval to collect, process, store and distribute adipose tissue and adipose 
derived stem cells is established.  
 
The second part of this thesis demonstrates the specific identity, location and 
frequency of stem cells within adipose tissue; revealing them to reside in a 
perivascular niche. Using this data, protocols to rapidly purify stem cells from 
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adipose tissue using Fluorescence Activated Cell Sorting are developed. The 
frequency of cells, and both the patient and procedure based variables that 
can affect this yield are also examined.  
 
The final section of this thesis uses a high-throughput microarray platform to 
screen thousands of polymers to identify potential substrates that can 
support the attachment, stable proliferation and subsequent differentiation of 
stem cells purified from adipose tissue. From the initial screen, 5 distinct 
polymers have been identified, characterised and their effects on the stem 
cells examined and quantified.  
 
Combined together, these elements provide significant advances in our 
understanding, and the basis for on going research to deliver a tissue 
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1.1 Regenerative medicine and plastic surgery 
 
Regenerative medicine is a rapidly expanding field of research, with many 
strategies currently being translated toward the clinic (Giordano et al. 2007). 
Regenerative medicine is defined as; 
 
“process of replacing or regenerating human cells, tissues or organs to restore or 
establish normal function” (Mason & Dunnill 2008). 
 
This definition is very similar to that of plastic surgery that aims to achieve;  
 
“restoration of form and function”. 
 
Throughout the history of plastic and reconstructive surgery, the primary 
challenge facing surgeons has been finding suitable donor tissue that can 
reconstruct the defect without causing significant additional disfigurement 
and disability. Common defects encountered that require reconstruction 
include multiple composite tissues such as skin, adipose tissue, muscle, 
bone, nerve and cartilage. Whilst the potential application of regenerative 
strategies to plastic surgery is huge, the focus of this thesis will be its 
application to ear reconstruction surgery. 
 
Ear reconstruction is widely regarded as one of the most technically 
demanding reconstructive challenges. For this reason surgery is usually only 
performed by small numbers of surgeons who are experts in this particular 
! 3!
type of procedure. The Scottish Ear Reconstruction Service 
(http://www.nsd.scot.nhs.uk/services/specserv/autearrecon.html) is run by Mr 
Ken Stewart, a consultant plastic surgeon based at the Royal Hospital for 
Sick Children in Edinburgh. Approximately 40 new patients are treated each 
year covering referals from all of Scotland and other parts of the UK.  
 
1.2 The Ear 
 
The external ear consists of the auricle or pinna, and the external ear canal. 
It is a complex piece of elastic cartilage covered in the most part by hairless 
skin, and there is wide variation in its size, shape and position (Tolleth 1978). 
The primary function of the pinna is to channel sound waves into the ear 
canal and reflect them efficiently on to the tympanic membrane. It also 
serves to block out unwanted noise from other directions. People who lack a 
pinna but have a patent ear canal report loss of specific noise volume, with 
an increase in general interference from unwanted background noise.  Ears 
have also developed a number of secondary functions such as holding 
reading glasses, sunglasses and headphones. In addition to this, they are 
important paired aesthetic units that contribute to the normal appearance of 
the face. Amputation and mutilation of the ears has been used for centuries 
in different cultures as a form of humiliation, retaliation and punishment for a 







The auricle is a complex 3-dimensional structure whose delicate and intricate 
architecture is a result of the interlocking curves and tensile forces of the 
fibroelastic cartilage underlying the skin. The auricle is comprised of 3 major 
units that are the helix-antihelix, the concha and the lobule. Within these 
units there are many other smaller subunits which each contribute to the 
overall appearance  (Figure 1.1). Minimal disruption to any of these can lead 
to significant alterations in the overall appearance of the ear.  
 
Figure 1.1: Topographical anatomy of the ear 
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The auricle begins to develop between the 3rd and 6th weeks, with definitive 
features evident by the ninth week, and is fully formed by the fourth month  
(Figure 1.2). It begins as 6 precartilaginous swellings  (hillocks) of 
mesodermal tissue that arise on the first  (mandibular) and second  (hyoid) 
branchial arches with the pharyngeal groove lying between them. These 
grooves and arches represent what were the primordial ‘gill slits’ of a fish. 
The auricle develops around the external auditory meatus that forms from the 
first branchial cleft that begins to canalise at 28 weeks. 
 
In the early classic description of ear embryology by His, the anterior 3 
swellings that arise on the first arch formed the tragus, the helical root and 
the superior helix and the posterior 3 swellings from the second arch form the 
antihelix, antitragus and lobule. However, in later descriptions it was 
suggested that these hillocks are just incidental and represent early foci of 
mesenchymal condensation and proliferation of the underlying branchial 





Figure 1.2: The embryological development of the ear. A.) 6 early swellings  (hillocks) 
present from the 3rd gestational week. B.) Fusion of the hillocks is apparent at 6 weeks. C.) 
The appearance of the adult ear. 
 
The ear begins to develop in an infero-medial position below the mandible, 
and by the 20th week migrates to a postero-superior position overlying the 
temporal bone. This rapid sequence of events that results in the migration of 
the pinna can be disrupted by a range of genetic and environmental factors, 
with a variety of resulting abnormalities. Therefore patients who present with 
premature arrest or other congenital auricular abnormalities frequently have 
low  (caudal) and anteriorly set ears (Pham et al. 2014). As the migrating 
pinna crosses multiple structures, it is not surprising that over 50% of 
children with severe ear anomalies also have other associated craniofacial 
anomalies. 
 
Sensation to the ear is supplied by both cranial and extra cranial nerves that 
have a varied distribution. The lesser occipital and great auricular nerves 
supply the posterior surface of the auricle and the lobule. The lesser occipital 
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being the dominant nerve supplying the superior ear and mastoid fossa. 
Injury to the great auricular nerve is common in surgical approaches around 
the infero-posterior border of the ear (Pantaloni & Sullivan 2000). The 
anterior surface of the auricle and the tragus are supplied by the 
auriculotemporal branches of the 3rd  (mandibular) division of the trigeminal 
nerve. Sensation to the external auditory meatus is from the auricular branch 
of the vagus nerve  (Arnold’s nerve) (Beahm & Walton 2002). 
 
!
The blood supply of the auricle is by 2 distinct but interconnecting networks 
both derived from the external carotid artery. An understanding of the blood 
supply to the auricle and surrounding soft tissues is of paramount importance 
in ear reconstruction surgery to prevent necrosis when dissecting and 
transposing structures.  
 
Original descriptions of the lymphatic system suggest that the drainage 
reflects the embryonic development with the concha and meatus draining to 
parotid and infraclavicular nodes, and the external meatus and superior 
auricle drain to mastoid and superior cervical nodes. Subsequent 
lymphoscintigraphy studies have demonstrated that patterns are frequently 
more complex and unpredictable than originally thought. 
!
There are 3 extrinsic muscles of the ear which are the anterior, superior and 
posterior auricularis muscles. In addition there are 7 intrinsic muscles which 
are mainly vestigial and they are the transverse and oblique muscles, 
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tragicus, antitragicus, helicis major and helicis minor (Beahm & Walton 
2002). 
 
1.3 Auricular anomalies 
 
The exact incidence of auricular anomalies is hard to estimate as they 
encompass a huge spectrum of malformations, and the less severe are often 
under reported. The most severe types of malformation such as microtia or 
anotia are rare and occur between 0.8 and 8.3 per 10,000 live births. 
Incidence of the least severe auricular malformations may be as high as 55% 
(Porter & Tan 2005). Many different classification systems have been 
suggested to address these anomalies however no one particular system 
appears to satisfy the issue. In their broadest form, congenital anomalies can 
be categorized in to either malformational or deformational. The former are 
due to aberrations in the normal embryological development of the ear, whilst 
the latter are due to either in utero or ex utero deformational forces applied to 
normal ears (Tan et al. 2003). The two may occur concurrently as malformed 
ears are more likely to encounter deformational force (Porter & Tan 2005). 
Tanzer suggested a classification for auricular defects based on the severity 
of the defect (Tanzer 1959). 
 
• Class I: Anotia 
• Class II: Complete hypoplasia 
o  II A: with atresia of the auditory canal 
o II B: without atresia of the auditory canal 
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• Class III: Hypoplasia of the middle third of the auricle 
• Class IV: Hypoplasia of the superior third of the auricle 
o IV A: Contricted  (cup or lop) 
o IV B: Cryptotia 
o IV C: Hypoplasia of entire superior third 
• Class V: Prominent ears 
 
A widely accepted and used classification scheme which links the severity of 
the defect to the degree of reconstruction required is that proposed by 
Weerda (Weerda 1988); 
• 1st degree dysplasia: Well formed auricle with clear but minor 
deformity. No additional tissue required for reconstruction 
• 2nd degree dysplasia: Some recognizable features within a 
rudimentary and moderately disfigured pinna. Partial reconstruction 
with skin and/or cartilage is required. 
• 3rd degree dysplasia: Severe disfigurement of the pinna with no 




Microtia is a rare developmental malformation of the auricle with an 
estimated prevalance between 0.8 and 4.2 per 10,000 live births (Alasti & 
Van Camp 2009). It has a relatively low prevalence in European and Blacks 
compared to Asian and Hispanic races, with the highest recorded prevalence 
seen amongst the Japanese and Navajo Indians (Porter & Tan 2005). 
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Unilateral cases represent 90% of microtia cases, with the right ear twice as 
likely to be affected than the left ear. It is more frequent in males with a ratio 
of 2:1 (Alasti & Van Camp 2009). Half of patients who present with microtia 
also have other features of first and second branchial arch syndrome. This 
led to suggestions that isolated microtia is the mildest form of hemifacial 
(craniofacial) microsomia. It is also associated with syndromes such as 
Treacher-Collins and Goldenhaar  (Figure 1.3). 
 
 
Figure 1.3: Microtia and associated syndromes. A.) Bilateral microtia in a patient with 
Treacher-Collins syndrome, with bone anchored hearing aid on the right side. B.) Unilateral 






1.4.1 Classification of microtia 
 
Although general classifications of auricular anomalies have previously been 
described  (see above), the most widely accepted classification specific to 
microtia is that of Nagata. This classification is particularly useful as the 
classification also correlates to the surgical procedure used to reconstruct it 




These deformities are characterised by the presence of a malpositioned 




These patients have an ear remnant comprising of a malpositioned earlobe, 
concha  (with or without acoustic meatus), tragus and antitragus. (Nagata 
1994b) 
Small concha type 
!
Similar to conchal type, however these patients have a small indentation 
instead of a concha. (Nagata 1994c) 
Anotia 
!
Patients with no, or a very tiny ear remnant 
Atypical microtia 
!




Fig 1.4: Examples of common sub-types of microtia based on the classification 
system described by Nagata (Nagata 1994). A.) Lobular type characterised by the 
presence of a malpositioned lobule and ear remnant. There is no concha, acoustic meatus 
or tragus. B.) Conchal type comprising of a malpositioned earlobe, concha  (with or without 





1.4.2 Treatment of microtia 
 
Total ear reconstruction is a relatively new procedure, with most modern 
techniques being pioneered in the second part of the 20th century. There are 
a number of historical cases of partial ear reconstruction documented. 
According to The Susruta, an Indian text of ancient medicine, reconstruction 
of the earlobe was performed using a partial cheek flap in 900BC. 
Tagliacozzi, an Italian surgeon, described the use of a transferred flap from 
the arm to reconstruct an auricle in 1597. In the 18th century a case using a 
folded mastoid flap was described to reconstruct a traumatic defect 
(Converse 2014).  
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Total ear reconstruction for microtia was thought to be impossible, and 
resulted in the trial of a number of unsuccessful materials to create a new 
framework including bone, allografts and xenografts (Romo & Reitzen 2008). 
In the 1930s the experimental and clinical use of costal cartilage as an 
autologous graft paved the way for modern reconstructive techniques used in 
microtia (Pierce et al. 1947). Most modern techniques use a variety of 
materials to fabricate a framework that is placed under the skin to create an 
ear form. Although different surgeons have advocated the use of different 
materials, autologous costal cartilage is widely regarded as the gold standard 
(Beahm & Walton 2002). 
 
1.4.2.1 Reconstruction using autologous cartilage 
All of the modern versions of autologous cartilage reconstruction are 
adaptations of the pioneering work of Tanzer who described and evaluated 
his technique of creating a carved cartilage framework (Tanzer 1959; Tanzer 
1971; Tanzer 1978). Notable variations have been made by surgeons 
including Brent (Brent 1980a; Brent 1980b) and Nagata (Nagata 1993; 
Nagata 1994a; Nagata 1994b; Nagata 1994c).  
 
1.4.2.1.1 Tanzer technique 
!
Tanzer’s original description was a 6 stage procedure using contralateral 
costal cartilage and composite skin and cartilage grafts from the contralateral 
ear (Tanzer 1959).  
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• Stage 1: Transposition of the lobular remnant to its normal anatomical 
position. 
• Stage 2: Performed when the swelling and induration from stage 1 has 
resolved. Framework is created by harvesting cartilage sub-
perichondrally from the contralateral 6th-8th ribs. Ribs 6 and 7 are used 
to construct the base and antihelix, with the 8th rib being used to 
create the helical rim. The different pieces of the framework are 
secured together using fine gauge wire. 
• Stage 3 and 4: Performed 4 months after stage 2. The framework is 
elevated from the side of the skull to give a more natural projection. 
Postauricular skin is advanced, and the retoroauricular sulcus that is 
created is covered with a split thickness skin graft. This is done initially 
at the inferior aspect  (Stage 3) followed 2 months later at the superior 
aspect  (Stage 4), to preserve to blood supply to the ear. 
• Stage 5: Performed 4 months after stage 4. Closure of the ear tunnel 
with a retroauricular flap with either a split, or full thickness graft. 
• Stage 6: Performed 6 weeks after stage 5. The concha and tragus are 
reconstructed using composite skin and cartilage grafts from the 
contralateral ear. 
 
Laterly Tanzer refined this technique by combining stages 1 and 2. However 
in cases where extensive mobilisation of the lobule was required, the original 
6 stage description was advocated to minimize the risk of vascular 
compromise to the lobule (Tanzer 1978).  
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1.4.2.1.2 Brent technique 
!
The technique developed by Brent is a 3 or 4 stage technique based on the 
technique of Tanzer, but where the sequence of reconstruction is varied 
along with other modifications. 
 
• Stage 1: A framework is created from the contralateral ribs. The 
synchondrosis of the 6th and 7th ribs is used to form the base, and the 
floating 8th rib is used to create the helix. Clear non-absorbable 
sutures are used to join the various elements together. Brent also 
exaggerates the 3-dimensional features of the construct to overcome 
the effects of the thickened overlying skin pocket. This is augmented 
by the use of suction drains which have the added advantage of 
reducing the complication rate associated with pressure dressings 
(Brent 1992). 
• Stage 2: Transposition of the lobule is performed several months after 
the first stage, and the perceived advantage to this change in order is 
to minimize the disruption to the vascular supply of the skin flaps from 
the dissection required to transpose the lobule. In some cases this is 
combined with the 3rd stage. 
• Stage 3: The construct is elevated as in the Tanzer technique 
described previously.  
• Stage 4: Brent uses the framework to reconstruct the tragus. At this 
stage he also exaggerates the conchal bowl by excavating it, and also 
performs any further symmetrizing procedures. 
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1.4.2.1.3 Nagata technique 
!
Nagata’s original 2 stage technique was first described in 1993 (Nagata 
1993), with subsequent revisions and refinements made by the author based 
on the different type of microtia encountered as described in his eponymous 
classification. 
 
• Stage 1: Creation of a cartilage framework from the ipsilateral 6th – 9th 
ribs, with concurrent transposition of the lobule and tragal 
reconstruction. 
• Stage 2: The construct is elevated 6 months following the initial stage 
with a crescenteric piece of costal cartilage placed behind the ear to 
increase projection. A combination of temporoparietal fascial flap and 
split thickness skin graft from the scalp, or advancement of the 
retroauricular skin and graft is used to create and resurface the 
postauricular sulcus. 
 
1.4.2.1.4 Complications of autologous reconstruction 
The complications and morbidity associated with autologous reconstruction, 
particularly those pertaining to the donor site, are not insignificant and have 
been the principle criticism of this type of reconstruction. Complications 
associated with the reconstruction site include scarring, infection, flap 
necrosis, skin loss, exposure of the framework and extrusion. Complications 
associated with the harvest of costal cartilage include scarring, significant 
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post-operative pain, chest wall deformity, pneumothorax and thoracic 
deformities (Uppal, Sabbagh, Chana & Gault 2008a; Thomson et al. 1995). 
 
Uppal et al published series of 26 patients undergoing costal cartilage 
harvest for ear reconstruction (Uppal, Sabbagh, Chana & Gault 2008b).  
They reported significant postoperative pain that peaked at day 7, and 
continued for over 3 months in 12% of patients.  Thomson et al (Thomson et 
al. 1995) followed up their series of 80 patients to evaluate the appearance of 
chest scars, topography and contour deformities of the donor site. 14% of 
patients considered their scars unacceptable, with increasing age correlating 
to poorer scarring. 25% of patients had noticeable retrusion in chest wall 
topography with 6% of patients having severe retrusion. Younger patients 
were more likely to encounter severe retrusion. All patients demonstrated 
some degree of alteration in their ribcage contour. Another study examining 
chest wall deformities and thoracic scoliosis following costal cartilage 
harvesting noted chest wall deformities in 50% of the 18 patients in their 
study. They also observed that younger patients were more likely to develop 
deformities compared to older patients. In addition, they noted thoracic 
scoliosis in 25% of the patients in their study (Ohara et al. 1997).  
 
In attempt to minimize the morbidity associated with the donor site harvest, 
techniques have been described that aim to preserve the regenerative 
capacity of the ribs!(Yang et al. 2015; Fattah et al. 2010). Nagata advocates 
the subperichondral elevation of cartilage which preserves a perichondral 
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pocket to which the excess cartilage can be returned. This method allows 
regeneration of histologically mature cartilage at 12 months that is of 
sufficient bulk and quality to be used in subsequent reconstruction 
(Kawanabe & Nagata 2006). Using this technique, improvements in the chest 
wall contour have been noted (Uppal, Sabbagh, Chana & Gault 2008a). 
Fattah et al analysed 38 patients, 23 who had reconstruction of the rib with 
the preservation of the perichondrium versus 15 who did not. In those 
patients who did not have reconstruction, all had a palpable defect, whereas 
those who did have reconstruction had no palpable defect (Fattah et al. 
2010). 
 
Extrusion of autologous costal cartilage frameworks leading to their removal 
has not been commonly reported in any of the large published series (Brent 
1992; Brent 1980a; Tanzer 1978; Fukuda & Yamada 1978; Wray & Hoopes 
1973). The largest single series of autologous ear reconstruction was 
published by Brent in 1992 (Brent 1992). In this series he reported 
significantly lower complication rates compared with others, and also when 
compared to his own earlier series. This reduction was attributed to the 
introduction of suction drains to replace the bolster sutures and pressure 
dressings previously used to coapt the skin to the underlying framework. In 
this series he reported an infection rate of 0.5% and skin loss rate of 0.8%, 




1.4.2.2 Reconstruction using synthetic frameworks 
 
Due to the complications associated with harvesting costal cartilage, the use 
of synthetic frameworks has been advocated by a number of groups. The 
majority of these frameworks are silicone based or polyethylene based eg. 
Medpor®. In addition to eliminating the need to harvest costal cartilage, 
synthetic implants eliminate the associated operator variability in the quality 
of frameworks carved from costal cartilage, and the potential for loss of 
contours which has been described with resorbtion of cartilage frameworks 
(Tanzer 1978). Conversely, there is no capacity for the synthetic implant to 
grow as the patient ages which is a feature of cartilage implants (Tanzer 
1978). The principle complications associated with alloplastic implants that 
have prevented their widespread application are that of inflammation, 
erosion, fracture, infection and extrusion of the implant. This process also 
results in significant damage to the overlying and surrounding soft tissue 
which may limit and even preclude the potential for subsequent autologous 
reconstruction. In early studies that evaluated the use of silastic implants, 
infection around the implants was very high and ranged from 3% - 81%, 
resulting in very high rates of extrusion and removal ranging from 1% - 81% 
(Romo et al. 2014).  
 
The first work describing the routine use of a synthetic framework was by 
Cronin in 1966 (Cronin 1966). In this early work Cronin described the use of 
a soft silastic framework, however he acknowledged the principle problem of 
extrusion associated with this type of implant. Cronin initially advocated the 
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use of additional tissue flaps and grafts to overcome this, however when he 
continued to experience extrusion he subsequently abandoned the technique 
in favour of autologous methods.  
 
The most common synthetic framework in current use is Medpor® which is a 
porous polyethylene scaffold. It was initially described in 1991 by Dr John 
Reinisch. In the largest published series comparing autologous and 
Medpor® based reconstructions, 1864 patients were studied and 
significantly higher extrusion rates were seen in the Medpor® group  (13.5%) 
versus the autologous group  (1%). There was also greater overall 
satisfaction in the autologous group versus the Medpor® group  (98% versus 
84% respectively) (Yanyong Zhao et al. 2009).  
 
In another smaller study that compared the complication rates of a single 
surgeon using silastic versus autogenous cartilage, 81% of silastic implants 
required removal compared to none of the cartilage implants. Whilst this was 
a small study, and the total length of follow up was not recorded, these 
results prompted the authors to abandon the use of silastic. To minimize this 
risk, proponents advocate the use of a temporoparietal fascial  (TPF) flap to 
cover the implant. However, this procedure adds to the morbidity of the 
procedure and often results in prominent scars and areas of hair loss within 
the temporal region. Using a Medpor® implant covered with a TPF flap Romo 
et al report a complete loss of implant in 0.8% of patients, however they 
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acknowledge a much higher number who encounter problems associated 




Another alternative to autologous reconstruction is the use of prosthetic ears 
that can be fixed to the side of the head either with an adhesive, or by the 
use of bone anchored titanium screws. The advantages of this technique are 
that it eliminates the need for costal cartilage and the associated morbidity. It 
can therefore be preferable in patients who are not good candidates for 
lengthy surgical procedures, or who lack suitable cartilage (Thorne et al. 
2001). In addition, the cosmetic appearance of prosthetic ears made by 
skilled and experienced prosthetists can be excellent. Despite this, there are 
a number of disadvantages that have limited their use. Although the ear itself 
may have excellent cosmetic appearance, the seam where it adjoins the 
head is very difficult to conceal often making the prosthesis conspicuous. In 
addition, the colour of the prosthetic ear is very difficult to match to the native 
skin and it will not respond to the changes in skin tone frequently seen 
throughout the year, or in response to emotions such as blushing. The need 
to frequently remove the prosthesis can cause wearing and failure of the 
implant and therefore they may need to be replaced at frequent intervals 
(Giot et al. 2011). The placement of titanium screws can cause local irritation 
and inflammation to the adjacent soft tissues. The placement of these screws 
and subsequent damage to the soft tissues can mean that any subsequent 





Figure 1.5: Bilateral prosthetic ears in a patient with Treacher-Collins syndrome. A.) 
Anterior view. B and C.) Lateral view demonstrating poor colour match. D.) Titanium bone 
anchors causing tissue inflammation and erosion over the sight where subsequent 
reconstruction would occur. A bone anchored hearing aid is also present which can affect 
reconstructive options if placed incorrectly. 
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1.4.2.4 Acquired ear deformities 
!
In addition to congenital deformities requiring reconstruction there are a 
number of acquired deformties requiring reconstruction. The most common 
causes of acquired deformity are trauma including bites and burns, 
infections, cancer and failed previous surgery such as prominent ear 
correction  (Figure 1.6).  
 
 
Figure 1.6: Acquired ear deformities. A.) Severe deformation requiring total reconstruction 
and soft tissue coverage due to complications following previous surgery. B.) Partial ear loss 






1.4.2.5 The perfect solution for ear reconstruction 
 
Reconstruction using autologous costal cartilage is regarded as the gold 
standard, however it is far from perfect. Even in skilled hands the 
reconstruction process is lengthy, expensive, exposes patients to significant 
morbidity and can have variable results.  
 
Studies of costal cartilage have demonstrated wide variation in the 
biomechanical properties, with age related changes to cartilage such as 
calcification make its behavior unpredictable (Qing-Hua et al. 2011). In a 
study that examined the biomechanical properties of the cartilage of 90 
patients, it was determined that the optimum age for reconstruction based on 
the biomechanical properties of the cartilage was 5-10 years. This is in 
keeping with that suggested by Nagata for microtia reconstruction based on 
chest wall circumference and the amount of cartilage required (Nagata 
1993), and by Bulstrode et al based on psychological factors (Bulstrode et al. 
2015). However for those patients requiring reconstruction in later life, the 
cartilage is likely to be suboptimal and in some instances not suitable. 
 
It is widely acknowledged that an alternative framework that reduces the 
burden of rib harvest and the associated morbidity, but that behaves as 
autologous tissue with optimal and reproducible characteristics would be a 
significant advancement on current best practice. Tissue engineering may 
present an exciting alternative strategy for ear reconstruction that would 
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minimise, and potentially eliminate much of the morbidity associated with 
current techniques (Uppal, Sabbagh, Chana & Gault 2008a).  
 
For auricular reconstruction, any tissue engineered solution should aim to 
replace the current gold standard which is costal cartilage. Native elastic 
cartilage of the ear lacks the required biomechanical properties to overcome 
forces associated with ear reconstruction and would deform under these 
strains. Costal cartilage has the structural integrity required maintain its 3-
dimensional structure and detail whilst overcoming the forces of the overlying 
skin envelope. In addition, it retains sufficient elasticity and memory to 
overcome the daily forces applied to the ear (Qing-Hua et al. 2011). For 
these reasons, any solution in auricular reconstruction will require both a 
scaffold for structural integrity, and an appropriate cell source to generate 
new cartilage  (Fig 1.7.1) (Y. Liu et al. 2010). 
 
The history, principles and current state of the art in tissue engineering are 
discussed fully in the next section.  
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1.5 Tissue engineering 
!
!
Tissue engineering is defined as; 
 
“an interdisciplinary field that applies the principles of engineering and life sciences 
toward the development of biological substitutes that restore, maintain, or improve 
tissue function or a whole organ" 
 
It is estimated that over half of all money spent on healthcare in the US, is 
spent treating tissue or organ loss and failure (Langer & Vacanti 1993). 
Traditional methods used to treat these conditions include transplantation  
(either allograft or xenograft), surgical repair and reconstruction, artificial 
prostheses, mechanical devices and drugs. Whilst these treatments have 
saved and improved the lives of many people, they are not ideal. There is a 
global shortage of suitable donor organs to meet the increasing needs of 
patients with end stage organ failure. Surgical repair often results in 
suboptimal function, and has the associated morbidity and mortality of the 
operation. Artificial prostheses and mechanical devices may exert an 
inflammatory response in the host, are prone to failure and have a limited life 
often requiring increasingly complex procedures to replace them. 
Furthermore, many mechanical devices and prostheses are unable to 
perform all of the complex functions of the tissue or organ they aim to replace 
(Langer & Vacanti 1993). Tissue engineering has the potential to eliminate 
many of these problems as the aim is to generate identical – and where 
possible autologous - replacement tissue to that which is lost or damaged. 
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There are three general strategies when addressing the generation of new 
tissue  (Fig 1.7). In addressing whole organ loss or failure, it is likely for a 
scaffold to act as a structural support whilst the cellular component replaces 
the lost tissue. Here the scaffold is required to have structural properties 
including spacial organization and mechanical strength, as well as the 
bioactive properties necessary to stimulate and coordinate regeneration. If 
the scaffold is designed to be biodegradable, it must be designed with a 
resorption rate that allows the mechanical strength of the scaffold to remain 
until the cellular component has remodeled and can resume its natural role. 
In addition, the potential implications of this type of construct are the need for 
significant periods of in vitro cell culture in a suitable bioreactor to attain the 
required number of cells prior to differentiation or implantation  (Fig 1.7.1). 
 
There are other scenarios where the aim of the scaffold is to allow the 
ingress of native stem cells, progenitors cells and blood vessels to 
repopulate the graft. Hence the role of the scaffold is to promote ingress and 
facilitate differentiation of the native cells eg. small tissue defects, coating of 
medical implants  (Fig 1.7.2).  
 
Thirdly, the aim is to deliver bioactive factors and/or cells directly to the site 
of injury to either stimulate, supplement, replace or modulate existing stem 
cell populations eg non-unions, avascular necrosis.  (Fig 1.7.3). 
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Figure 1.7: General strategies for tissue engineering. 1.) Cells and scaffolds for whole 
organ or large defect replacement. 2.) Scaffold only implants designed to stimulate and 
coordinate native repair and regeneration. 3.) Delivery of cells and/or bioactive factors to 
stimulate regeneration. 
 
Despite the interest in tissue engineering strategies to address significant 
health problems, the application in clinical practice is not routine and is 
limited to small case reports and series. The majority of these clinical 
applications involved relatively ‘simple’ tissue types such bone and cartilage 
that do not perform complex functions such as major organs. However, more 
recently the ability to grow complex organized and functional organs from 
stem cells has been described in vivo (Bredenkamp et al. 2014). In the case 
of auricular engineering, there are significant forces applied upon the 
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reconstructed ear when it is placed under the skin envelope, therefore the 
biomechanical properties of any scaffold must be sufficient to overcome 
these forces until adequate replacement tissue has been generated. Tissue 





Biomaterials are any materials that interface with biological systems, and can 
include ceramics, metals, glass, polymers and hydrogels. The use of 
synthetic materials in medicine is well established and has significantly 
improved the quality of life in patients suffering from tissue loss and 
degeneration. To date the majority of these implants used to replace 
damaged tissue are orthopaedic implants made from metals and ceramics.  
 
Initial biomaterial and implant research focused on finding inert substrates 
that could replace lost or damaged tissue, but evoke minimal effects on the 
native tissue. Coupled with advances in cell based therapies and the 
emergence of regenerative medicine, there has been a significant shift in 
focus from looking at the application of inert materials that replace lost and 
damaged tissue, to trying to identify biocompatible and bioactive materials 
that can stimulate and co-ordinate the replacement and regeneration of 
tissue (McMurray et al. 2011). 
 
Whilst metals and ceramics are widely used in orthopaedics to replace 
diseased joints from degenerative diseases such as arthritis, their application 
! 30!
as a biomaterial to regenerate cartilage and support chondrogenesis has 
been largely unsuccessful due to undesirable biomechanical properites (Seal 
et al. 2001).  
 
The ability to accurately and reproducibly engineer a material to its targeted 
purpose and end use makes synthetic polymers and hydrogels ideal 
candidates as biomaterials for cartilage tissue repair and regeneration. 
Critically for chondrogenesis and cartilage tissue engineering, the stiffness, 
elasticity, load bearing capacity, biodegradability, surface structure and 
chemistry, and can all be tailored to the desired outcome. Polymers and 
hydrogels have therefore been the priniciple biomaterials investigated for 





Hydrogels are three-dimensional structures formed by the crosslinking of 
either natural or synthetic homopolymers, copolymers or macromers. Their 
hydrophilic structure allows them to retain amounts of water within their 3-D 
networks. Hydrogels have been extensively employed in tissue engineering 
and regenerative strategies due to their ability to imitate the native 
extracellular matrix and the stem cell niche (S. Q. Liu et al. 2010). The high 
water content of hydrogels results in excellent biocompatibitly and 
biodegradability and the mechanical properties can be easily manipulated 
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(Alakpa et al. 2016). This makes hydrogels an ideal candidate for tissue 
regeneration and cellular support. 
 
Natural hydrogels include proteins found in the ECM of human tissues such 
as collagen and hyalauronic acid (HA), proteins derived from plants and 
algae such as cellulose and alginate, and those derived from animal cell lines 
such as Matrigel which contains ECM proteins produced from a mouse 
sarcoma cell line.  
 
Polymers are the most widely used biomaterials and have been utilized in a 
diverse range of applications including sutures, heart valves, surgical mesh 
and screws. They are excellent candidates for biomaterials as they are easy 
to manufacture and produce in a cost efficient manner with highly 
reproducible characteristics. Polymers are incredibly versatile and can be 
manipulated to have the desired physical and mechanical properties for their 
intended application. They can be manufactured in many different forms 
including solids, gels, liquids and fibres. In addition, they can be used 
directly, in combination with other materials or coated onto surfaces (Seal et 
al. 2001). They can be both biodegradable and bioactive, with many 
examples of polymers supporting and enhancing differentiation of stem and 
progenitor cells into hepatic (Hay et al. 2011), bone (F. Khan et al. 2010) and 
endothelial lineages (Pernagallo et al. 2012).  
 
Polymers have also been tested for their capacity to support chondrogenesis 
of stem cell populations and specifically auricular tissue engineering (Shieh 
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et al. 2004). The commonest group of synthetic polymers used for auricular 
tissue engineering are aliphatic polyesters such as poly(glycolic acid) (PGA), 
poly(lactic acid) (PLA) and poly(caprolactone) (PCL), which are 
biodegradable through hydrolysis of the ester linkages. These groups have 
been shown to be biocompatible and support the growth and differentiation of 
both chondrocytes and stem cell populations (Cao et al. 1997). Problems 
arising with these polymers come from acidic degradation products that can 
cause resorbtion of the engineering structure, immunogenictiy of the 
degradation products (Nayyer et al. 2012), and insufficient biomechanical 
strength to maintain the shape of the engineered structure long term in vivo 
(Shieh et al. 2004) (Cao et al. 1997). Blending of different polymers allows for 
alterations in their degradation rates and has demonstrated improved 
biomechanical function in longer terms studies of 20 weeks in vivo 
implantation (Pomerantseva et al. 2016).  
 
Table 1.2 summarises some of the most common classes of polymers in use 











Features / Outcomes 
Polyphosphazene Bone cements, tissue 
engineering. 
Biodegradable and highly tunable 
with changes in side groups. 
Comparable effect to PLGA when 
tested in vivo. Able to neutralize 




 (PLA, PLLA, PLGA, 
PGA) 
Tissue engineering, drug 
delivery  (also used as 
sutures, stents, dressings). 
Most widely used and investigated 
biomaterials. Highly tunable and easy 
to combine with other materials. 
Acidic degradation products cause 
strong inflammatory response. 
Random degradation can lead to 
premature failure of scaffolds. 
Hydrophobic and therefore needs 
modification to support cellular 
adhesion. PLA scaffolds have been 
used in auricular tissue engineering 
but unable to support 3-D structure in 




Multiple uses including 
intramedullary fracture pins, 
craniofacial repair, bone 
and cartilage regeneration, 
tissue engineering. 
Biodegradable polymer with FDA 
approval as medical device. Many 
uses on own or often in combination 
with other materials such as ceramics  
(added strength and mineralization).  
Has been used in combination with 
PLA to engineer auricular strutures 
that demonstrate sufficient 




Tissue engineering Biodegradable, however acidic 
degradation products can cause 
inflammatory reaction. Highly tunable 
with variable crosslinking. Liquid 
before crosslinking therefore easy to 
fabricate into custom made shapes or 
directly inject. Good biomechanical 
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strength.  
Poly (Vinyl alcohol)  
(PVA) 
Joint resurfacing – cartilage 
replacement 




Tissue engineering Biodegradable with harmless 
degradation products. Able to support 
attachment, proliferation and 
phenotype of osteoblasts when 
manufactured appropriately. 
Poly (Acrylate)s Cartialge and bone 
replacement, tissue 
engineering 
Nondegradable. Many individual 
polyacrylates can be prepared from a 
huge range of monomers. Excellent 
tunability. Favourable biomechanical 
properties. Able to support stem and 
progenitor cell attachment, 
proliferation and differentiation. 
Table 1.2. A summary of the most common polymers in clinical use. Adapted from 




1.7 Cells for tissue engineering 
 
Early research into tissue engineering frequently used mature cells such as 
chondrocytes or epithelial cells (Cao et al. 1997). Mature tissue cells are 
capable of generating new tissue, however there are limitations to their use. 
Donor sites are often limited and also may be affected by the disease they 
are trying to treat such as arthritis in chondorcytes. Furthermore, cells require 
extended periods of in vitro culture prior to use and mature cells have been 
shown to have limited ability to expand in vitro with associated deterioration 




Stem cells are defined as cells with the capacity to self renew and in 
response to intrinsic and extrinsic factors, differentiate into multiple cell types 
with specialised function. The potency of a stem cell refers to the number of 
different cells/tissues a particular cell is able to differentiate into. For 
example, a totipotent cell from a newly fertilsed morula is capable of 
differentiating into all intra and extra embryonic tissues, where as a 
multipotent cell is capable of differentiating into cells form within its own germ 
layer such as mesenchymal stem cells  (Figure 1.8). 
 
Stem cells have generated great interest for the use in tissue engineering. 
Whilst mature tissue cells have limited ability to expand in culture, stem cells 
by their nature are capable of prolonged periods of expansion and culture 
with no significant change in their function. In addition, stem cells can be 
harvested from multiple different sources (Covas et al. 2008). Although 
embryonic stem cells are able to generate all tissue types, they have a 
number of ethical and practical implications that have limited their use in 
tissue engineering. Conversely, adult stem cells have a narrower potency, 
but are potentially better suited to clinical translation. They can be harvested 
relatively easily from autologous sources and have not demonstrated any 






Figure 1.8: Hierarchy of potency of stem cells. Totipotent cells of the morula capable of 
generating all intra and extra embryonic tissues. Pluripotent cells from the inner mass of the 
blastocyst capable of generating all cell types within the embryo. Multipotent cells capable of 
generating cells from within a specific germ layer. Unipotent cells capable of generating a 







1.7.1 Mesenchymal stem cells 
!
The presence of non-haematopoietic stem cells in the bone marrow was first 
described by Julius Conheim, a German pathologist in 1867 (Prockop 1997). 
Using an analine dye, he observed the presence of non-haematopioetic 
fibroblast like cells in wounds created at distal sites. He concluded that these 
cells had migrated from the bone marrow, and that bone marrow was thus a 
source of non-inflammatory cells that contributed to wound healing.  
 
It was the pioneering work of the Russian scientist Friedenstein in the 1960s 
who first demonstrated that these bone marrow derived, adherent, non-
haematopoietic, fibroblast like cells had the ability to form colonies and 
differentiate into bone and cartilage in vitro, and could generate bone when 
transplanted to ectopic locations in vivo (Friedenstein et al. 1966; 
Friedenstein et al. 1970; Friedenstein et al. 1974). Furthermore, in models of 
serial implantation they were able to regenerate heterotopic bone in vivo 
demonstrating their capacity for self renewal (Owen & Friedenstein 1988). 
Due to their appearance in vitro, Friedenstein referred to these cells as 
colony forming unit – fibroblast  (CFU-F), a name that was routinely used 
before Caplan introduced the term Mesenchymal Stem Cell  (MSC) in 1991 
(Caplan 1991). 
 
Since their initial description, these cells have been the focus of much 
attention for their ability to differentiate into multiple mesodermal lineages, to 
modulate the immune system and to stimulate regeneration through trophic 
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support and the secretion of cytokines (Caplan 2007). MSC have the general 
perception of being ‘safe’ stem cells due to the fact that these cells can be 
harvested relatively easily from autologous donors and have not 
demonstrated any evidence of tumour formation in vitro or in vivo, one of the 
principle concerns with the use of pluripotent cells. In addition, MSC can be 
selected and rapidly expanded using standard culture methods and are 
reported to have a broad therapeutic action. It is not therefore surprising that 
MSC have been the focus of a number of clinical trials, many of which have 
aimed to demonstrate a function beyond just mesenchymal repair and 
regeneration (www.clinicaltrials.gov). Despite many trials, the application of 
MSC in routine clinical practice is not currently prevalent. This is possibly due 
to disappointing trial outcomes, and the high cost of manufacturing cells to 
the standards required for clinical application. Despite this, there is still much 
promise for the application of these cells to treat a range of diseases, and 
they are the most frequently used cell in research focusing on 
chongrogenesis and cartilage repair (Table 1.3). 
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Disease Phase of trial 
 I I/II II II/III III IV ND 
Overall 31 40 15 3 4 1 10 
Haematological disease 1 2 1 0 0 0 0 
GVHD 0 4 2 0 1 0 0 
Diabetes 1 1 0 0 0 0 1 
Liver disease 0 3 0 0 0 0 0 
Kidney disease 0 0 0 0 0 0 1 
Lung disease 3 0 1 0 0 0 0 
Cardiovascular disease 2 11 4 1 0 0 1 
Bone and cartilage disease 12 8 3 1 2 0 3 
Neurological disease 9 8 2 0 0 0 1 
Crohn’s disease 0 1 1 1 0 0 1 
Lupus erythematous 0 0 0 0 0 0 0 
Other 3 2 1 0 1 1 2 
 
Table 1.3 Completed clinical trials of MSC. Table giving details of completed MSC based 
clinical trials with details of the disease type and phase of trial. The majority of trials (81/104) 
are focused on tissues of non-mesedermal origin suggesting a trophic mode of action rather 
than direct contribution of MSC. Data from www.clinicaltrials.gov 
!
!
1.7.2 Defining MSC 
!
Due to the widespread interest in MSC, there have been many attempts 
made to standardise and simplify the nomenclature associated with these 
cells. However, there has been significant variation used to isolate and grow 
MSC, and also in the assays used to examine their function. This has made 
interpreting and standardising information on MSC both challenging and 
potentially misleading (Tallone et al. 2011). In an attempt to address these 
issues, the Mesenchymal and Tissue Stem Cell Committee of The 
International Society for Cellular Therapy (ISCT) published a position 
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statement that addressed the minimum criteria required to define an MSC 
(Dominici et al. 2006). They stated that cells must: 
 
• Be adherent to plastic in standard conditions. 
• Have positive (>95%) expression of CD105, CD90, CD73. 
• Have negative (<2%) expression of CD45, CD34, CD14 or CD11b, 
CD79α or CD19, and HLA-DR. 
• In vitro differentiation into osteoblasts, adipocytes and chondroblasts 
by demonstration of staining of cell cultures. 
 
Whilst the position statement published by ISCT aimed to clarify some of the 
issues surrounding MSC identity, subsequent studies have demonstrated 
variable expression of the markers described by the ISCT and that many of 
these markers appear to be neither inclusive nor exclusive of MSC function. 
In addition, many subsequent studies have identified many new and different 
cell surface antigens that are associated with MSC  (summarized in table 1.4, 
reviewed in (da Silva Meirelles 2006; Murray et al. 2013; Crisan et al. 2008)). 
It is therefore recognized that MSC selected according to their ability to 
adhere to plastic represent a heterogenous pool of cells with significant 
variation in their immunophenotype and function. Attention has focused on 
identifying surface markers that might represent functionally distinct subsets 
with enhanced potential. STRO-1 has been identified as a marker that 
represents a subset of bone marrow derived MSC with enhanced 
clonogenicity which contains osteoprogenitors (Arai 2002; Gronthos et al. 
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1994; Simmons & Torok-Storb 1991). If cells expressing STRO-1 and VCAM-
1 were selected, this effect was enhanced (Gronthos 2003). A subset of MSC 
from human intrapatellar fat pads that expressed the pericyte marker 3G5 
demonstrared enhanced chondrogenesis in vitro, interestingly these cells 
were negative for STRO-1 expression further supporting the hypothesis that 
MSC contain subsets of cells with enhanced ability toward a specific function. 
 
One problem associated with assessing surface marker expression in vitro is 
that many of these markers can be modulated by culture conditions, and they 
play no direct role in the underlying fate decision relating to self renewal and 
differentiation. For example, CD105 is one of the surface markers that is 
defined in the ISCT minimal criteria, however studies have demonstrated that 
expression of this marker is inversely related to the osteogenic potential of 
MSC (Levi et al. 2011). In addition, Jones et al demonstrated lines of MSC 
with uniform expression of HLA-DR  (a marker that should not be expressed 
according to the ISCT criteria) which co-expressed CD90 and CD105 and 
were capable of multi-lineage differentiation (Jones et al. 2002). Therefore 
although numerous markers have been reported as being either expressed 
or negatively expressed in MSC, there is very little data about how this 







CD Marker +/- Reference 
 
CD3  (Mariotti et al. 2008) 
CD9  (Gronthos et al. 2001; Niehage et al. 2011; Mariotti et al. 2008; Gimble et al. 
2007) 
CD10 + (Gronthos et al. 2001; Crisan et al. 2008) 
CD11a - (Pittenger et al. 1999; Dominici et al. 2006) 
CD11b - (Dominici et al. 2006) 
CD13 + (Gronthos et al. 2001; Crisan et al. 2008)  
CD14 - (Kern et al. 2006; Dominici et al. 2006; Pittenger et al. 1999; Niehage et al. 
2011) 
CD16 - (Mariotti et al. 2008) 
CD18 + (Brooke et al. 2008) 
CD19 - (Pittenger et al. 1999; Dominici et al. 2006) 
CD27 - (Mariotti et al. 2008) 
CD28 - (Mariotti et al. 2008) 
CD29 + (Niehage et al. 2011; Brooke et al. 2008; Gronthos et al. 2001; Mariotti et al. 
2008; Gimble et al. 2007; Wagner et al. 2005; Kern et al. 2006) 
CD31 - (Brooke et al. 2008; Mariotti et al. 2008; Gimble et al. 2007; Tallone et al. 
2011) 
CD33 - (Mariotti et al. 2008) 
CD34 + (Gronthos et al. 2001; Niehage et al. 2011; Corselli et al. 2012; Tallone et al. 
2011; Zimmerlin et al. 2012; Zimmerlin et al. 2009) (Wagner et al. 2005; 
Tallone et al. 2011) 
CD34 - (Dominici et al. 2006) (Mariotti et al. 2008; Kern et al. 2006; Tallone et al. 
2011) 
CD36 - (Mariotti et al. 2008) 
CD44 + (Gronthos et al. 2001; Niehage et al. 2011; Brooke et al. 2008; Mariotti et al. 
2008; Gimble et al. 2007; Wagner et al. 2005; Kern et al. 2006; Crisan et al. 
2008) 
CD45 - (Kern et al. 2006; Dominici et al. 2006; Niehage et al. 2011; Mariotti et al. 
2008; Gimble et al. 2007) 
CD49A + (Brooke et al. 2008; Mariotti et al. 2008; Gimble et al. 2007; Gronthos et al. 
2001) CD49B + 
CD49C + 
CD49E + 
CD50 - (Brooke et al. 2008) 
CD51 + (Brooke et al. 2008) 
CD54 + (Gronthos et al. 2001; Niehage et al. 2011; Brooke et al. 2008; Gimble et al. 
2007) 
CD55 + (Gimble et al. 2007; Gronthos et al. 2001) 
CD56 + (Brooke et al. 2008; Tallone et al. 2011) 
CD58 + (Mariotti et al. 2008) 
CD59 + (Gronthos et al. 2001; Campioni et al. 2006) 
CD61 + (Niehage et al. 2011) 
CD63 + (Niehage et al. 2011) 
CD71 + (Niehage et al. 2011; Mariotti et al. 2008; Gimble et al. 2007) 
CD73 + (Dominici et al. 2006; Mariotti et al. 2008; Gimble et al. 2007; Wagner et al. 
2005; Kern et al. 2006; Crisan et al. 2008) 
CD79a - (Dominici et al. 2006) 
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CD90 + (Dominici et al. 2006; Niehage et al. 2011; Mariotti et al. 2008; Gimble et 
al. 2007; Wagner et al. 2005; Kern et al. 2006; Tallone et al. 2011; Crisan et 
al. 2008) 
CD97 + (Niehage et al. 2011) 
CD98 + (Niehage et al. 2011) 
CD99 + (Niehage et al. 2011) 
CD102 - (Brooke et al. 2008) 
CD104 + (Brooke et al. 2008) 
CD105 + (Dominici et al. 2006; Gronthos et al. 2001; Niehage et al. 2011; Gimble et 
al. 2007; Kern et al. 2006; Crisan et al. 2008) 
CD106  + (Gronthos et al. 2001; Niehage et al. 2011; Brooke et al. 2008; Kern et al. 
2006) 
CD117 - (Zimmerlin et al. 2009) 
CD120A + (Pittenger et al. 1999) 
CD124 + (Pittenger et al. 1999) 
CD133 - (Kern et al. 2006; Niehage et al. 2011) 
CD140 + (Bűhring et al. 2007; Masuda et al. 2012; Crisan et al. 2008; Tallone et al. 
2011) 
CD144 - (Kern et al. 2006; Crisan et al. 2008) 
CD146  + (Crisan et al. 2008; Zimmerlin et al. 2009; Tallone et al. 2011; Zimmerlin et 
al. 2012; Gronthos et al. 2001) 
CD166 + (Gronthos et al. 2001; Niehage et al. 2011; Brooke et al. 2008; Gimble et al. 
2007; Wagner et al. 2005) 
CD243 - (Mariotti et al. 2008) 
CD271 + (Tallone et al. 2011; Bűhring et al. 2007; Flores-Torales et al. 2010) 
CD276 + (Niehage et al. 2011) 
CD304 + (Niehage et al. 2011) 
CD324 + (Brooke et al. 2008) 
CD340 + (Bűhring et al. 2007) 
CD349 + (Bűhring et al. 2007) 
αSMA + (Crisan et al. 2008; Tallone et al. 2011) 
NG2 + (Tallone et al. 2011; Crisan et al. 2008) 
STRO-1  + (Dennis et al. 2002; Simmons & Torok-Storb 1991; Gronthos et al. 1994) 
Table 1.4. Surface markers associated with MSC. A list of published studies 
demonstrating positive  (+), and negative  (-) expression of surface markers. Almost all these 
studies relate to in vitro studies and provide little evidence about the relative function of MSC 









1.7.3 Functions of MSC 
!
!
In addition to their ability to differentiate in to multiple mesodermal tissues, 
MSC also have been shown to have a number of further functions that make 
them attractive therapeutic targets. 
 
In his initial series of experiments, Friedenstein demonstrated the vital role 
that MSC play in the support of haematopoeisis. In these experiments, MSC  
(called CFU-F in the work), were transplanted into heterotopic locations in 
semi-syngeneic animals. The formation of heterotopic ossicles was observed 
with the haematopoietic cells being of recipient origin, but the bone forming 
cells being donor derived. Friedenstein concluded that MSC provided an 
environment for HSC homing, engraftment and subsequent establishment of 
haematopoiesis (Friedenstein et al. 1974).  
 
The long term ability of MSC to support haematopoiesis was demonstrated in 
an in vitro murine model by Dexter et al (Dexter et al. 1977). Culture systems 
were established demonstrating the maintainance of haematopoiesis over 
several months. Within these cultures of MSC it was shown that subsets 
expressing the STRO-1 antigen were those capable of supporting 
haematopoiesis, whilst also having the ability to differentiate into multiple 
mesenchmyal lineages(Simmons & Torok-Storb 1991; Dennis et al. 2002). 
 
Based on this early experimental work, MSC have been investigated 
extensively for their ability to support haematopoiesis and promote HSC 
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engraftment and repopulation in vitro and in vivo. Co-transplantation of HSC 
with MSC has been shown to increase the haematopoietic engraftment and 
recovery in both animal and human studies (Bensidhoum et al. 2004; Devine 
et al. 2001). 
 
Immunomodulation is another key property displayed by MSC, and this 
immunosuppression has allowed allogeneic transplantation of these cells, 
avoiding host immune surveillance and without obvious immune response 
from the host (Aggarwal 2005; Wada et al. 2013). The immunomodulatory 
properties of MSC are mediated via the secretion of bioactive molecules 
affecting dendritic cells, B Cells and T Regulatory, Helper and Killer cells, 
and also by direct cell-to-cell contact (Aggarwal 2005; Caplan & Correa 
2011). The exact mechanisms by which MSC exert this effect remains to be 
elucidated, however several studies have demonstrated numerous different 
factors that may play a role. MSC have been shown to release 
immunomodulatory biomolecules such as IL-10, interferon-γ, indoleamine 
2,3-dioxygenase which prevented arteriosclerosis and enhanced graft 
survival in a porcine model of femoral artery transplantation (Jui et al. 2012). 
In a porcine model of hind limb composite tissue allotransplantation, 
administration of autologous MSC resulted in significantly increased graft 
survival associated with T-cell regulation (Kuo et al. 2012). Furthermore the 
immunosuppressive effects of MSC where shown to have a 
chondroprotective function in a murine model of arthritis. Following injection 
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of MSC into affected joints, T cell numbers were reduced and disease 
progression slowed (Wu et al. 2016). 
 
Many of the studies examining the therapeutic function of MSC have 
observed benefits that extend beyond differentiation into mesodermal 
lineages alone. This broad therapeutic action of MSC may be as a result of 
the vast secretome they possess and has lead to MSC being referred to as 
‘an injury drugstore’ (Caplan & Correa 2011). This therapeutic function has 
been examined in over 100 completed and nearly 500 on going clinical trials, 
and in the vast majority of these trials the proposed mechanism of action has 
been attributed to immunomodulation and secretion of trophic factors and not 
direct contribution to new tissues  (Table 1.3 & 1.5) 
 
Disease Phase of trial 
 I I/II II II/III III IV ND 
Haematological disease 4 6 12 1 1 1 1 
GVHD 4 14 9 3 3 0 2 
Diabetes 7 11 3 3 3 0 0 
Liver disease 4 15 8 0 1 0 3 
Kidney disease 0 3 3 2 0 0 1 
Lung disease 9 8 3 1 0 0 2 
Cardiovascular disease 16 27 20 3 4 0 3 
Bone and cartilage disease 19 30 15 4 4 0 17 
Neurological disease 21 39 14 1 3 0 7 
Crohn’s disease 2 4 2 0 4 0 1 
Lupus erythematous 0 2 0 0 0 0 0 
Other 20 26 10 1 3 2 11 
Table 1.5 All currently open clinical trials of MSC. Table giving details of all 493 currently 




1.7.4 MSC in multiple tissues 
!
Since their initial isolation from bone marrow, seemingly identical cells have 
been isolated from almost all foetal and post natal tissues based on their 
adherence to plastic (da Silva Meirelles 2006) (Table 1.5). This includes 
organs that contain no native mesenchymal tissue, further supporting the 




Human Tissue Reference 
Aorta (da Silva Meirelles 2006) 
Adipose (Zuk et al. 2002; Crisan et al. 2008; De Ugarte et al. 2003) 
Amniotic Fluid (Tsai et al. 2004; In 't Anker et al. 2004) 
Bone marrow (Friedenstein et al. 1966; Friedenstein et al. 1974; Friedenstein et al. 1970; 
Pittenger et al. 1999; Shi & Gronthos 2003; da Silva Meirelles 2006; Crisan et 
al. 2008; Campagnoli 2001)  
Blood (Villaron et al. 2004) 
Brain (da Silva Meirelles 2006; Crisan et al. 2008; Paul et al. 2012) 
Cartilage (Alsalameh et al. 2004; Hiraoka et al. 2006) 
Cord Blood (Campagnoli 2001; Erices et al. 2000; Secco et al. 2009; Jager et al. 2009) 
Dental Pulp .(Shi & Gronthos 2003; Feng et al. 2011; Gronthos et al. 2000; Nakamura et al. 
2009; G. T.-J. Huang et al. 2009; Valtieri & Sorrentino 2008; Shi et al. 2005) 
Endometrium (Schuring et al. 2011; Spitzer et al. 2012) 
Eyes (Crisan et al. 2008) 
Gut (Lanzoni et al. 2009; Crisan et al. 2008) 
Heart (Crisan et al. 2008) 
Kidney (da Silva Meirelles 2006) 
Liver (Campagnoli 2001; da Silva Meirelles 2006) 
Lungs (da Silva Meirelles 2006; Crisan et al. 2008) 
Muscle (Asakura et al. 2001; da Silva Meirelles 2006; Crisan et al. 2008) 
Pancreas (da Silva Meirelles 2006; Crisan et al. 2008) 
Perichondrium (Arai 2002) 
Periodontal (da Silva Meirelles 2006; Seo et al. 2004) 
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ligament 
Placenta (Zuk et al. 2002; Igura et al. 2004; Crisan et al. 2008; In 't Anker et al. 2004; 
De Ugarte et al. 2003) 
Salivary Glands (Friedenstein et al. 1966; Tsai et al. 2004; Friedenstein et al. 1974; Rotter et al. 
2008; Friedenstein et al. 1970; In 't Anker et al. 2004; Pittenger et al. 1999; Shi 
& Gronthos 2003; da Silva Meirelles 2006; Crisan et al. 2008; Campagnoli 
2001) 
Skin (Villaron et al. 2004; Friedenstein et al. 1966; Toma et al. 2001; Friedenstein et 
al. 1974; Crisan et al. 2008; Friedenstein et al. 1970; Pittenger et al. 1999; Shi 
& Gronthos 2003; da Silva Meirelles 2006; Campagnoli 2001) 




(Alsalameh et al. 2004; da Silva Meirelles 2006; Hiraoka et al. 2006; De Bari 
et al. 2001; Crisan et al. 2008; Paul et al. 2012) 
Tendon {Salingcarnboriboon:2003hs}  
Thymus (Campagnoli 2001; Alsalameh et al. 2004; Erices et al. 2000; da Silva 
Meirelles 2006; Secco et al. 2009; Hiraoka et al. 2006; Jager et al. 2009) 
Umbilical cord (Shi & Gronthos 2003; Campagnoli 2001; Feng et al. 2011; Rogers & Casper 
2004; Gronthos et al. 2000; Erices et al. 2000; Nakamura et al. 2009; Romanov 
et al. 2003; G. T.-J. Huang et al. 2009; Secco et al. 2009; Valtieri & Sorrentino 
2008; Crisan et al. 2008; Shi et al. 2005; Jager et al. 2009) 
Veins (Schuring et al. 2011; Shi & Gronthos 2003; Spitzer et al. 2012; da Silva 
Meirelles 2006; Feng et al. 2011; Campagnolo et al. 2010; Gronthos et al. 
2000; Nakamura et al. 2009; G. T.-J. Huang et al. 2009; Valtieri & Sorrentino 
2008; Shi et al. 2005) 




Whilst MSC derived from different tissues appear broadly similar and fulfill 
the criteria specified by the ISCT, differences in their morphology, 
immunophenotpye and function have been observed. Significant variation in 
the surface marker profile has been observed between cells from different 
sources (Brooke et al. 2008; Gimble et al. 2007; Niehage et al. 2011), 
however different methods of isolation, culture and assessment make direct 
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comparison of results difficult (Nery et al. 2012). Clonal analysis of cell 
populations varies between donors and tissues and the frequency of tripotent 
cells can range from 30 – 50% (Guilak et al. 2005).  
 
It has been demonstrated in a murine model that the progenitors of white 
adipose tissue reside in the blood vessel wall. Although these cells are found 
in blood vessels throughout the body, it is only those found in adipose tissue 
that can differentiate into adipocytes suggesting a tissue specific role of MSC 
(Tang et al. 2008). When examining MSC from bone marrow and adipose 
tissue it was seen that MSC preferentially differentiated into osteocytes and 
adipocytes respectively, again suggesting a tissue specificity (Peng et al. 
2008). With reference to chondrogenesis, it has been demonstrated that in 
standard conditions MSC from bone marrow have a greater chondrogenic 
potential than those from adipose tissue (Diekman et al. 2010). However, 
these were not matched samples, and subsequent studies have shown that 
this difference can be eliminated with modifications to the culture medium 
used with the supplementation of additional growth factors (Hennig et al. 
2007).  
 
1.7.5 Stem cells in adipose tissue 
!
!
In 2001, Zuk et al aimed to establish if adipose tissue contained populations 
of stem cells that could be used for clinical application (Zuk et al. 2001). They 
noted the ethical issues surrounding ES cells, and the practical implications 
of harvesting and expanding bone marrow derived MSC. As uncommitted 
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MSC had been observed in the connective tissue of multiple organs from 
different mammalian species, and bone marrow and adipose tissue both 
derive from mesoderm and contain heterogeneous stromal cell populations, 
they hypothesized that adipose tissue may harbor populations of MSC. 
 
Adipose tissue was enzymatically dissociated and centrifuged to generate 
SVF, before being cultured under standard conditions. Cells rapidly attached 
and expanded in vitro and had typical fibroblast like appearance – in this 
experiment they were termed Processed Lipoaspirate cells  (PLA). These 
cells continued to stably proliferated in vitro for extended periods  (>165days) 
showing minimal signs of senescence. When placed in appropriate media 
and conditions they demonstrated multilineage potential and differentiated 
into osteogenic, chondrogenic, adipogenic and myogenic lineages in a 
manner identical to the bone marrow MSC controls. They concluded that 
adipose tissue is an autologous source of multipotent MSC, that can be 
easily harvested in significant numbers making them excellent candidates for 
tissue engineering and cell based therapies (Zuk et al. 2001). The principle 
advantage of adipose tissue when compared to other sources of MSC is the 
ability to harvest large volumes of otherwise redundant tissue with minimal 
morbidity, even in patients of healthy BMI. The function of ASC has been 
investigated in numerous studies and they have been shown to have a 




1.7.6 MSC in vivo 
!
!
The study of MSC has almost exclusively been observed in vitro with little 
understanding of their native location and identity. Therefore despite our 
perceived expansion in understanding these cells, their native role in 
development, homeostasis, repair and regeneration has been largely 
overlooked. 
 
In early development there is a huge recruitment, expansion, migration and 
differentiation of stem cells; however this process is relatively short lived and 
decreases throughout the life of an organism. In adult organisms the 
frequency of stem cells is rare and the ability of tissues to repair and 
regenerate becomes increasingly diminished. Adult stem cells are known to 
live in specific niches in their corresponding tissue of origin such as HSC in 
the bone marrow, epidermal stem cells in hair follicles and neural stem cells 
in the subventricular zone (Watt & Hogan 2000). Despite isolating MSC from 
multiple different and distinct tissue types, identifying their native location and 
niche proved challenging. The main tissue types that are believed to derive 
from MSC are not limited to one anatomical location  (eg bone, muscle, fat 
and cartilage), therefore for MSC to be able to repair and regenerate these 
tissues, they must either be locally available or able to mobilise and reach 
distant sites.  
 
For MSC to be able to mobilise and reach distant sites, it is intuitive that 
these cells would be present in peripheral blood, however identifiying and 
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establishing growth of MSC cultures from blood has proved extremely difficult 
even after stimulation with cytokines (da Silva Meirelles 2006; Lazarus et al. 
1997). In a rat model it was observed that low oxygen conditions resulted in 
the specific mobilisation of MSC detected in peripheral blood (Rochefort et al. 
2006), and raised numbers of MSC were also observed in the blood of 
patients following traumatic hip injury (Alm et al. 2010), however in both 
cases this elevation was modest. 
Therefore the alternative hypothesis that MSC are locally available and 
ubiquitous throughout the body was proposed. The ability to derive 
functionally and phenotypically similar cells from multiple tissues supports the 
hypothesis that these cells may share the same in vivo location or niche 
throughout the body.  
 
1.7.7 A perivascular origin of MSC 
 
!
Based on the hypothesis that MSC share a ubiquitous niche throughout the 
body, groups have demonstrated MSC like characteristics of distinct subsets 
of cells isolated from blood vessel walls. Pericytes  (also known as mural or 
Rouget cells) reside on the abluminal surface of endothelial cells and are 
recognised as a distinct cellular entity with a unique immunophenotype (Sims 
1986). In a comprehensive examination of pericytes in multiple foetal and 
adult tissues, Crisan et al demonstrated that pericytes express specific 
perivascular surface markers  (CD146, NG2, PDGFRβ), they also natively 
express MSC associated markers  (CD29, CD44, CD73, CD90, CD105, 
alkaline phosphatase), and lack expression of markers specific of endothelial  
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(CD31, CD34, CD144, von Willebrand Factor) or haematopeiotic lineages  
(CD34, CD45) (Crisan et al. 2008) (Figure 1.9). These results have been 
confirmed in further studies and are summarized in Table 1.6. 
 
 
Figure 1.9: Identification of pericytes in multiple human tissues. Immunohistochemaical 
analysis of multiple human tissues. A = myocardium, B, D, G - I = skeletal muscle, C & F = 
placental villus, E = pancreas. Figure taken from (Crisan et al. 2008) 
 
In addition, it has been demonstrated that pericytes have a differentiation 
potential identical to that of conventional MSC (Covas et al. 2008; Crisan et 
al. 2008), and are able to differentiate into bone (James, Zara, Corselli, 
Askarinam, et al. 2012; James, Zara, Corselli, Chiang, et al. 2012), fat 
(Zimmerlin et al. 2012), cartilage (Crisan et al. 2008; Farrington-Rock 2004; 
W. S. Khan et al. 2008) and skeletal muscle (Crisan et al. 2009; Park et al. 
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2011). Other functions commonly attributed to MSC include the ability to 
suppress T-lymphocyte function which has also been observed in studies 
examining pericytes (Tu et al. 2011; Maier & Pober 2011), and support of 
haematopoiesis (Corselli, Chin, et al. 2013). 
 
By performing a rigorous analysis of different subsets of cells within SVF of 
multiple tissues Corselli et al identified a second population of perivascular 
cells with MSC like features capable of multi lineage differentiation. These 
cells reside in the adventitial layer of blood vessels  (adventitial cells) and 
have a unique surface marker profile distinct from pericytes  (CD34+, CD146-
, CD31-, CD45-) (Corselli et al. 2012). No other cells were found outside of 
these 2 distinct populations within the SVF that displayed any MSC features. 
 
In studies by other groups that have examined subsets of stem cells within 
SVF similar populations were confirmed. Zimmerlin et al performed an 
extensive analysis of SVF and observed the presence of pericytes and 
supra-adventitial cells, in addition they documented the presence of 
endothelial progenitor cells  (EPC) (Zimmerlin et al. 2012; Zimmerlin et al. 
2009). Their finding confirmed those of Corselli and Crisan that pericytes and 








+/- Pericyte Reference Adventitial Reference 
CD10 + (Crisan et al. 2008)  
CD13 + (Crisan et al. 2008)  
CD14 - (Zannettino et al. 2007; Dar et al. 
2012) 
 
CD29 + (Dar et al. 2012)  
CD31 - (Psaltis et al. 2010; Zannettino et al. 
2007; Crisan et al. 2008; Dar et al. 
2012; Tallone et al. 2011; 
Zimmerlin et al. 2012; Zimmerlin et 
al. 2009) 
(Psaltis et al. 2010; Tallone et al. 
2011; Zimmerlin et al. 2009) 
CD34 +  (Psaltis et al. 2010; Corselli et al. 
2012; Zimmerlin et al. 2009; 
Tallone et al. 2011) 
CD34 - (Psaltis et al. 2010; Crisan et al. 
2008; Tallone et al. 2011; 
Zimmerlin et al. 2012; Zimmerlin et 
al. 2009) 
 
CD44 + (Crisan et al. 2008; Zannettino et al. 
2007; Psaltis et al. 2010; Dar et al. 
2012) 
(Corselli et al. 2012) 
CD45 - (Psaltis et al. 2010; Zannettino et al. 
2007; Crisan et al. 2008; Dar et al. 
2012; Zimmerlin et al. 2012; 
Zimmerlin et al. 2009) 
(Corselli et al. 2012; Zimmerlin et 
al. 2009) 
CD56 - (Psaltis et al. 2010; Crisan et al. 
2008) 
 
CD73 + (Psaltis et al. 2010; Crisan et al. 
2008; Dar et al. 2012; Zimmerlin et 
al. 2012) 
(Corselli et al. 2012; Zimmerlin et 
al. 2012) 
CD90 + (Psaltis et al. 2010; Zannettino et al. 
2007; Crisan et al. 2008; Dar et al. 
2012; Tallone et al. 2011; 
Zimmerlin et al. 2012; Zimmerlin et 
al. 2009) 
(Corselli et al. 2012; Zimmerlin et 
al. 2012; Zimmerlin et al. 2009; 
Tallone et al. 2011) 
CD105 + (Psaltis et al. 2010; Zannettino et al. 
2007; Crisan et al. 2008; Dar et al. 
2012) 
(Corselli et al. 2012) 
CD106 - (Zannettino et al. 2007)  
CD117 - (Zimmerlin et al. 2009) (Zimmerlin et al. 2009) 
CD133 - (Crisan et al. 2008)  
CD140 + (Psaltis et al. 2010; Crisan et al. 
2008; Dar et al. 2012; Tallone et al. 
2011) 
 
CD144 - (Crisan et al. 2008)  
CD146  + (Psaltis et al. 2010; Zannettino et al. 
2007; Crisan et al. 2008; Dar et al. 
2012; Tallone et al. 2011; 
Zimmerlin et al. 2009; Zimmerlin et 
al. 2012) 
 
CD146 -  (Corselli et al. 2012; Tallone et al. 
2011; Zimmerlin et al. 2012; 
Zimmerlin et al. 2009) 
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CD166 + (Zannettino et al. 2007)  
αSMA + (Psaltis et al. 2010; Crisan et al. 
2008; Tallone et al. 2011) 
 
αSMA -  (Corselli et al. 2012; Tallone et al. 
2011) 
NG2 + (Psaltis et al. 2010; Crisan et al. 
2008; Dar et al. 2012; Tallone et al. 
2011) 
(Tallone et al. 2011) 
NG2 -  (Corselli et al. 2012) 
STRO-1  + (Psaltis et al. 2010; Zannettino et al. 
2007) 
 
Table 1.6. Surface marker profile of pericytes and adventitial cells. 2 anatomically and 
phenotypically distinct populations of cells have been described that represent in vivo 
populations of MSC, namely pericytes and MSC. Whilst these 2 populations share common 
markers, differential expression of markers such as CD146 and αSMA allows distinction. 
!
1.7.8 Pericytes in development, repair and regeneration 
 
A lack of understanding of the in vivo identity and location of MSC, and a lack 
of unique and specific markers had previously made their in vivo study 
difficult. In particular studies examining their role in development, repair and 
regeneration has been hampered by lack of adequate lineage tracing 
models. Our current understanding that the in vivo counterpart of MSC are 
perivascular cells has allowed pericyte specific lineage tracing models to be 
developed.  
 
In vivo bone healing models have demonstrated the ability of transplanted 
pericytes to regenerate critical size calvarial defects in mice (James, Zara, 
Corselli, Askarinam, et al. 2012) and promote spinal fusion in rats (C. G. 
Chung et al. 2014). Recovery of hindlimb ischaemia has been demonstrated 
in murine models using pericytes derived from ES cells (Dar et al. 2012), and 
human blood vessels (Campagnolo et al. 2010). In murine models of 
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myocardial infarction, human muscle derived pericytes were injected intra-
myocardially and demonstrated reduced fibrosis and enhanced functional 
recovery (Chen et al. 2012). These findings were supported by a subsequent 
study using human vein derived pericytes that demonstrated longterm 
improved functional recovery following transplantation (Katare & Madeddu 
2013). In vitro myogenic differentiation, enhanced angiogenesis and muscle 
regeneration in vivo were seen in a murine model of muscle dystrophy when 
human placental derived pericytes were injected (Park et al. 2011). 
 
Indirect evidence that pericytes may play a major role in development was 
observed by the spontaneous appearance of pericytes in cultures of 
embryoid bodies differentiating from human ES cells. In addition, these cells 
demonstrated MSC phenotype, function and the ability to rescue hind limb 
ischaemia in a murine model (Dar et al. 2012). 
 
Tang et al demonstrated that pericytes were the native progenitors of white 
adipose tissue in murine adipose tissue with the use of a PPARγ (a central 
regulator of adipogenesis) reporter. Interestingly, whilst pericytes were found 
throughout the body, the cells responsible for adipogenesis were not found in 
tissues other than adipose tissue suggesting a tissue specific role (Tang et 
al. 2008). 
 
Using NG2 as a pericyte marker, Feng et al used a NG2-Cre reporter mouse 
to demonstrate that vascular pericytes contribute to the regeneration of bone 
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following tooth injury (Feng et al. 2011). However they concluded that their 
contribution was not exclusive and other populations of cells were involved. 
Dellavalle et al utilised an Alkaline Phosphatase–Cre reporter mouse in a 
murine model of chemical induced skeletal muscle damage in which 
pericytes were shown to both differentiate into muscle fibres and also 
generate satellite cells (Dellavalle et al. 2011).  
 
1.7.9 Pericytes and chondrogenesis 
The long bones and the synovial joints are formed from condensations of the 
apical ectodermal ridge. Within the vascular channels of the developing 
foetal epiphyseal cartilage, pericytes are observed (H. C. Anderson et al. 
2000). It was also observed that the vascular region of foetal menisci 
contained greater proportion of perivcascular stem cells compared to the 
avascular part. When purified and grown in vitro these cells were capable of 
multi lineage differentiation and contributed to repair in a murine model of 
meniscal injury (Osawa et al. 2013). 
 
Using an inducible pericyte reporter mouse, Matthews et al demonstrated 
that αSMA+ pericytes were responsible for a large proportion of the cells 
within the fracture callous (Matthews et al. 2014). The pericytes within the 
callous have also been shown to contribute to the chondroblasts and repair 
of the fracture (Brighton & Hunt 1997). 
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Studies that have described the ability of pericytes to function as multipotent 
MSC have demonstrated chondrogenesis of these cells in vitro (Crisan et al. 
2008; Zannettino et al. 2007). The ability of microvascular pericytes to 
produce aggrecan (a key constituent of cartilage ECM), collagens and 
proteins associated with chondrogenesis has been observed in vitro 
(Diefenderfer & Brighton 2000; A E Canfield 2001), and has also been noted 
on histological examination of soft tissue wounds (Diaz-Flores, Gutierrez, 
Varela, et al. 1991). When transplanted in vivo, it was observed that bovine 
retinal pericytes gave rise to mature cartilage comprising cells embedded in 
an extracellular matrix rich in sulfated proteoglycans and type II collagen 
(Farrington-Rock 2004).  
 
Early in vivo evidence that pericytes contribute to chondrogenesis was seen 
in a rabbit rib fracture model. 3 days following fracture, the proliferation, 
separation and migration of pericytes from the microvasculature was 
observed. Chondrogenic differentiation was observed by the presence of 
collagen fibrils and the production of matrix. In addition, mature chondrocytes 
retained elements of the basement lamina on their surface suggesting a 
vascular origin (Brighton & Hunt 1997). When perichondrium was 
transplanted in ectopic locations in mice, pericytes were seen to leave the 
vessel wall and contribute to neochondrogenesis (Diaz-Flores, Gutierrez, 
Gonzalez, et al. 1991).  
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In a related set of studies that examined the chondrogenic and 
chondroprotective function of subsets of MSC, it was observed that the 
CD146+ (pericyte) fraction showed enhanced function when compared to 
either CD146- or unsorted MSC. Hagmann et al compared CD146+ cells 
purified from human bone marrow derived MSC with unsorted MSC as 
controls. They observed that the CD146+ cells showed no difference in 
osteogenic or adipogenic ability when compared to controls. However, 
CD146+ cells showed increased amounts of GAG production following 
chondrogenic differentiation when compared to controls (Hagmann et al. 
2014). When tested in a murine arthritis model, CD146+ cells showed 
reduction in the T-Helper cells associated with progession of disease and an 
increase in the levels of new cartilage produced in the diseased joint surface 
when compared to CD146- controls (Wu et al. 2016). In a further study, cells 
grown clonally from the human infrapatellar fat pad showed enhanced 
chondrogenesis and expression of the pericyte marker 3G5 (W. S. Khan et 
al. 2008). 
 
Taken together these studies suggest a functional role for pericytes in the 
normal development of cartilage and the protection and repair of cartilage. In 
addition they contribute to neo-chondrogenesis in vivo, and also possess the 
ability to generate cartilage in vitro. They therefore have a justifiable potential 




1.8 Auricular tissue engineering 
 
!
Surgeons and scientists have long recognised the need for a tissue 
engineered auricle to replace either the burden of harvesting costal cartilage, 
or the problems associated with alloplastic alternatives such as extrusion. 
Despite much research and early promise, a satisfactory solution still 
remains elusive.  
 
The majority of strategies aimed at tissue engineering for auricular 
reconstruction consist of implantation of chondrocytes or stem/progenitor 
cells seeded on a scaffold. This is either implanted following a period of in 
vitro growth and/or differentiation, or implanted with the appropriate cues to 
promote in vivo maturation of the implant. 
 
Early pioneering work by Cao and Vacanti used bovine articular 
chondrocytes seeded onto a synthetic, biodegradable polyglycolic acid  
(PGA) scaffold created in the shape of a 3 year old child’s ear. Following 
implantation into nude mice for 12 weeks, mature neocartilage was observed 
that was able to retain the complex 3-dimensional shape of the ear. However 
during the 12 week process external splints were applied to maintain the 
shape and structure and when these were removed the detail and 
architecture was lost (Figure 1.10) (Cao et al. 1997). Although this study did 
not deliver a clinically relevant solution, it was fundamental in demonstrating 
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the role tissue engineering could play in solid tissue and organ growth with 
the appropriate choice of cells and scaffolds. 
 
 Figure 1.10. Photo taken from the original work of Cao and Vacanti demonstrating an ear 
shaped PGA scaffold seeded with bovine chondrocytes on the back of a mouse. 
Examination of constructs after 12 weeks demonstrated the presence of mature 
neochondrium with maintenance of 3-D architecture  (Cao et al. 1997). 
 
In selecting cells for auricular tissue engineering, scientists have explored the 
use of mature chondrocytes  (articular, costal and auricular), and a variety of 
stem cells including perichondrium, bone marrow and adipose derived MSC 
(Jessop et al. 2016).  
 
Chondrocytes have been shown to be able to produce neo-cartilage that 
resembles and functions like normal cartilage and is able to produce 
sufficient matrix to support 3-D structures (Cao et al. 1997). The application 
of chondrocytes is limited by the small amount of tissue able to be harvested 
without significant morbidity. This therefore requires cells to undergo serial 
expansion with a significant reduction in their chondrogenic phenotype with 
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increasing passage (C. Chung et al. 2006). However recent work has shown 
that with the addition of specific growth factors (bFGF) to the culture medium, 
auricular chondrocytes can be passaged to produce enough cells for 
auricular reconstruction without a significant reduction in their function from a 
small biopsy. These chondrocytes produced high quality cartilage that was 
rich in GAGs and elastin after 20 weeks in vivo implantation in a sheep 
model (Pomerantseva et al. 2016). 
 
In the only reported clinical application of tissue engineered cartilage in ear 
reconstruction, Yanaga et al peformed a 2 stage procedure where at the first 
stage cultured expanded auricular chondrocytes from the auricular remnant 
were injected into a pocket in the abdominal wall and left for 6 months. After 
this time, mature neo-cartilage had formed and was used in the 2nd stage to 
reconstruct the auricle. The authors report 2 - 5 year follow up with good 
retention of shape of the ear and no obvious signs of resorption (Yanaga et 
al. 2009). 
 
Both bone marrow MSC and adipose derived MSC have been shown to be 
able to undergo chondrogenesis in vitro in numerous published studies 
(Kemmis et al. 2010; Jiang et al. 2010; Diekman et al. 2010; Jakobsen et al. 
2009). The ease with which these cells can be harvested, and expanded with 
minimal change in their function makes them attractive candidates for use in 
tissue engineering. Despite these promising findings, the use of MSC in 
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auricular tissue engineering has been limited by the relatively small amounts 
of ECM produced (Shieh et al. 2004).  
 
Variations in the chondrogenic capacity of MSC from different anatomical 
sites has also been demonstrated with bone marrow MSC showing greater 
cartilage production than adipose MSC in patient-matched controls (A. H. 
Huang et al. 2005).  However these differences can be ameliorated with 
changes to the growth factors in the differentiation media with the addition of 
BMP-6 (Hennig et al. 2007; Diekman et al. 2009). However the addition of 
further growth factors is undesirable for clinical translation. 
 
Recently, a population of highly clonogenic and chondrogenic CD44+, 
CD90+ perichondral stem cells were described. These cells were isolated 
from human auricular perichondrium and were capable of long term 
expansion without any obvious loss of function. When injected in to nude 
mice they were able to generate 2cm pieces of mature elastic cartilage with 
both perichondrium and chondrium that maintained its structure for over 10 
months (Kobayashi et al. 2011). The minimal morbidity associated with 
harvesting perichondrium makes this source attractive, however the low yield 
of cells will require long periods of in vitro expansion prior to transplantation. 
Previous studies support the ability of chondroprogenitors derived from 
perichondrium to undergo serial expansion to the numbers required for 
auricular reconstruction whilst retaining their ability to differentiate in to 
chondrocytes and generate elastic cartilage (Yanaga et al. 2012; Van Osch 
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et al. 2000).  In vitro expansion is less of a logisitical problem in ear 
reconstruction as it is a staged, elective procedure and therefore could be 
planned around the required periods of in vitro growth. Furthermore the in 
vivo implantation in this model did not take into account the likely forces that 
would be placed on the structure in auricular reconstruction surgery. 
 
As discussed in Chapter 1.7.9, pericytes have demonstrated the ability to 
undergo chondrogenesis in vitro, and produce GAGs and collagens when 
implanted in vivo (Diaz-Flores, Gutierrez, Gonzalez, et al. 1991; Farrington-
Rock 2004). They have been shown to have a higher chondrogenic potential 
and chondroprotective function when compared to conventional MSC (Wu et 
al. 2016) (W. S. Khan et al. 2008).  
 
 




Able to produce high quality 
cartilage in vivo 
(Pomerantseva et al. 2016). 
 
Limited donor site 
availability. Loss of function 
with ex vivo expansion (C. 
Chung et al. 2006) requires 
additional growth factors to 
prevent loss of function 
(Pomerantseva et al. 2016) 
Bone marrow MSC Large body of evidence to 
support ability of BM-MSC to 
differentiate into 
chondrocytes in vitro and in 
vivo. 
Morbidity associated with 
harvest. Small quantities 
available. Production of ECM 
inadequate to support 3-D 




Adipose derived MSC Easy to harvest large 
volumes with minimal 
morbidity. 
Lower chondrogenic 
potential when compared to 
other sources of MSC (A. H. 
Huang et al. 2005), requires 
additional growth factors to 





Able to generate mature 
elastic cartilage in vivo 
(Kobayashi et al. 2011), no 
loss of function with serial 
passaging (Yanaga et al. 
2012; Van Osch et al. 2000). 
 
Low yield rates. Long term in 
vivo function not assessed. 
Pericytes A pure and defined 
population that can be 
isolated from any tissue 
(Crisan et al. 2008). Greater 
chondrogenic potiental when 
compared to other MSC 
(Hagmann et al. 2014). 
Shown to produce cartilage 
specific ECM in vitro and in 
vivo. 
No previous examination of 
their ability to engineer 
cartilage in vivo and maintain 
3-D structure. 
Table 1.7. Table detailing the advantages and disadvantages of different types of cells used 
in studies focused on auricular reconstruction. 
 
In addition to different cell types, numerous different biomaterials have been 
examined for their ability to support chondrogenesis and act as scaffolds for 
tissue engineering (Table 1.9). One of the most common groups of synthetic 
biomaterials tested are the aliphatic polyesters such as polyglycolic acid  
(PGA), polylactic acid  (PLA) and polycaprolactone  (PCL). These polymers 
have demonstrated the ability to support cell growth, differentiation and 
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production of cartilage ECM (Cao et al. 1997; Mahmoudifar & Doran 2010; 
Valonen et al. 2010). They are biodegradeable through hydrolysis of the 
ester linkages, however they produce acidic by-products which can cause 
local tissue reaction and also degradation of the engineered tissue (Puppi et 
al. 2010). In a rabbit model both PCL and PLA constructs were tested and 
lacked sufficient structural integrity to overcome the forces applied to them 
resulting in the detail and architecture of the 3-d structure being lost (Shieh et 
al. 2004). Furthermore, the degradation products of aliphatic polyesters have 
demonstrated antigenicity when implanted in immunocompetent animals 
(Nayyer et al. 2012). 
 
Naturally occurring biomaterials such as silk, chitosan, alginate and 
hyaluronic acid have also been used in cartilage tissue engineering (Awad et 
al. 2004; Wang et al. 2005). Whilst these naturally occurring biomaterials 
have demonstrated good bioactivity and ability to support chondrogenesis, 
problems with their long-term structural properties to maintain complex 3-D 
structures have been raised and require further long-term in vivo assessment 
(Sterodimas et al. 2009).  
 
Whilst these biomaterials have been used extensively, the use of natural 
products should be done with caution, especially in clinical application. 
Products derived from natural sources can show significant batch to batch 
variation due to inherent biodiversity and as such are poorly defined. Any 
product/cell that is intended for clinical use must have all elements defined 
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for both consistency and traceability (EU directives 2003/94/EC and 
2004/24/EC). In addition to this, those derived from animal products can 
induce immune responses and risk contamination with pathogens (Martin et 
al. 2005). 
 
Synthetic biomaterials offer potential advantages over natural alternatives by 
eliminating batch to batch variability and any risk of infection or 
immunogenicity. In addition to this they offer much greater tunability such as 
molecular weight, cross-linking, chemical composition, addition of growth 
factors, mechanical strength and degradability. The ability to consistently 
predict, control and reproduce these factors are especially advantageous for 
synthetic biomaterials as a construct for tissue engineering in clinical 
applications. This is particularly relevant to auricular engineering when much 
of the long term failure of previous biomatierials has related to unpredictable 















• Full, rapid and natural degradation  
(this is not always beneficial when 
long term support is needed eg 
bone) 




• Potential for transmission of 
pathogens 
• Lot to lot variability 
• Poor biomechanical properties 





• Minimal lot to lot variation 
• Mechanical and chemical properties 
easily altered 
• Cheap and easily scalable 
• Many currently in clinical use with 
FDA approval 





• Chronic inflammation 
• Biocompatibility hard to predict 
and must be tested 
• Incomplete degradation with 
harmful degradation products!
 
Table 1.8: Advantages and disadvantages of natural and synthetic biomaterials 
 
 
Recent developments in 3-D printing have allowed researchers to use 
imaging systems to design and print individual auricular shape scaffolds. 
Using computer-aided design, a CT scan of an ear was used to produce a 
PLA/PGA woven scaffold in the shape of a human ear. The scaffold was 
seeded with articular chondrocytes and after 12 weeks of in vitro growth 
showed mature cartilage and good mechanical strength (Y. Liu et al. 2010). 
Whilst this study showed promising results, 12 weeks of in vitro growth is not 
sufficient to determine of the biomaterials will retain sufficient integrity for 
long term in vivo use. 
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Biomaterial Advantages Disadvantages 
Silicone/silastic Cheap and easy to 
manufacture. 
High rates of extrusion and 
infection mean its use has 
been abandoned (Cronin 
1966). 
Medpore Reproducible charactersitcs. 
Relatively easy to 
manufacture and quick to 
implant. 
High rates of extrusion, 
infection and fracture (Romo 
& Reitzen 2008). 
POSS-PCU Porous structure promotes in 
growth of fibroblasts and 
blood vessels (Nayyer et al. 
2014). Has shown ability to 
support chondrogenesis of 
ADSC (Guasti et al. 2014). 
Biophysical properties similar 
to native elastic cartilage 
(Nayyer et al. 2014)  
No long term in vivo data. 
Not biodegradable so may 
encounter same problems of 
extrusion as medpore 
PLA/PGA/PCL Able to support growth and 
chondrogenesis of 
chondrocytes and also MSC 
populations. Can be 
manufactured in many 
different ways including 3-D 
printing (Y. Liu et al. 2010) 
Unable to maintain structure 
in long term in vivo studies . 
Acidic degradation products 
damaging to cartilage (Shieh 
et al. 2004)  
HA 
 
Highly biocompatible and 
naturally occurring 
component of ECM. Has 
shown ability to support 
chondrogenesis 
Heterogeneity of cartilage 
within constructs. No data on 
structural ability of HA to 
maintain 3-D architecture 
   
Table 1.9. Table detailing the advantages and disadvantages of different types of 





Plastic and reconstructive surgery is a surgical discipline that aims to restore 
form and function to patients. One of the major limiting factors in the ability of 
surgeons to reconstruct defects is adequate donor tissue that can be used 
without siginificant additional morbidity to the patient.  
 
In the case of ear reconstruction, the current gold standard tissue to replace 
the deficient cartilage of the ear is costal cartilage due to both the quantity 
required, and the necessary biomechanical properties. The burden of 
harvesting ribs for this purpose is significant and results in prolonged periods 
of in patient stay in hospital and can result in adverse scarring, chest 
deformity, pneumothorax and spinal deformity. It has therefore been long 
recognized that an alternative to costal cartilage would be advantageous.  
 
Synthetic structures have been used in ear reconstruction including silastic 
and Medpor® (porous poly ethylene), however their use has failed to gather 
widespread support due to high rates of infection, extrusion and fracture of 
the implants. Tissue engineering is an appealing alternative that could 
potentially deliver an autologous implant with the required biomechanical 
properties with minimal morbidity to the patient. The ultimate aim of 
engineering a suitable replacement for auricular reconstruction will require a 
cell source capable of chondrogenesis and producing sufficient cartilage 
ECM (GAGs and cartilage specific collagens) to maintain 3-D structure and 
detail whilst overcoming the external forces applied to the ear. In addition, a 
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suitable scaffold will be required to promote chondrogenesis and provide the 
structural and biomechanical support required whilst the neocartilage 
develops. 
 
Previous work on auricular engineering has used a variety of cell types and 
biomaterials. Chondrocytes have shown the ability to produce large amounts 
of neocartilage and ECM, however limited donor sites and the requirement 
for extended periods of in vitro growth to generate sufficient numbers have 
limited their clinical application. Conversely, MSC can be derived from 
multiple readily accessible sources and have shown the abilty to undergo 
extended periods of in vitro growth with minimal reduction in their function. 
However, longer term in vivo studies have demonstrated that MSC produce 
insufficient amounts of ECM to support 3-dimensional structures. Pericytes 
have recently emerged as candidates for cartilage tissue engineering. They 
are present in all vascularized tissues and represent the in vivo precursor of 
the MSC observed in vitro. Studies have demonstrated the abilty of pericytes 
to undergo chondrogenesis and produce cartilage specific ECM in vitro and 
in vivo. Comparative studies examing the chongrogenic potential of pericytes 
have shown enhanced chondrogenic function when compared to 
conventional MSC.  
 
The most widely investigated biomaterials in auricular engineering are the 
aliphatic polyesters such as polyglycolic acid  (PGA), polylactic acid  (PLA) 
and polycaprolactone  (PCL). They have demonstrated the ability to support 
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the growth of chondrocytes and stem cell populations both in vitro and in 
vivo, and the production of ECM. However, the degradation rates and acidic 
products of degradation have resulted in loss of architecture and mechanical 
stability in longer term in vivo studies. Therefore identification of novel 
polymers with the required biological and biomechanical properties are 
fundamental to the successful generation of a tissue engineered auricle. 
 
 
1.10 Thesis aims 
 
The aim of this thesis is to identify cells and polymer based substrates that 
can be used for human auricular tissue engineering. To do this, the thesis 
has been structured with the following general aims. Further details of the 
specific aims are contained within the relevant chapter. 
 
Tissue procurement  (Chapter 3) 
To establish a working biobank of human adipose tissue and adipose derived 
cells with all the appropriate ethical approval for subsequent research. 
 
Cell characterisation and isolation  (Chapter 4) 
To perform a detailed analysis and characterisation of the identity, location 
and frequency of pericytes within adipose tissue, and to develop methods for 




Polymer identification and analysis  (Chapter 5) 
To use high-throughput polymer microarray screening to identify potential 
substrates with high binding affinity for adipose derived pericytes. To 
examine and quantify the effect that these polymers have on the functions of 
pericytes with relevance to tissue engineering. 
 
Taken together these achievements would represent a clear advance in the 
steps towards the clinical translation of auricular tissue engineering. 
2 Materials and methods 
 
2.1 Tissue collection and processing 
 
Subcutaneous adipose tissue was collected from healthy adult volunteer 
donors undergoing cosmetic lipectomy procedures with prior written consent. 
A small number of samples were also collected from patients undergoing 
breast reconstruction surgery. Ethical approval for the collection, processing, 
storage and subsequent research was granted in November 2010 by South 
East Scotland Research Ethics Committee 03 (SESREC03). For full details 
of the process please see Chapter 3. Tissue was collected immediately after 
surgical removal and stored in sterile containers at 4°C until required for the 
preparation of SVF. 
 
2.1.1 Preparation of SVF 
 
Whole Fat 
Incisions were made using a scalpel in the adipose tissue to divide the 
Scarpa’s fascia and expose the superficial adipose tissue. Adipose tissue 
was mechanically minced prior to enzymatic digestion using a standard 
cheese grater that was cleaned with 70% IMS prior to use. Approximately 
150cc of grated adipose tissue was mixed with equal volumes of PBS and 
transferred to 50ml ‘Falcon’ centrifuge tubes  (Corning – 430828) and shaken 
vigorously for 30 seconds. Tubes were centrifuged at 1800rpm for 10 
minutes. After spinning, the tissue separated into 3 phases, oil at the top, fat 
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in the middle and blood and liquid at the bottom. The top and bottom phases 




50cc of lipoaspirate was transferred into each of 4 x 50ml ‘Falcon’ centrifuge 
tubes   (Corning – 430828) and then centrifuged at 1800rpm for 10 minutes. 
After spinning, the top and bottom layers were discarded, and the fat 
transferred to 4 fresh 50ml centrifuge tubes and made up to a total volume of 
50cc in each tube with PBS. Tubes were shaken vigorously for 30 seconds 
and then centrifuged at 1800rpm for 10 minutes. The top and bottom phases 





100ml of digestion solution (DMEM + 3.5% BSA + 1mg/ml type II 
collagenase) was added to the fat and transferred to the shaking water bath 
at 37°C 250rpm for 40 minutes. After 40 minutes the reaction was quenched 
by adding 40ml of FBS  (Gibco, 10270-106). 50ml of the solution was then 
transferred to each of 4 50ml falcon tubes and centrifuged at 1800rpm for 10 
minutes. The supernatant  (containing oily fat and adipocytes) was aspirated 
and the pellets resuspended in 25ml of PBS-5mM EDTA.  Clumps were 
disrupted as much as possible by pipetting up and down and any persistent 
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clumps discarded. The solution was then successively filtered through 
100µm and 70µm cell strainers  (Fisherbrand, 22363547).  The filtered 
solution was made up to a total volume of 50cc with PBS-5mM EDTA and 
centrifuged at 1500rpm for 10 minutes. Following centrifugation, the 
supernatant was aspirated and discarded and the pellet resuspended in 10ml 
of RBC lysis buffer and left at room temperature for 5-10minutes. Red cell 
lysis buffer was made from 2 stock solutions (stock 1 = 8.3g ammonium 
chloride in 1000ml water, and stock 2 of 20.59g Tris base in 1000ml water 
after adjusting pH to 7.65 with 1M hydrochloric acid). The final solution 
contains 9 parts of stock 1, and 1 part of stock 2 and the pH is adjusted pH to 
7.65 with 1M hydrochloric acid. 
 
20ml of PBS-5mM EDTA was added to the tube and the resulting suspension 
filtered through a 40µm cell strainer. The filtrate was made up to a total 
volume of 50ml with PBS-5mM EDTA and centrifuge at 1500 rpm for 10 
minutes. The supernatant was aspirated and discarded and the pellet  
(comprised of the SVF) was resuspended in 1ml of 2% FBS in PBS for 
counting and immunostaining.  
 
2.2 Flow cytometry 
 
2.2.1 Immunostaining of fresh adipose tissue for FACS 
 
Samples resuspended in 1ml of 2% FBS in PBS were stained for 20 mins in 
the dark on ice using the following antibodies and concentrations: 
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CD31 PE  (BD Biosciences – 555446) 1:100  
CD34 FITC  (BD Biosciences – 555821) 1:100 
CD45 APC Cy7  (BD Biosciences – 557748) 1:100 
CD146 Alexa 647  (AdB Serotec - MCA2141A647) 1:100 
Table 2.1. Antibodies and the concentrations used for FACS of adipose derived pericytes. 
 
Excess antibody was washed off by adding 3ml of PBS + 2% FBS and 
centrifuging for 5 minutes @ 1200rpm before being resuspended in PBS + 
2% FBS for FACS. 
 
To allow for appropriate set up of the flow cytometer, a sample with no stains 
added was collected. Samples were also stained in identical manner with 
matching isotype controls with all stains in a single sample - PE Mouse IgG κ 
Isotype Control  (BD Biosciences, 555749), FITC Mouse IgG1 κ Isotype 
Control  (BD Biosciences, 555748), APC Cy7 κ Isotype Control  (BD 
Biosciences, 557872), Alexa 647 Mouse IgG1 Negative Control  (AdB 
Serotec, MCA928A647). Compensation beads  (BD Biosciences – 552843) 
were stained with each of the individual antibodies to allow for any spillover 






2.2.2 Analysis of cultured cells by flow cytometry 
 
Cultured cells were washed with PBS and then covered with an appropriate 
amount of 0.25% trypsin  (Gibco, 25200-072)  (12 well plate = 100µl / well, 
T75 flask = 1ml) and placed in the incubator for 5 minutes to detach the cells. 
20 times the volume of SGM was added to each well to quench the action of 
the trypsin. The solution was then transferred to a 15ml or 50ml centrifuge 
tube and centrifuged at 1000rpm for 5 minutes. The supernatant was 
aspirated and the cells resuspended in an appropriate volume of 2% FBS in 
PBS for immunostaining.  
 
Multicolour panels of antibodies were established based on available 
fluorochromes for pericyte and MSC markers. All antibodies were used at a 
concentration of 1:100, and samples were stained for 20 minutes on ice in 
the dark. Excess antibody was washed off by adding 3ml of 2% FBS in PBS 
and centrifuging for 5 minutes @ 1200rpm before being resuspended in 2% 
FBS in PBS for analysis. In addition to the stained samples, matched isotype 
controls, individual compensation beads and an unstained sample were all 
processed. 
 
2.3 Long term culture of pericytes 
!
The Standard Growth Medium  (SGM) used in the culture of pericytes was 
DMEM + Glutamax  (Gibco, 61965-026), with 20% FBS  (Gibco, 10270-106) 
and 1% Penicillin / Streptomycin  (Sigma, P4333). 
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Passage 0: For the first passage, cells were cultured on gelatin coated 
plates. To prepare the plates, 200µl of 0.1% gelatin  (Sigma - G1393) was 
added to each well of a 12 well plate and left for 10 minutes at 4°C before 
excess gelatin was aspirated and discarded. Immediately following sorting, 
the pericyte containing solution was centrifuged at 1500rpm for 5 minutes. 
The supernatant was aspirated and discarded and the cells resuspended in 
EGM2  (Lonza - CC-3162) to give a final concentration of 20000 cells/ml. The 
cell containing solution was pipetted to the gelatin coated 12 well plates at a 
density of 40000 cells/cm2 and transferred to a humidified incubator. Media 
was changed every 5 days until cells reached confluency.  
 
Passage 1: When confluent, wells were washed with PBS and then covered 
with 100µl of 0.25% trypsin and placed in the incubator for 5 minutes to 
detach the cells. 2ml of SGM was added to each well to quench the action of 
the trypsin. The solution was then transferred to a 15/50ml centrifuge tube 
and centrifuged at 1000rpm for 5 minutes. The supernatant was aspirated 
and the cells resuspended in an appropriate volume of SGM. Cells were split 
in a 1:6 ratio and transferred to uncoated cultureware. 24 hours after plating, 
the media was aspirated and discarded to remove and dead and non-
adherent cells. Cells were washed with PBS and re-covered with SGM which 
was changed 3 times per week until confluent.  
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Passage 2 onwards: For all subsequent passages cells were split as above 
and replated at a ratio of 1:6 and cultured in SGM. 
 
2.3.1 Cryopreservation of PSC 
 
Cells were stored for subsequent experiments in frozen cryovials with one 
confluent T75 flask per cryovial. Cells cultured in T75 flasks had media 
aspirated and were rinsed with PBS. 1ml of 0.25% trypsin was added to each 
flask and placed in an incubator for 5 minutes. 10ml of SGM was added to 
each flask and the cell containing solution transferred to 50ml falcon tubes 
and centrifuged at 1200rpm for 5 minutes. Supernatant was aspirated and 
discarded and the pellet was resuspended in 1ml of freezing media  (FBS + 
10% EDTA) for each T75 flask of cells. The freezing media and cells were 
vortexed to ensure the cells were equally distributed and 1ml of solution was 
transferred to a labeled 1.5ml cryovial. Cryovials were placed in the wells of a 
Mr Frosty™  (Thermo Scientific) freezing container and placed in a -80°C 
freezer for a mimumum of 24 hours. Cells stored for less than 3 months 
could then be transferred to a standard container within the -80°C freezer, 
those to be stored for periods greater than 3 months were transferred to 
liquid nitrogen storage tanks. 
 
Thawing of cryopreserved PSC 
When required, cells were retrieved from the -80°C freezer or liquid nitrogen 
and transported to the tissue culture laboratory on dry ice. Cryovials were 
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rapidly thawed at 37°C in a waterbath and the solution of freezing media and 
cells transferred to a 50ml falcon tube and resuspended in an appropriate 
volume SGM. Depending on requirements, 1 cryovial was replated in a ratio 
of 1:1 to 1:4 in T75 flasks. 
 
2.4 Immunohistochemistry of adipose tissue 
 
Fresh whole subcutaneous adipose tissue was cut into pieces of 
approximately 1cm3. The pieces of adipose tissue were washed thoroughly in 
PBS to remove blood and then fixed overnight in 4% paraformaldehyde  
(PFA) at 4°C. 
 
Samples were removed from PFA, washed 3 times in PBS and immersed in 
solutions of increasing concentrations of sucrose in PBS at 4°C. 10% 
sucrose for 1 hour, followed by 20% sucrose for 1 hour, followed by 30% 
sucrose overnight. 
 
Samples were removed from sucrose and placed in OCT containing foil 
molds and allowed to soak for 20-30 minutes. Samples were then freeze 
dried on dry ice and stored at -80°C until required. Frozen human adipose 
tissue was cut in 10µm section using a cryostat at -50° C and mounted on 
Superfrost™ Plus microscope slides  (Fisher Scientific). 
 
Day one: The slides with the adipose tissue were taken out of the -80°C 
freezer and left at room temperature for 30mins to air dry. Sections were then 
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fixed in a solution of ice cold Methanol/Acetone  (50:50) for 10 minutes. 
Slides were then washed in PBS/Tween 20, three times for five minutes 
each. Sections of the slides without specimen on were dried using a tissue 
and then the sections were drawn around using a wax pen. Sections were 
blocked with protein block  (Dako) and incubated for one hour at room 
temperature. Slides were then washed with PBS/Tween20, three times for 5 
min each. Slides were then incubated overnight at 4°C with primary 
antibodies  (Table 2.1) diluted at 1:100 in antibody diluent  (Dako). Typically 
100µl of antibody containing solution was added to each slide, however this 
would vary depending on the size of the sample.  
Second day: Slides were washed with PBS/Tween20 three times for 5 
minutes, to remove the primary antibody. Secondary antibodies  (goat-anti-
rabbit Alexa Fluor 546/ goat-anti-rabbit Alexa Fluor 488/ goat-anti-mouse 
Alexa Fluor 488) diluted at 1:600 in antibody diluent were then added in 
equal volumes to the primary antibody. The secondary antibodies were 
incubated for 1 hour at room temperature in the dark. After incubation, 
samples were washed with PBS/Tween20 three times for five minutes each.   
For co-staining with unconjugated second antibodies, the previous stages 
were repeated. For co-staining with conjugated secondary antibodies, 
samples were blocked with protein block  (Dako) at room temperature for one 
hour. Subsequently conjugated secondary antibodies diluted at 1:100 in 
antibody diluent  (Dako) were added and incubated at RT for 2 hours. After 
incubation, slides were washed with PBS/Tween20 three times for 5 minutes 
each followed. Finally, Fluorescent Media with DAPI counterstain was 
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mounted and the slides were cover slipped. Samples were visualized using 
an upright widefield Olympus BX61 microscope. 
 
Target protein  Supplier Catalog No. 
αSMA Sigma-Aldrich, St. Louis, MO, USA F3777 
CD146 Abcam Inc, Cambridge, MA, USA ab75769 
CD34 Abcam Inc, Cambridge, MA, USA ab54208 
PDGFRβ Abcam Inc, Cambridge, MA, USA ab32570 
NG2 Abcam Inc, Cambridge, MA, USA ab83508 
CD31 Abcam Inc, Cambridge, MA, USA ab76533 
CD90 Abcam Inc, Cambridge, MA, USA ab92574 
vWF Sigma-Aldrich, St. Louis, MO, USA F3520 
CD105 R&D Systems, Minneapolis, MN, 
USA 
MAB10972 
OCT4 Santa Cruz Biotech, Santa Cruz, 
CA, USA  
sc-5279 
NANOG Santa Cruz Biotech, Santa Cruz, 
CA, USA 
sc-30332 
Table 2.2: Antibodies used for immunostaining of adipose tissue and pericytes. 
 
2.5 Immunocytochemistry of cultured cells 
 
Cells were cultured to desired confluency in 12 well plates, or on standard 
glass coverslips and placed in 12 well plates. Wells were washed twice in 
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PBS and cells were then fixed in ice cold methanol for 10 minutes before 
being washed twice again in PBS. Blocking was performed for 30 minutes 
with protein block (Dako), followed by a single wash with PBS/Tween20. 
Finally, the cells were covered with the appropriate primary antibody. 100µl 
of the antibody diluted 1:100 with antibody diluent  (Dako) was added to each 
well. For the negative controls, only PBS was added to the well in place of a 
primary antibody. Plates were then covered with foil and incubated overnight 
on a rocking platform in a cold-room  (4°C).  
 
The next day, the wells were washed for 5 minutes, three times in PBS-
Tween20 in a rotating plate. For primary conjugated antibodies, wells were 
allowed to air dry before 1 drop of DAPI-containing mountant was added and 
then coverslips placed in each well and left to dry in the dark. For 
unconjugated primary antibodies, each well was treated with a secondary 
antibody for one hour at room temperature in the dark. The secondary 
antibodies were made up at a 1:400 in antibody diluent. After one hour, wells 
were washed for 5 minutes, three times in PBS. Wells were left to air dry 
before one drop of DAPI mounting medium was added to each well and a 
small coverslip was dropped into the wells. To make sure that there were no 
bubbles, coverslips were pressed lightly. The samples were imaged by a 





2.6 Differentiation protocols and quantification 
 
As detailed in the criteria described by the ISCT to define MSC, cells must be 
able to demonstrate differentiation to adipocytes, osteoblasts and 
chondrocytes in vitro (Dominici et al. 2006). Many different protocols to do 
this have been published, but all rely on the addition of a variety of growth 
factors to media. In addition, many ‘off the shelf’ differentiation kits are 
available. To establish that cells had differentiated, functional stains were 
performed as detailed below. In addition, and where possible, quantification 
of differentiation was performed as described below. 
 
Pericytes were grown in T75 flasks in SGM until sufficient numbers of cells 
were obtained. Flasks had media aspirated and were rinsed with PBS. 1ml of 
0.25% trypsin was added to each flask and placed in an incubator for 5 
minutes. 20mls of SGM was added to each flask and the cell containing 





Cells were then transferred to 12 well plates with 20,000 cells in each well in 
2ml of SGM. Cells were then placed in an incubator and allowed to attach 
and grow to 40% confluency (approximately 48hours). Media was aspirated 
and then rinsed with PBS. 1ml of adipogenic media (StemPro® Adipogenesis 
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Differentiation Kit, Gibco) was added to each well and plates returned to the 
incubator. Media was changed 3 times per week for a total of 3 weeks. 
Controls were performed by using SGM instead of adipogenic media. 
 
Assessment of adipogenesis - Oil red O staining 
Wells were washed four times with PBS. 4% PFA was added to the wells and 
incubated at 37oC for 10mins, before washing four times with ddH20. ddH2O 
was aspirated and 60% isopropanol was added for 5 minutes at room 
temperature. Wells were then dried without washing, before adding 1ml of Oil 
red O solution and incubating at room temperature for 10 minutes (Working 
solution made by adding 6mls of oil red O stock to 4 mls distilled water). 
Wells were then washed with ddH2O four times.  
 
Quantification of adipogenesis 
Adipogenesis was quantified using an Oil Red O elution assay  (Chemicon® 
International – ECM950). Following 3 weeks of differentiation in adipogenic 
growth media cells were fixed and stained with Oil Red O as described 
above. Following this, 0.5ml of Dye Extraction Solution was added to each 
well and transferred to an orbital shaker for 15 minutes. 150µl of the solution 
was then transferred in triplicate to the wells of a 96 well plate and quantified 







Cells were transferred to 12 well plates with 10,000 cells in each well in 2ml 
of SGM. Cells were then placed in an incubator and allowed to attach and 
grow to 25% confluency (approximately 48hours). Media was aspirated and 
then rinsed with PBS. 1ml of osteogenic media (StemPro® Osteogenesis 
Differentiation Kit, Gibco) was added to each well and plates returned to the 
incubator. Media was changed 3 times per week for a total of 3 weeks. 
Controls were performed by using SGM instead of osteogenic media. 
 
Assessment of osteogenesis - Alizarin Red staining 
Wells were washed four times with PBS, and then 4% PFA was added and 
incubated at room temperature for 30 minutes. Wells were then washed four 
times with ddH20, after the ddH2O was aspirated 1ml of alizarin red solution 
added to each well for 30 minutes. Wells were then washed with ddH2O four 
times. Plates could either be processed/imaged immediately or stored at -
20°C until required.  
 
Quantification  
800µl of 10%  (v/v) acetic acid was added to each well and incubated for 30 
minutes at room temperature on a rotating platform. The loosely attached 
monolayer of cells was removed with cell scraper if necessary and 
transferred with the 10% acetic acid to a 1.5ml microcentrifuge/eppendorf 
tube and vortexed for 30 secs. The solution was then heated to 85°C for 10 
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minutes, before being transferred to ice for 5 minutes. It was then centrifuged 
at 20,000g for 15 minutes, before 500µl of the supernatant was transferred to 
a new 1.5ml microcentrifuge tube. 200µl of 10%  (v/v) ammonium hydroxide 
was added to neutralize the acid. 150µl aliquots of the supernatant were 
transferred in triplicate  (or more if required) into the wells of a 96 well plate. 





Cells were then transferred to 12 well plates with 20,000 cells in each well in 
2ml of SGM. Cells were then placed in an incubator and allowed to attach 
and grow to 50% confluency (approximately 48hours). Media was aspirated 
and then rinsed with PBS. 1ml of chondrogenic media (StemPro® 
Chondrogenesis Differentiation Kit, Gibco) was added to each well and 
plates returned to the incubator. Media was changed 3 times per week for a 
total of 4 weeks. Controls were performed by using SGM instead of 
chondrogenic media. 
 
3-D culture (pellet) 
Solution of SGM containing 100,000 cells/ml was prepared and 3ml added to 
a 15ml centrifuge tube. Tubes were centrifuged at 300g for 3 minutes and 
then transferred to the incubator. Over 48 hours the cells condensed to a 
pellet that was freed from the sides/bottom of the tube by gentle agitation. 
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SGM was carefully aspirated to avoid aspiration of the pellet and replaced 
with 1ml of chondrogenic media (StemPro® Chondrogenesis Differentiation 
Kit, Gibco). Media was changed 3 times per week for a total of 4 weeks and 
at each change the pellet was freed from the bottom of the tube. Controls 
were performed by using SGM instead of chondrogenic media. 
 
Assessment of chondrogenesis - Alcian Blue staining   
Pellets were removed from the centrifuge tubes and air dried for 20 minutes 
before being placed in the bottom of OCT containing foil molds. Samples 
were then freeze dried on dry ice and stored at -80°C until required. Frozen 
pellets was cut in 10µm sections using a cryostat at -50° C and mounted on 
Superfrost™ Plus microscope slides  (Fisher Scientific). 
 
Wells/slides were washed four times with PBS and then 4% PFA was added 
and incubated at room temperature for 10 mins. Wells/slides were washed 
four times with ddH20, and then Alcian Blue solution  (1% Alcian Blue in 1% 
Acetic acid) was added to each well/slide for 15 minutes (1ml per well, 100l 
per section). Wells/slides were washed with ddH2O four times. 
 
Quantification of chondrogenesis (monolayer) 
0.5ml of 1M HCl was added to each well and placed on a rotating plate for 30 
minutes. 150µl aliquots of the supernatant were transferred in triplicate  (or 
more if required) into the wells of a 96 well plate. Readings were made at 




The polyacrylate/acrylamide library was synthesised by Dr. Mizomoto, and 
the polyurethane library was synthesised by Dr. Thaburat under the 
supervision of Professor Mark Bradley  (University of Edinburgh).  
 
2.7.1 Preparation of agarose coated slides 
 
Glass slides were placed in to 1M NaOH for 4 hours and then rinsed with 
distilled water followed by 100% acetone. Glass slides were then air dried 
before being immersed in an acetonitrile solution of 2-amine ethyl 
trimethoxysilane  (1% wt/v) for 1 hour. The glass slides were then washed 
with acetone and placed face down on an aluminium foil-lined tray in a 
vacuum oven at 100oC for 2 hours. The glass slides were then dip-coated in 
1% agarose aqueous solution at 60oC. Agarose was wiped from the 
underside and the agarose coated glass slides were air dried for 24 hours 
before being used for printing. 
 
2.7.2 Printing of microarrays 
 
Polymers were contact printed onto agarose coated slides using a Q-
arrayermini  (Genetix, UK), using aQu solid tipped pins  (K2785, Genetix, UK) 
inked from a 384 well plate containing 1%  (w/v) polymer solutions in N-
methylpyrrolidone  (NMP). Each spot was stamped 5 times with 200ms 
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inking time and 100ms stamping time resulting in spots of an approximate 
diameter of 310µm. For the initial screen polymers were printed in 
quadruplicate in a 8 x 48 pattern with 2 empty areas resulting in 1536 dots of 
382 discreet polymers. Slides were dried in a vacuum oven at 40 °C 
overnight. 
 
2.7.3 Screening of microarrays 
 
Each polymer spot was printed on the slide in quadruplicate to act as an 
internal control, and each sample was screened in duplicate to act as an 
external control. The polymer microarray screen was performed with 4 
separate patient samples  (n=4), and flow cytometry prior to use assessed 
the purity of each sample. Slides were placed in 4 well slide trays and 
sterilised for 30 minutes under UV light. Pericytes were suspended in SGM at 
a concentration of 100,000 cells/ml, and 5ml of the cell containing media was 
placed on each slide. Slides were then placed in an incubator  (37°C + 5% 
O2) for 24 hours. At the end of the incubation, slides were washed in PBS for 
5 minutes on a rotating plate to remove any non-adherent cells or loosely 
attached cells. Cells were fixed by immersion in ice cold methanol for 10 
minutes then rinsed in PBS for 5 minutes before being left to air dry. 
Coverslips were attached using DAPI containing mountant  (Vectashield, 
Vector Laboratories). Analysis of the binding of cells to the polymer spots 
was performed using a high resolution, high content screening  (HCS) 
platform equipped with a Nikon 50i fluorescence microscope  (x20 objective) 
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with a motorised X-Y-Z stage. The automated scanning platform is 
programmed to capture multiple channel  (DAPI, FITC, bright field) high 
resolution images for each spot at defined intervals based on the spatial 
arrangements of the polymer spots on the microscope slide.  The microscope 
is equipped with Pathfinder™ software that performs automated analysis of 
the captured images allowing rapid analysis of multiple parameters including 
cells number, shape, size and fluorescence intensities. 
Data was analysed using Graphpad software. Overall differences between all 
groups were calculated using Kruskall-Wallis test, and differences between 
individual groups and controls were calculated using Dunnett’s multiple 
comparison test  (One way ANOVA), which allows multiple groups to be 
compared to control.  
 
2.7.4 Spin coating 
 
22mm diameter glass coverslips  (Menzel-Gläser, Germany) were cleaned 
with tetrahydrofuran  (THF). 60µl of each of the polymer solutions  (PA133, 
136, 337 and 338 in 2.0% w/v in THF, PA210 2.0% w/v in NMP) was placed 
onto the coverslips and spin coated for 2 seconds at 2000 rpm using 
spincoater Model P6700 Series  (Specialty Coating Systems, Inc). Coverslips 
were dried in a vacuum oven overnight at 45 °C / 200 mbar, and irradiated 
with UV light for 20 minutes prior to use. 
3 Analysis of patients attitudes towards the donation of 
adipose tissue for medical research, and the 
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In this chapter the legal, ethical and practical issues relating to the banking of 
human adipose tissue for research in the UK are examined, with reference to 
international guidelines and regulations. An analysis of the perceptions of 
patients towards donating tissue was performed using a questionnaire aimed 
to help with the design of appropriate information sheets and tailor the 
application to the needs of the researchers without compromising the 
expectations of the patients. The experiences of establishing a research 
tissue bank  (RTB) are shared, including the necessary infrastructure and the 
submission of an application to a Research Ethics Committee  (REC). 
 
Stem cells are central to regenerative medicine, and understanding these 
cells is fundamental to developing new treatments. One of the challenges 
facing regenerative medicine is finding suitable, safe and ethical sources of 
stem cells for both research and therapy. Native stem cells come in many 
forms from the totipotent and pluripotent cells found in the morula and 
blastocyst respectively,through to multipotent, bipotent and unipotent stem 
cells found in adult organisms (Kørbling & Estrov 2003). Embryonic Stem 
Cells  (ES) are pluripotent cells derived from the inner cell mass of early 
embryos, and offer huge promise in regenerative medicine. However their 
collection, storage and use raises many ethical concerns. In addition, their 
application is more strictly regulated in comparison to adult stem cells such 
as mesenchymal stem cells  (MSC). MSC are multipotent cells that are 
capable of differentiating into bone, cartilage, fat, muscle and tendon (Caplan 
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1991). In addition, MSC secrete many bioactive molecules that are 
immunomodulatory, anti-apoptotic, anti-fibrotic, angiogenic and mitotic 
therefore suggesting a general regenerative function not just limited to 
differentiation into cells of a mesenchymal lineage (Caplan & Correa 2011). 
The discovery that these cells can be found in almost all postnatal tissues is 
of particular interest in their clinical application as it means that cells that are 
broadly identical in their function and phenotype can be isolated from 
redundant tissue such as placenta or deciduous teeth, or from dispensable 
sources such as adipose tissue. 
 
Access to human tissue is critical to medical research, however the laws and 
regulations surrounding gaining ethical and legal access to tissue are often 
poorly understood. Recently, there has been a huge increase in the interest 
surrounding the therapeutic application of adipose tissue, and adipose 
derived stem cells. Adipose tissue is easily accessible and readily abundant 
even in individuals of healthy weight and therefore offers an excellent source 
of stem cells (Gimble et al. 2007). As plastic surgeons routinely remove large 
volumes of adipose tissue through reconstructive and cosmetic procedures, 
this has resulted in many surgeons being either directly or indirectly involved 
in research using adipose-derived stem/stromal cells  (ASC). In addition to 
ASC, adipose tissue is also an excellent source of adipocytes, endothelial 
cells and vascular smooth muscle cells. In cases where there is excision of 
redundant skin there are also abundant dermal and epidermal cells. 
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The chondrogenic potential of ASC has been demonstrated in vitro and in 
vivo (Diekman et al. 2010; Betre et al. 2006; Awad et al. 2004). Their ability 
to generate chondrocytes has been shown to be equal to bone marrow 
derived MSC with minor alterations to the differentiation protocols (Hennig et 
al. 2007). In addition, subsets of stem cells within adipose tissue with highly 
chondrogenic potiential have been identified (W. S. Khan et al. 2008). 
Therefore adipose tissue is an excellent source of cells with potential for 
auricular tissue engineering. 
 
Tissue banks (or biobanks) represent a broad and heterogenous range of 
facilities. They may include small collections of tissue with minimal 
associated data held by a single institution, through to population wide 
biobanks collecting a variety of tissue and specimen types along with 
comprehensive medical and epidemiological data (Asslaber & Zatloukal 
2007; Riegman et al. 2008). An example of the latter is The UK Biobank that 
is a multisource-funded initiative that has recruited over 500,000 participants 
and was opened to access by researchers in 2012 (www.ukbiobank.ac.uk).  
 
In their broadest context, tissue banks collect and store biological materials 
that may be accompanied with varying amounts of medical, demographic 
and epidemiological data. They are linked with current  (planned) research, 
but also serve to facilitate future research. They are continuous projects 
where material and data are collected on a prospective and long term basis. 
They apply procedures to ensure anonymity, whilst under specific conditions 
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allow clinically relevant information to be traced back to the donor and 
accessed by authorised parties. They serve to protect the rights of donors 
and the interests of researchers by incorporating relevant governance 
legislation (eg. ethical committee review) and procedures (eg. anonymity and 
consent) (Yuille et al. 2009). It is this last feature that distinguishes a biobank 
– a facility that facilitates access to outsiders - from a research collection 
(Gottweis & Petersen 2008).  
  
The integrated research application system (IRAS) provides a single point of 
application for all research ethics applications in the UK. It is supported by 
many of the research-associated charities, organisations and legislative 
bodies including the Human Tissue Authority and NHS Research & 
Development.  Apart from receiving applications for ethical review, the REC 
are a valuable source of information and advice to facilitate good practice. 
 
The application system is accessed via their website  
(https://www.myresearchproject.org.uk) where applicants must register an 
account prior to submitting an application. Once registered, applicants are 
required to complete a Project Filter Questionnaire that asks basic questions 
about the proposal, and based on these answers compiles a project specific 
application form. This application form is a mandatory part of the final 




• Application form (mandatory) 
• Protocol for management of the tissue bank (mandatory) 
• Participant Information Sheet 
• Participant Consent Form 




Based on the answers given in the Project Filter Questionnaire, an 
application form specific to the proposed project is generated. This contains 
general information such as where the project will take place, and those 
persons responsible for the project. There are also a number of questions 
that specifically address the issues relating to tissue banking including; 
• Tissue 
o What type(s) of tissue are to be collected 
o Where will this tissue be collected 
o What is the intended use of this tissue 
• Consent 
o What is the planned process of consent 
o Does the project include vulnerable adults or children unable to 
consent 
• Confidentiality and access to data 
o What level of confidentiality is proposed 
o Who will have access to this data 
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o What safeguards are in place to provide this 
o If relevant how will relevant findings be notified to patients 
• Access to tissue 
o How will external researchers access tissue/data and what 
processes are in place to facilitate this 
o What information will be released with the tissue 
o Does the bank want to seek generic ethical approval for all 
subsequent research 
o Is there any potential commercial exploitation of the tissue 
The Human Tissue Act 
 
The collection, storage and subsequent use of human tissue is regulated in 
England, Wales and Northern Ireland by The Human Tissue Act  (2004), and 
in Scotland by The Human Tissue  (Scotland) Act 2006. The legislation in 
Scotland focuses on three principal areas: 
1. Organ / tissue donation for the purposes of transplantation, research, 
teaching and audit  
2. Organ / tissue removal and storage as part of post mortem 
examination.  
3. Donation of bodies / organs / tissues for use under The Anatomy Act 
1984.  
Although The Human Tissue (Scotland) Act 2006 aims to address the use of 
tissue for research, it does not directly address the issue of donation of 
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surplus tissue from live donors for research - the most likely scenario in 
adipose tissue banking. However, it does refer to the use of human tissue 
from the deceased for research, and also the use of tissue from live donors 
for transplant. In each of these occasions it states that the stance of the 
Scotland Act is to promote equity across the UK, and that their legislation 
mirrors that of the Human Tissue Act (2004). The HTA requires all tissue 
banks to have a license from the HTA (except in Scotland). Most NHS and 
research sites will have a HTA license and the local tissue governance team 
were contacted prior to the application to get details of this. 
There are no formal or legal requirements for tissue banks to obtain ethical 
approval under the Human Tissue Act or NHS research and governance 
systems. However any research using the tissue will require individual 
project based ethical approval. If a RTB seeks ethical approval there is an 
option to seek generic ethical approval prospectively for any subsequent 
research using the tissue. Under these circumstances the establishment 
and/or persons responsible for the RTB assume responsibility for only 
releasing tissue to third parties whose planned research meets the conditions 
of the original RTB ethical approval. This has many benefits if the bank plans 
to supply multiple similar but unrelated projects, and prevents repeated 
applications to the REC. An example would be to specify that tissue is to be 
used in research projects within the field of regenerative medicine. This 
would satisfy the REC that the research was focused, but also allow multiple 




Consent is the process by which a person gives permission for an action to 
happen. In this context it refers to patients consenting to donate their tissue 
for research. For this consent to be informed and valid, it must be an 
autonomous action by a subject that authorises a professional to involve the 
subject in research. Informed consent is given if: 
“a subject with substantial understanding in the absence of control by others 
intentionally authorizes a professional to perform a procedure.” 
 (Ruth R. Faden Johns Hopkins University School of Public HealthTom L. 
Beauchamp Georgetown University 1986). 
 
It is stated by the General Medical Council (GMC) in their publication Good 
Medical Practice that any doctors who are involved in research: 
 
“must be satisfied that you have consent or other valid authority before you 
carry out any examination or investigation, provide treatment or involve 
patients or volunteers in teaching or research.” 
 
This includes the use of patients’ organs and tissues. 
It might be assumed that consent is a mandatory requirement under all 
circumstances, however this is not the case. Consent is always required to 
remove tissue from the deceased for research purposes under the HTA.  It is 
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also required under common law to remove tissue from the living; however 
this consent may be for a diagnostic or therapeutic intervention and not 
explicitly for research. Specific consent for use of tissue in research is not 
required if the tissue is from a live donor, who can’t be identified by the 
researcher, and the research has been ethically approved.  Other significant 
exceptions under the HTA include: 
 
• Tissue which was collected prior to the introduction of the HTA  
• Imported tissue  
 
Despite this, it is regarded as good practice to obtain consent when collecting 
tissue from living donors wherever possible (Andrews 2005), and that this 





Confidentiality refers to the promise not to disclose information about the 
donor that they do not wish to be disclosed. Whilst this is of paramount 
importance, there are a number of practical and ethical issues that should be 
considered. For example, if absolute confidentiality is desired this is 
logistically very difficult if not impossible to achieve. Additionally, any findings 
associated with the tissue that cannot be linked back to information regarding 
the sample or to the patient, may limit its utility. 
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For the purposes of detailing confidentiality, a nomenclature of hierarchy has 
been established (Bauer et al. 2004): 
 
• Anonymous: The source of the tissue was never known 
• Anonymised: The identity of the source of the tissue is irreversibly 
unlinked from the specimen. 
• Identifiable or linked anonymised: The tissue and donor are indirectly 
linked (eg. an ID number), but the identity can only be found by tracing 
that link. 
• Identified: The tissue source is known and the identity is directly linked 
to the sample. 
 
In practical terms, the level of confidentiality should be tailored to the 
intended applications of the tissue bank and those persons or institutions 
wishing to utilise it. For research that focuses on specific conditions or 
diseases then the ability to link that specimen with demographics and 
medical data is essential and therefore anonymous donation may be 
undesirable. It has even been argued that under these circumstances, 
doctors have a moral obligation to ensure that the relevant data is collected 
to maximize the benefit derived from the tissue (Secko et al. 2009). If 
confidential information, such as that disclosed in medical records, is to be 
accessed, then further safeguards will be required to protect the 
confidentiality of the donor and anyone else associated with that data. 
However, if the intended use does not require medical and demographic 
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data, then anonymous or anonymised donation may be preferable. In the 
case of an adipose tissue bank, such as the one proposed for the work in this 
thesis, the principle purpose is to provide cells for research into regenerative 
medicine and tissue engineering. Therefore it is unlikely that any significant 
amount of demographic or medical data is necessary. Patients undergoing 
elective cosmetic surgery represent a fairly unique cohort as they are 
predominantly female, middle aged and free from significant disease and 
pathology (West et al. 2014).  
 
Whatever standard of confidentiality is proposed and adopted by a tissue 
bank, it should be explicitly detailed and explained to the donor as part of the 
consent process. In addition, satisfactory infrastructure should be in place to 





There is a general sense of anxiety surrounding the commercialisation of 
human tissue. Many believe that seeking to make profit from human tissue 
transgresses the principles of altruistic donation on which we rely (Wilkinson 
2005). However there are clear benefits, not just financial, that can be gained 
through commercialisation. 
 
The MRC and GMC state that there should be no financial incentives made 
to the donors, as this may compromise the process of informed consent. 
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When there is a financial incentive to participate in research or donate tissue 
this may affect the voluntary nature of taking part. It is also likely to influence 
people to do things or accept risks that they would not do were that incentive 
to be removed. Payment of reasonable costs and expenses that are incurred 
by the participant are entirely appropriate (MRC 2001).  
 
Both the GMC and the MRC are very clear in stating that human tissue 
should not be used for financial gain (MRC 2001). Any financial remuneration 
for supplying tissue to third parties should be limited to recovering 
administrative costs and doctors should not be involved directly, or indirectly 
in buying or selling tissues. There are a number of private sector companies 
operating within the UK offering monetary donations to surgeons able to 
supply tissue, including adipose tissue. As previously stated, this money 
should be used to recover costs and associated administration charges and 
not for personal gain.   
 
Any intellectual property that is gained from research using human tissue can 
legitimately be exploited for financial gain. Indeed it should be encouraged 
and facilitated. Commercial sector access to human tissue is fundamental to 
the discovery and delivery of new medicines and pioneering techniques, 
which are of immense benefit to the public. It also provides industry with 
additional incentives to invest in academic research that might otherwise not 
receive funding (MRC 2001). 
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There is a general grey area surrounding what amount of intellectual property 
needs to be added to human tissue to allow it to be a commercially 
exploitable commodity. Some argue that the labour associated with 
collecting, processing and storing tissue is in itself enough to allow the tissue 
to be sold. However, others suggest that significant changes from the starting 
tissue, such as the generation of immortalised cell lines, are required to 
satisfy the addition of substantial intellectual property (Lock 2001; Andrews 
2001). 
 
It is fundamental to the consent process that any planned or potential 
commercial activity relating to the tissue is fully explained to the participants. 
It should also be stated that the participant is not entitled to any share of any 




Regenerative medicine and tissue engineering is a rapidly expanding area of 
medical research that shows huge potential in the treatment of many 
diseases including microtia and acquired ear deformities. Access to ethically 
sourced human tissue is fundamental to research and the ultimate delivery of 
successful new treatments. At the outset of this work there was no provision 
to collect or store adipose tissue, or adipose derived stem cells within the 
University of Edinburgh or NHS Lothian. 
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Adipose tissue represents an excellent potential source of stem cells due to 
the relative ease with which it can be safely harvested and the quantities of 
tissue available. Studies have also demonstrated the multipotential ability of 
ASC and the subsets of cells contained within it. Studies examining the 
potential role of adipose tissue and adipose derived stem cells specific to 
chondrogenesis and cartilage tissue engineering have demonstrated the 
chondrogeneic potential of ASC, and also identified chondrogenic subsets of 





1. To investigate the attitudes of patients towards the donation of 
adipose tissue for research. 
 
2. To use this knowledge to design appropriate patient information 
sheets and consent forms, and to decide the most appropriate model 
for a tissue bank. 
 
3. To apply for ethical approval to establish a biobank of adipose tissue 
and adipose derived cells with the appropriate ethical approval for all 
subsequent research 
 
4. To establish a working biobank of human adipose tissue and adipose 
derived cells.   
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3.2 Patient questionnaire 
!
 
Adipose tissue is a unique source of stem cells as it is frequently removed in 
large quantities and discarded as part of routine cosmetic procedures. It is 
therefore an ideal source, and patients undergoing cosmetic surgery 
procedures to remove surplus fat make ideal potential donors. In order to 
gain a better understanding of the perceptions of patients towards donating 
tissue for research, and also to help in the design of effective and appropriate 
information sheets and consent forms, a questionnaire was designed by 
myself to distribute to plastic surgery patients (Figure 3.1). The questionnaire 
aimed to gain a basic understanding of what patients know about stem cells, 
stem cell research and general attitudes towards tissue donation. It then 
focused on the areas highlighted earlier in this chapter including; 
 
• Consent and specifically how much information patients would like to 
know. 
• Confidentiality and if issues relating to this would influence a potential 
donors decisions. 
• The intended use of the tissue including non-medical research and 
animal research 
• Distribution and commercialisation of tissue 
 
Following ethical approval (Formal amendment to SESREC03 10/S1103/45), 
the questionnaire was distributed to patients attending outpatient 
appointments at the Spire Hospital, Murrayfield. 
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3.2.1 Patient details 
 
A total of 50 questionnaires were completed with 1 patient declining to 
participate. 35 (70%) respondents were female, with the mean age being 45 
years (range 22-88) which represents a typical cohort of cosmetic surgery 
patients. 34% of patients were on an existing donor register for blood (20%), 
bone marrow (14%) and organs (20%), seven of whom (14%) having 
previously donated blood. 
 
Demographic data of patients responding to questionairre 
Sex Female = 35 
Male = 15 
Age  (Years) Mean = 45   (Range 22 – 88) 
BMI  (kg/m2) Mean = 25.6  (Range 20.5 – 35.3) 
Procedure Abdominoplasty = 36 
Liposuction = 17 
Arm / thigh reduction = 5 
Other = 4 
(Some patients had more that 1 procedure) 
Registered donor Blood = 10 
Organs = 10 
Bone marrow = 7 
Table 3.1. Demographic data of patients responding to questionnaire. Questionnaires 
were distributed to patients attending out patient appointments at Spire Murrayfield Hospital. 
A total of 50 patients responded with 1 declining to participate. 
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3.2.2 Stem cell knowledge 
 
 
Forty one (82%) patients asked had heard of stem cells and were aware of 
stem cell research. Despite this broad general awareness, only one patient 
(2%) was aware that adipose tissue was a source of stem cells, compared 
with bone marrow (28%), umbilical cord (22%), blood (24%), embryos (16%), 
skin (14%) and muscle (14%) (Figure 3.2). Of those patients that had heard 
of stem cells, the majority (73%) were aware due to media coverage, with 
seven patients (17%) being aware through a family members, and four 
patients (10%) learning about it through work. The one patient who was 
aware that adipose tissue was a potential source of stem cells knew this due 





Figure 3.2. Patients understanding of stem cell sources. N=50 patients responded to a 
questionnaire designed to ascertain their prior understanding of stem cells and stem cells 
research. This graph demonstrates the percentage of patients who believed stem cells were 
present in the respective tissues. Embryos = 16%, skin = 14%, muscle = 14%, fat = 2%, 
umbilical cord = 2%, blood = 24%, bone marrow = 28%. 
 
To further analyse the results of the questionnaire, patients were divided into 
groups based upon their perceived knowledge of stem cells. Those who were 
aware of stem cells and had correctly identified 3 or more tissues in which 
they are present were grouped as having “good” knowledge (n = 18), and 
those who were not aware of stem cells or only able to name 1 correct tissue 
were grouped as having “poor” knowledge (n = 26). Differences between 
groups were analysed using Chi-Square and Mann-Whitney U tests.  
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No significant differences were noted between the groups based on age 
(Good; mean = 38.5 years, range 22 – 60. Poor; mean = 41.7 years, range 
24 - 88) or sex. Significant differences were observed between the good and 
poor groups with repsect to whether or not they were existing blood/tissue 
donors. 56% of patients with good knowledge were existing donors 
compared to 15% of those with poor knowledge (p = 0.028). 
 
3.2.3 Factors influencing patients decisions to donate 
!
 
When patients were made aware that adipose tissue was a source of stem 
cells that could be used for research and that these cells were potential 
targets for novel therapies in regenerative medicine, they all stated that they 
would be happy in principle for surplus adipose tissue to be used for 
research. It was then sought to establish what other factors might influence a 
persons decision to donate. 96% of patients stated that the level of 
anonymisation would not influence their decision to donate and they would 
be happy for researchers to access all of their medical and demographic data 
and for this to be directly linked with the specimen. However, 4% said they 
would only donate if the tissue was anonymised and their medical records 
were not accessed. There were no differences between these 2 groups 
based on age, sex or previous stem cell knowledge.  
 
Whilst they stated that it might not influence their decision to donate tissue, 
twenty-one (42%) patients said they would expect to be told as part of the 
consent process if their tissue was to be used in either cosmetic, commercial 
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or animal research. 22% of patients had specific concerns relating to the use 
of their tissue in animal research, however this was often due to a 
misunderstanding of exactly the type of research being performed. There 
were no differences in the attitudes towards the use of tissue in animal 
research based on age (Yes; mean = 42.2 years, range 22-88 versus No; 
mean = 37.8 years, range 25 – 45), or previous stem cell knowledge. 
Interestingly all of those patients who would not want their tissue used for 
animal research were female however this was not statistically significant. 
8% of patients would not want their tissue to be used for non-medical 
research such as the testing of cosmetics. 12% of patients would not want 
their tissue to be used for, or shared with parties who intended to exploit it for 
commercial purposes. 
 
All patients said they would be happy for their tissue to be shared with 
researchers other than those collecting the tissue irrespective of where the 
other researchers were based. All patients said they would be happy for their 
cells to be used to treat other humans. 
 
Of those patients that were questioned, 38% expressed a desire to learn 
more about stem cell research as a result of completing the questionnaire. 
Previous stem cell knowledge was not a significant factor in determining if 
people wanted to know more about stem cell research with equal numbers 
(n=8) of patients from both the good and poor knowledge groups seeking 
further information. Significantly, all patients said that they would be more 
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likely to donate tissue in the future as a result of completing the questionnaire 
and discussing the relevant issues. 
 
3.3 Working model for the Edinburgh tissue bank 
 
Based on the results from the patient questionnaire and the anticipated 
requirements of the tissue bank, it was decided that the most appropriate 
model was one where tissue was collected anonymised whereby the link 
between the tissue and the donor is irreversibly broken. Whilst anonymous 
collection might have been theoretically more favorable, and there appeared 
to be no concerns from patients about this type of collection, it was felt that 
achieving this level of confidentiality was unlikely given the close working 
proximity of the clinical and research teams, and the need to access 
operating lists. Furthermore, as the primary proposed purpose of the tissue 
bank is to be a source of cells for regenerative medicine, and specifically 
within this project for tissue engineering, it was decided that medical data 
was not necessary for the RTB in its current proposed format. As such, very 
basic demographic data (Age, sex, BMI and anatomical site of fat removal) 
was all that was required. This basic demographic data would not 
compromise the anonymised tissue collection, and it would limit the amount 
of data accessed should any breaches in confidentiality occur. 
 
Twenty-two percent of patients raised concerns about the potential use of 
their tissue in animal experiments and stated that it may adversely influence 
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their decision to donate. Despite this relatively high number, it was felt that 
the potential need to perform animal based research was critical and so 
should be part of the ethical review and hence part of the consent process. It 
was my personal feeling from speaking to patients that much of their 
concerns relating to animal testing were due to a misunderstanding of the 
type of animal research that is commonly performed, and that at present this 
is almost always essential prior to the translation to human use. Furthermore, 
the use of animals in research is sometimes required as a surrogate for 
humans due to a lack of access to human tissue, and whilst their single act of 
donating fat would not alter the overall need for animals in research, better 
access to human tissue may eventually reduce this burden. 
 
A small number of patients (12%) stated an objection to their tissue being 
used for or shared with parties for commercial gain. Again, on discussion the 
main concern raised by patients was the idea of their tissue being ‘sold’ for 
personal profit. Given the high costs associated with processing tissue, and 
the potential to recuperate these costs through sharing of tissues with third 
parties it was decided that the potential for commercialisation should be 
incorporated into the ethics application, and that this should be explicitly 
detailed on the PIS and consent forms. Furthermore an explanation of the 
type of commercialisation would be of benefit to patients to understand what 




3.3.1 Patient information sheet (PIS) 
!
 
This is a fundamental part of the consent process and allows the research 
team to summarise all the salient issues relating to the study. Ideally the 
research team should explain all the details with the PIS to the patient, and 
then give them time to consider their decision, however this is not always 
practically possible. The PIS should be broken up into small paragraphs and 
should cover a number of essential issues such as: 
 
! An invitation to participate. 
! Details of the proposed work and why the patient has 
been asked. 
! Benefits/risks of participation including a statement that 
participation is voluntary. 
! Details of confidentiality arrangements. 
! Plans for the donated tissue (processing and disposal). 
! Responsible persons, complaints procedures, contact 
details. 
! Details of the ethical review process. 
 
The PIS used for the Edinburgh tissue bank was written based on the above 
guidelines, the specific nature of the proposed bank and the issues 
highlighted by the patient questionnaire. A copy of the final PIS accepted by 
the REC can be seen in Figure 3.3. 
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Figure 3.3: Patient information sheet for the Edinburgh Tissue Bank.!
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3.3.2 Consent form 
 
This provides a chance to reiterate the key points from the PIS. A member of 
the research team as well as the participant should sign it. It is advised that 
the form is filled in triplicate. One copy should be retained by the patient, one 
copy stored in the patient’s medical notes, and one copy to be stored in a 
secure place at the research site. In the case of anonymous or anonymised 
data, this form should not be transported, stored or associated with the 
tissue. Based on the findings of the patient questionnaire, it was decided that 
the potential use of tissue in animal research and for commercial purposes 
should be highlighted again on the consent form. A copy of the final consent 






Figure 3.4: Consent form for the Edinburgh Tissue Bank. 
 
 










Title of project:   Adipose tissue (fat) bank 
 
Name of researcher: Mr Christopher West 
 
• I confirm that I have read the information sheet for the above study dated 
26.10.10. I have had the opportunity to consider the information, ask questions 
and have had them answered satisfactorily. 
YES / NO 
 
• I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected. I understand that my tissue may be used for commercial 
purposes, but that I will receive no financial gain from this. 
 
YES / NO 
 
• I agree to my tissue being used in experiments involving animals. 
 
YES / NO 
 
• I agree to take part in the above study 
YES / NO 
 





















3.3.3 Research protocol 
 
 
A mandatory part of the application is a detailed research protocol that 
describes the processes and procedures by which the intended project will 
abide.  For proposals that include a specific project, then a detailed 
description of the methodology is required. However in the case of a tissue 
bank which seeks generic rather than specific approval this is not the case 
and the focus is on demonstrating how the proposed tissue bank will ensure 
the appropriate procedures are followed to according to the boundaries set 
out in the application form. It is therefore important to demonstrate a practical 
understanding of how you intend to establish and implement the day to day 
working and function of the proposal and anticipate and problems. Figure 3.4 






Figure 3.5: Flow diagram of the protocol used in the Edinburgh Adipose Bank. 
Potential donors identified preoperatively and given PIS to read. On day of surgery patient 
discusses donation with a member of research team and signs consent form if happy to 
participate. Tissue is collected at the end of surgery and either frozen immediately or 






In addition to the ethical and legal considerations, there are also a number of 
practical issues that needed to be addressed. The stages of collection, 
processing, expansion, purification, storage and shipment of adipose tissue 
and subsets of cells each require specific equipment and infrastructure.  
 
It is the responsibility of the tissue bank to ensure any data collected, or 
forms containing patient data are stored in a secure place  (eg. locked filing 
cabinet) at the research site. If the data/tissue has been collected either as 
anonymous, anonymised or identifiable, then any patient data should be kept 
separate from the tissue at all times. 
 
The first stage in the process to extract stem and progenitor cells is the 
isolation of the stromal vascular fraction  (SVF) from the adipose tissue  
(Figure 3.5). There are a number of commercially available automated 
machines that have been developed to isolate SVF with many of these doing 
so with the purpose of returning the SVF to the patient for a range of 
therapeutic purposes (Pérez-Cano et al. 2012). Manual processing of tissue 
is quick, simple and cost efficient compared to automated alternatives. Full 
details of the process developed and used in this thesis can be found in 
Chapter 4. For research purposes the processing of tissue should be 
performed in a class 2 biosafety cabinet. Initial stages require the disruption  
(usually by enzymatic digestion) of the adipose tissue. Centrifugation will 
then generate a pellet containing the stromal vascular fraction  (SVF). The 
! 129!
SVF is a heterogenous mixture of cells including haematopioetic cells, 
fibroblasts, endothelial cells and stromal stem/progenitor cells. ASC can be 
selected based on their adhesion to cultureware. Alternatively, specific 
subpopulations of cells within the SVF can be purified and isolated using 
methods such as flow cytometry (Corselli, Crisan, et al. 2013). 
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Figure 3.6 : Stages in the production of SVF 
from lipoaspirate. 
1. Lipoaspirate freshly harvested from a 
patient and allowed to settle. 3 
distinct phases can be seen with oil 
on top, above the fat in the middle, 
with the liquid phase comprising of 
infiltration fluid and blood at the 
bottom. 
 
A.) Following washing with PBS and 
centrifuging, the lipoaspirate 
separates into 4 phases with oil on top 
of the adipose tissue. Below which is 
the liquid phase of PBS, and in the 
bottom is a pellet containing mostly 
RBC. 
 
B.) Following enzymatic digestion and 
centrifugation the lipoaspirate 
separates into 4 phases. Oil on top of 
an adipose/connective tissue layer 
with fluid beneath. The cell pellet in 
the bottom contains the SVF  (white) 
and RBC  (red) which can be seen as 
two distinct layers. 
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Cells that are to be stored should be frozen in cryovials in specific freezing 
media. Cells can be stored for shorter periods of time  (weeks) in a -80°C 
freezer, however for longer periods storage in liquid nitrogen is 
recommended.  
 
Much of the equipment required is basic and institutions performing in vitro 
cell culture are likely to be in possession of most of it.  
 
3.3.5 Collaborations / supply / MTA 
 
Distribution of products with collaborators or other third parties should be 
done by a formal arrangement called a Material Transfer Agreement (MTA). 
This serves to ensure that the tissue is only used for permissible purposes 
agreed in the ethics application and information on the form should include 
contact details, description of the research and general conditions for the 
transfer and use of the tissue (Hallmans & Vaught 2010). The letter 
containing advice on applying for access to tissue from the Edinburgh tissue 




Figure 3.7. Coverletter and guidance supplied to parties interested in accessing tissue from 
the tissue bank. 
 
Centre or Regenerative Medicine 
Chancellor’s Building 











Many thanks for your enquiry regarding the adipose and skin tissue bank. 
 
All applications for the use of tissue from the bank are subject to review by Mr 
Christopher West Clinical Research Fellow at the University of Edinburgh Centre for 
Regenerative Medicine, and by NHS Lothian Tissue Governance Team. 
 
There are strict conditions concerning the release of tissue from the tissue bank, and 
you need to be aware of these before applying: 
 
• Tissue is to be used for research within the field of regenerative medicine. 
• No tissue should be used in research into termination of pregnancy or 
reproductive cloning. 
• No tissue should be used for the testing of cosmetic products. 
• No personal details of the donor will be recorded. Information regarding 
the sex, age, BMI of the donor  are the only details given. 
• Research projects in the UK using tissue provided by the bank in 
accordance with these conditions will be considered to have ethical 
approval from the committee under the terms of this approval. In England, 
Wales and Northern Ireland this means that the researcher will not require 
a licence from the Human Tissue Authority for storage of the tissue in 
relation to this project. 
• Applications from outside the UK should demonstrate they have the 
relevant local approval for the research. 
• Any proposed research using animals requires appropriate local approval. 
• A written report detailing the outcomes of any research using tissue from 
the bank is required on completion of the project. 
• Any breeches of these conditions must be reported immediately to Mr 





Application for tissue from the 





Figure 3.7. Coverletter and guidance supplied to parties interested in accessing tissue from 
the tissue bank. 
 
Please read the guidance below before completing the application form. Completed 
application forms should be returned via email to Mr Christopher West 
(c.c.west@doctors.net.uk), Clinical Research Fellow, University of Edinburgh Centre 
for Regenerative Medicine. 
 
1. Sponsor: Please give details of the person with overall responsibility for the 
research. 
 
2. Chief Investigator(s): Please give details of the Chief Investigator(s) for any 
research. 
 
3. Location: Please give details of where the tissue will be stored, and where the 
research will be conducted. 
 
4. Title of project: Please give a short title explaining the research. 
 
5. Brief description of the project: Please outline here what you plan to use the 
tissue for. Details should demonstrate that the work complies with the rules of 
the tissue bank. Any proposed work involving animals should be stated and 
evidence provided that approval has been sought from appropriate committees. 
Plans for any excess tissue should also be stated. 
 
6. Type of tissue requested: Please state which type of tissue you require eg 
whole tissue or individual cell types. 
 
7. Amount requested: Please state how much tissue you require and a brief 
justification for why you require this amount. 
 
8. – 10. Please leave blank. These are to be completed by the tissue bank. 
 
11.  Signature: Please sign, print and date the application form. 
 
 
Any questions relating to any of the topics above should be addressed to Mr 














3.4 Experiences of the Edinburgh tissue bank 
 
An application to establish an adipose RTB following the model proposed 
above was submitted through IRAS in September 2011. Following the 
review, interview and having made the necessary amendments, ethical 
approval was granted in November 2011. 
 
Since receiving ethical approval, 58 patient samples have been collected. 
During this period, two patients declined to donate their tissue. On both 
occasions this was due to an objection to the possibility of their tissue being 
used in animal research. No concerns or objections were voiced regarding 
the sharing of tissue with collaborators, potential commercial use of tissue, or 
the level of confidentiality.  
 
The majority of tissue samples were collected from patients undergoing 
cosmetic procedures such as liposuction and abdominoplasty in the private 
sector. A small proportion of samples came from surplus tissue from NHS 
patients undergoing breast reconstruction procedures. Under the HTA, NHS 
REC can review and approve applications for RTB using tissue from non-
NHS patients such as those having cosmetic procedures in the private 
sector. Whilst young, healthy donors are the ideal demographic for collecting 
adipose tissue for the purposes of stem cell isolation (El-ftesi et al. 2009), the 
unique demographics of these samples may limit their use in the study of 
some diseases. However, access to human tissue can serve as an ideal 
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comparison for animal based studies, or as a healthy positive control for 
disease based research (Esteves et al. 2013). 
 
Tissue collected and stored in the Edinburgh Tissue Bank has been used in 
numerous collaborations and independent projects both with academic 
institutions and commercial partners. This has provided a valuable resource 
for research in many different areas. An overview is found in Figure 3.4, with 
full details in Appendix 2. 
 






Adipose tissue provides an abundant and accessible source of multipotent, 
autologous mesenchymal stem cells (MSC) for clinical translation. Ease of 
access, and their ability to be readily expanded in vitro has seen a dramatic 
rise in the number of clinical trials aiming to harness their regenerative, 
immunogenic and angiogenic potential. The global recognition of this 
potential has seen growing use and commercialisation of ADSC in a 
widespread of clinical settings, from cosmetic breast augmentation, anti-
aging and depressed scar therapies, to regenerating and engineering lost 
tissue after trauma and malignancy.  Despite this perceived expansion in our 
understanding of these cells, they remain poorly understood. This has 
prompted stringent guidance from the US Food and Drug Administration  
(FDA) and European Regulation in 2011 for the preparation and processing 
of ADSC in accordance with current good manufacturing guidelines. 
Approved stem cell technology must be evaluated with regards to safety, 
purity, identity, potency and efficacy prior to biologic licensing and clinical 
use. Therefore access to ethically sourced tissue for research is fundamental 
to the successful delivery of novel therapies. 
 
 
The data presented in this chapter from the patient questionnaire 
demonstrates a significant lack of awareness of the potential use of adipose 
tissue and ADSC in medical research in a cohort of plastic surgery patients. 
There is however good potential acceptance for their use following simple 
provision of information, explanation and opportunity for understanding. This 
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highlights the significant positive impact engaging with the public and 
patients can have on the ability to procure tissue for medical research. The 
analysis of patient knowledge, concerns and expectations surrounding 
donation of adipose tissue from this study facilitated the design of tailored 
patient information and consent forms. Gaining information such as this will 
in turn improve the ability of researchers to engage with public and patients, 
thus enhancing patient understanding with this highly eligible population of 
adipose tissue donors. Data from this study suggests that this increased 
understading is likely to facilitate access to ethically sourced adipose tissue 
for future research and therapies. It also demonstrates a general lack of 
understanding in stem cell knowledge and therefore is applicable other 
tissues, and stem cell research in general.  
 
 
As previously discussed, the laws and regulations surrounding gaining 
ethical and legal access to tissue are often poorly understood, and this may 
impede access to tissue for researchers. In establishing this tissue bank 
these regulations were examined to ensure the protection of collaborators, 
patients and myself. Through developing collaborations between plastic 
surgeons, private healthcare providers, industry and academic institutions a 
biobank has been developed that serves to provide cells and tissues to 
multiple research groups both within the UK, and across the globe. It has 
also facilitated greater collaboration between clinicians, academics and 
commercial organisations within the University of Edinburgh and beyond, 
thus resulting in many new joint projects, grant applications and publications.
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4 Identification, isolation and analysis of frequency of 
pericytes within human adipose tissue. 
 
 
Parts of this chapter were published in: 
 
West CC, Khan NS, Crisan M 
Methods in Molecular Biology (In press) 
Characterisation of Pericyte Phenotype in vivo by 
Immunohistochemistry 
 
NS Khan, West CC, Rossi F, Crisan M 
Methods in Molecular Biology (In press) 
Assessment of Pericyte Phenotype by Flow Cytometry 
 
 
CC West, WR Hardy, IR Murray, A James, M Corselli, S Pang, C 
Black, SE Lobo, K Sukhija, P Liang, V Lagishetty, DC Hay, KL March, 
E Ting, C Soo, B Péault. 
Stem Cells Research and Therapy. Revisions made and under 2nd 
review. October 2015. 
Purification of perivascular presumptive mesenchymal stem cells from 
human adipose tissue: process optimization and cell population 
metrics across a large cohort of diverse demographics 
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Corselli C, Crisan M, Murray IR, West CC, Scholes J, Codrea F, Khan 
N, Péault B 
Cytometry Part A. 83 (8):714-20. August 2013. 








In a pioneering series of experiments in the 1960s, Friedenstein and 
colleagues identified a population of cells from rodent bone marrow that were 
adherent to plastic when grown under standard conditions, formed colonies, 
and could differentiate into osteoblasts in vitro (Friedenstein et al. 1970). In 
addition they were capable of generating bone when implanted into ectopic 
location in vivo (Friedenstein et al. 1966; Friedenstein et al. 1974). 
Friedenstein termed these cells Colony Forming Unit-Fibroblast  (CFU-F), 
which they were commonly known as until more recently Caplan suggested 
the term Mesenchymal Stem Cells (MSC) (Caplan 1991). Since this initial 
description, these cells have been the focus of much attention for their ability 
to differentiate into multiple mesodermal lineages, to modulate the immune 
system and to stimulate regeneration through trophic support and secretion 
of cytokines. 
 
Despite the ultimate desire to translate MSC research to novel clinical 
therapies, our understanding of these cells is based principally on 
observations made on in vitro populations and assays, with very little 
understanding of the in vivo location and identity of these cells. Hence their 
role in physiological and pathological processes remains relatively unknown. 
 
Since their initial description and derivation from bone marrow, identical cells 
have been derived from multiple tissues based on their adherence to plastic 
(da Silva Meirelles 2006). This lead to the hypothesis that these cells may 
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have a common in vivo location and identity. Crisan et al demonstrated that 
microvascular pericytes in multiple foetal and adult tissues express MSC 
markers in vivo, and when purified to homogeneity and cultured in vitro were 
identical to conventional MSC in terms of morphology, phenotype and 
function (Crisan et al. 2008). This lead to the conclusion that pericytes 
represent an in vivo ancestor of the MSC observed in vitro, a finding that has 
been validated by other groups (Covas et al. 2008). Subsequently, a second 
population of anatomically and phenotypically distinct cells with identical 
function to conventional MSC have been identified that reside in the 
adventitial layer of larger blood vessels – namely adventitial cells (Corselli et 
al. 2012). Collectively these 2 populations are refrred to by the authors as 
perivascular stem cells  (PSC). Since their description, PSC have been 
tested in a variety of in vitro and in vivo assays. The potential of these cells 
has been shown to replicate the known functions of MSC, and PSC have 
shown to be of equal function, and in some occasions superior to other stem 
and progenitor populations  (Reviewed in Corselli, Crisan, et al. 2013). 
 
Pericytes have demonstrated chondrogenic potential in vitro (Zannettino et 
al. 2007) and in vivo in murine models of meniscal injury (Osawa et al. 2013), 
rib fracture (Brighton & Hunt 1997) and ectopic transplantation (Farrington-
Rock 2004; Diaz-Flores, Gutierrez, Gonzalez, et al. 1991).  They have been 
shown to produce ECM proteins essential for cartilage development 
(Farrington-Rock 2004). When compared to conventional MSC, pericytes 
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have demonstrated enhanced chondrogenic potential with increased 
amounts of GAG production (Hagmann et al. 2014; W. S. Khan et al. 2008). 
 
Despite these promising findings, there are a number of challenges that must 
be addressed to facilitate the successful translation and wider clinical use of 
MSC. Standard techniques for deriving and enriching MSC based on 
adherence to plastic, and the low yield of cells from tissues such as bone 
marrow have necessitated extended periods of ex-vivo culture prior to 
transplantation. Further to the significant additional resources and expense 
required to culture cells in GMP compliant conditions, there are potential 
risks that in vitro expansion introduces. Infection and immunogenicity are 
potential consequences from the exposure of cells to animal based culture 
supplements (Gad 2008). Extended periods of in vitro expansion have been 
shown to adversely affect the function of cells with a reduction in their 
chondrogenic, adipogenic and osteogenic potential (James, Zara, Zhang, et 
al. 2012; Yimu Zhao et al. 2012; Wall et al. 2007). Furthermore, higher 
passage cells show modified and diminished expression of chemokine 
receptors and adhesion molecules resulting in diminished response to 
chemokines and high levels of senescence (Ma 2010). Concerns have also 
been raised about the development of genetic instability and the potential for 
malignant transformation in cultured cells. In addition there are significantly 
more stringent regulatory hurdles that must be addressed with the use of 
cultured cells compared to those that have been exposed to minimal 
manipulation (Mahalatchimy et al. 2012).  
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In an attempt to eliminate many of these issues, some groups have 
investigated the use of adipose derived stromal vascular fraction  (SVF) as a 
source of MSC / progenitor cells. SVF bypasses the need for in vitro culture 
and may be delivered at the point of use requiring only basic preparation 
such as enzymatic digestion, washing and centrifugation. Whilst SVF 
eliminates the requirement of ex vivo expansion, it is a very heterogenous 
cell population containing endothelial cells, inflammatory cells, fibroblasts as 
well as significant amounts of cellular debris. This heterogeneity may limit the 
regenerative potential of SVF when compared with a more homogenous 
MSC population as has been demonstrated in models of osteogenesis 
(James, Zara, Corselli, Askarinam, et al. 2012). Additionally, the use of a 
heterogeous population of cells makes demonstrating the specific action of 
the subpopulations and their mechanism of action practically very difficult to 
achieve. 
 
It is clear therefore that there is a dichotomy in the current approaches to 
delivering MSC for clinical use. Methods that use in vitro culture as a means 
of isolation provide a relatively enriched cell population but incur the 
practical, financial, ethical and regulatory problems this manifests. Those 
which use SVF do so at the expense of product identity, purity and function. 
We have therefore sought to develop methods for the prospective isolation of 
purified, homogenous populations of MSC based on our understanding of the 
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exact in vivo location and identity of these cells.  
 
Using high speed, multicolour FACS our group has previously purified cells 
from a range of adult and foetal tissues (Crisan et al. 2008; Corselli, Crisan, 
et al. 2013). Here the content of the SVF of human adipose tissue is 
analysed using flow cytometry to determine the potential yield of PSC and to 
establish if sufficient numbers of PSC can be purified for clinical application. 
Thus delivering a pure and defined population of cells without the need for ex 
vivo culture. Furthermore the patient and procedure based variables that may 




Adipose tissue is potentially an abundant source of pericytes that can be 
harvested relatively easily from patients.  Pericytes have been shown to 
share features with conventional MSC, and are capable of undergoing 
chondrogenesis. Subsets of MSC expressing pericyte markers have shown 
to have enhanced chondrogenic potential when compared to standard MSC 
(W. S. Khan et al. 2008). This makes them potential candidates for auricular 
tissue engineering. 
 
By identifying the native location and identity of these cells, they can be 
isolated to homogeneity without the need for ex vivo culture using FACS. 
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Given the quantity of adipose tissue frequently removed in cosmetic surgery 
procedures, this may eliminate the need for ex vivo expansion prior to 
transplantation for clinical application. This has a number of potential 




The specific aims of this experimental chapter are: 
 
1. Using immunohistochemistry to characterise and demonstrate the in 
vivo identity and location of pericytes within adipose tissue. 
 
2. To develop and optimise protocols for the efficient isolation and 
purification of pericytes using fluorescence activated cell sorting  
(FACS) and subsequent culture of pericytes in vitro.  
 
3. In vitro populations of pericytes will be characterised with reference to 
published data on MSC function and phenotype.  
 
4. The potential numbers of pericytes that can be isolated directly from 
adipose tissue will be assessed using FACS to determine if sufficient 
quantities of cells can be purified to eliminate the need for ex vivo 




4.2 Identification of pericytes by immunohistochmeistry 
 
A series of immunohistochemical stains were performed to establish the 
presence of pericytes, their relationship to endothelial cells  (EC), and their 
expression of MSC associated markers. Endothelial markers CD31  
(PECAM-1) and vWF were chosen due to the specificity for EC. CD146  
(MCAM) is ubiquitously expressed on pericytes, as are markers NG2, αSMA 
and PDGFRβ (Crisan et al. 2008). CD105 and CD90 are markers associated 























Table 4.1: Markers used in the identification and characterization of pericytes in 
adipose tissue 
 
Immunohistochemistry demonstrated the intimate relationship between 
endothelial cells and pericytes, with pericyte residing on the abluminal 
surface of endothelial cells in bloods vessels of varying size and calibres  
(Figure 4.1–3). As adipose tissue contains blood vessels of different sizes, 
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the selection of markers present on pericytes in all vessels is desirable. In 
Figure 4.1, CD31 expressing endothelial cells (red) can be seen surrounded 
by CD146 expressing pericytes (green) in transverse sections of vessels.  
 
Figure 4.2 A - C shows higher magnification of microvessels in longitudinal 
section demonstrating endothelial cells entirely ensheathed with pericytes. 
Figure 4.2 D shows a small vessel in transverse section. The microvessels in 
this figure are of small diameter and consist of only pericytes and endothelial 




Figure 4.1: Immunostaining of microvessels within adipose tissue. Transverse sections of 
blood vessels using indirect staining of pericytes  (CD146 – Red) residing on the abluminal 




Figure 4.2: Immunostaining of microvessels within adipose tissue demonstrating the 
intimate relationship between pericytes  (α-SMA – Green) and endothelial cells  (CD31 – 
Red).. A – C shows longitudinal sections of microvessels with endothelial cells entirely 
ensheathed within a layer of pericytes. D shows a smaller vessel in transverse section. 
Scale bar = 50µm 
 
 
Figure 4.3 shows co-expression of CD146 (Green - Pericytes and endothelial 
cells) with NG2 (Red - Pericytes). Whilst CD146 is ubiquitously expressed on 
pericytes, it is also present in subsets of endothelial cells as can be seen by 
the 2 concentric rings of green staining, with the outer layer also staining for 
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NG2 positive pericytes. For this reason when purifying pericytes from mixed 
populations of cells containing endothelial cells combinations of markers that 
are able to distinguish pericytes from endothelial cells would be required. 
 
Figure 4.3: Immunostaining of microvessels in adipose tissue. Co expression of 
pericyte markers CD146  (Green) and NG2  (Red). Concentric rings of CD146 (green) can 
be seen demonstrating co-staining of pericytes and endothelial cells with NG2 (red) only 
staining the outer ring of pericytes. Scale bar = 100µm. 
 
4.2.1 Co-expression of MSC markers by pericytes in vivo 
 
In the criteria stated for defining MSC, cells are required to express MSC 
markers CD44, CD73, CD90 and CD105. Although these criteria are used to 
define in vitro populations of cells, demonstration that pericytes express 
these markers in vivo would support their role as native MSC, and also to the 
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hypothesis that these cells could be used without expansion in vitro. Using 
markers confirmed to be pericyte specific in section 4.2, cells also 
demonstrated co-expression of markers CD105  (Figure 4.5) and CD90  
(Figure 4.6).   
 
Figure 4.5: Immunostaining of pericytes in adipose tissue. Demonstration of the native 
co-expression of MSC marker CD105  (Red) with pericyte marker PDGFR-B  (Green). Scale 
bar = 100µm. 
! 151!
 
Figure 4.6: Immunostaining of microvessels in adipose tissue. Native co-expression of 
pericytes  (αSMA - Green), with MSC marker  (CD90 – Red) in vessels of a variety of sizes 
and caliber. Scale bars; A = 50µm, B = 100µm, C = 120µm. 
 
4.3 Purification of pericytes by FACS 
!
!
To further analyse the potential of pericytes, in vitro populations of cells were 
established for further experimentation. To do this, a multi-colour FACS 
protocol for the purification of viable pericytes from adipose tissue was 
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developed. For the full protocol on the preparation of SVF see Chapter 2. 
Following mechanical and enzymatic digestion, cells were washed, filtered 





















CD34 FITC Adventitial cell Endothelial cells 
Haematopioetic 
stem cells 








B and T 
lymphocytes 
Table 4.2: Antibody and fluorchrome panel for the purification of pericytes from adipose 
tissue. 
 
FACS was performed using a BD FACS Aria II following adequate 
compensation with compensation beads, or single stained cells. Initial gate is 
forward scatter  (FSC) versus side scatter  (SSC). FSC is a representation of 
the density of the events passing through the laser, whilst SSC is a 
representation of their granularity. By plotting FSC v SSC it is possible to 
identify distinct populations of cells that can be used as a reference point for 
subsequent gates. Lymphocytes are small, dense cells that are relatively 
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homogenous resulting in a small population located in the lower left section 
of the plot  (Figure 4.7 A & B). All viable cells will be above and to the right of 
this  (Figure 4.7 C). 
 
 
Figure 4.7. Flow cytometric analysis of SVF from human adipose tissue. A.) FSC v SSC 
demonstrating the population of lymphocytes (arrow). B.) Confirmation of the lymphoctyes by 
demonstration of CD45+ phenotype of the sub-population. C.) Selection of the cellular 
fraction for subsequent analysis. 
 
By plotting the FSC-Height  (FSC-H) versus FSC-Area  (FSC-A) of cellular 
gate seen in Figure 4.7C, aggregates of double or multiple cells can be 
removed to ensure all remaining cells are single  (Figure 4.8). In a population 
of single cells there should be a linear relationship between the magnitude of 
the signal  (FSC-H) and it’s differential  (FSC-A) as the size of the cell 
increases. However, if 2 cells are joined together then the magnitude of the 
signal remains equal to that of a single cell, however the area increases  





Table 4.8. Flow cytometric analysis of SVF from human adipose tissue after the 
selection of cells from initial gates. A.) FSC-A versus FSC-H demonstrating the majority 
of events following a linear pattern. B.) Diagram showing the linear relationship between 
single cells but not multiple cells. C.) Gate applied to eliminate multiple cells. 
 
DAPI was used to exclude dead cells, before the selective removal of 
haematopioetic and endothelial cells by depleting the CD45+ and CD31+ 
populations respectively  (Figure 4.9). 
 
 
Table 4.9. Flow cytometric analysis of SVF from human adipose tissue. Elimination and 
selection of subpopulations based on staining. A.) DAPI negative live cells selected. B.) 
CD45- cells selected to exclude haematopioetic cells. C.) CD144- cells selected to exclude 
endothelial cells.  
 
Finally, pericytes can be purified by plotting CD146 versus CD34 and 




Figure 4.10. Final gate for selection of pericytes. Population of live, single, CD45-, CD31-, 
CD34-, CD146+ cells. 
 
4.4 In vitro culture of pericytes 
 
 
Immediately following FACS isolation, pericytes were cultured in vitro. It was 
observed that the initial conditions that the pericytes were grown in had 
profound effects on their ability to attach and proliferate. A minimum plating 
density of 20,000 cells per cm2 was required with a density of 40,000 cells 
per cm2 being optimal. We also observed that pericytes required gelatin 
coating to facilitate attachment. Cells grown in standard MSC/ASC media  
(DMEM+20%FCS+1%P/S), did not proliferate upon attachment and no 
colonies were observed, however cells grown in EGM-2 media did grow after 
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attachment.  Conversely, unsorted ASC would rapidly attach and proliferate 
at relatively low density, on un-coated plastic in standard media. These 
observations would suggest that conventional techniques for deriving 
MSC/ASC may bias against the selection of pericytes.  
 
4.4.1 Cultured pericytes display MSC like morphology and phenotype 
 
Typically, sorted pericytes remained quiescent for up to 7 days following 
sorting showing no signs of attachment and proliferation. After this period 
cells attached and spread out and began to form typical fibroblast like 
colonies, expanding into a standard monolayer of cells. At this point they are 
indistinguisable from conventional MSC based on morphology alone. 
 
Using ICC it was observed that pericytes grown in standard culture 
conditions demonstrate positive expression of pericyte markers CD146, 
PDGFR-β and αSMA, and the MSC marker CD105  (Figure 4.11). In addition 
they do not express markers associated with other lineages that could either 
have contaminated the populations during the sorting process, or be derived 
from pericytes  (Figure 4.12). Typical cells that could contaminate pericyte 
cultures that are present in the SVF are haematopoietic cells (CD45+) and 






































Figure 4.12: Immunocytochemical staining of pericytes  (Passage 3). 
Negative expression of CD31  (Endothelial), CD34  (adventitial, endothelial, 
haematopioetic), and OCT4  (Pluripotent cells)  (Top row), with matched 
isotype controls  (Bottom row). 
!
! 159!
The observations made on immunohistochemical analysis of pericyte 
cultures were then confirmed using flow cytometry  (Figure 4.13), using the 
protocols described in Chapter 2. Flow cytometry confirmed that the cultures 
were of pericytes (CD146+, PDGFR-β+, CD31-, CD34-, CD45-), and that 
they were of high purity with rates consistently of greater than 98%. Flow 
cytometry further confirmed uniformly high expression of MSC associated 
markers CD44, CD73, CD90 and CD105. Expression of the MSC markers 
mirrored the expression of pericytes markers and was consistently greater 
than 98% which is also one of the ISCT defining criteria for MSC (Dominici et 







Figure 4.13: Flow cytometric analysis of cultured pericytes (passage 6) demonstrating 
high purity of pericytes and uniformly high co-expression of MSC markers. Positive 
expression of pericyte markers  (CD146, PDGFR-B), the positive expression of MSC 
associated markers  (CD44, CD73, CD90, CD105) and the negative expression of markers 
for endothelial cells  (CD31, CD34) and haematopoietic cells  (CD34, CD45). Red = stained 
sample, blue = isotype control. 
 
4.4.2 Cultured pericytes are multipotent 
 
Thus far the in vivo location of pericytes within adipose tissue, and surface 
markers that can uniquely identify them have been demonstrated. In addition, 
the in vivo co-expression of markers typically used to identify MSC in vitro 
have been demonstrated. When purified to homogeneity using FACS and 
cultured in vitro pericytes retain their unique and specific surface marker 
profile and retain the expression of MSC markers in the absence of any 
markers associated with other lineages. To robustly demonstrate the 
association of pericytes with MSC, multilineage differentiation  (adipo-, osteo- 
and chondro-genesis) which is stated as a defining feature of MSC was 
demonstrated (Dominici et al. 2006). 
 
The ability of MSC to differentiate into mesodermal lineages is well 
documented and achieved by the supplementation of culture media with 
combinations of lineage specific growth factors. Growth factors commonly 
used to induce adipogenesis include dexamethasone, 3-isobutyl-1-
methylxanthine  (IBMX) and insulin. For osteogenic induction growth factors 
include dexamethasone, β-glycerophosphate  (BGP) and ascorbic acid. 
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Chondrogenic differentiation can be induced by supplementation of media 
with ascorbic acid, dexamethasone, insulin and transforming growth factor β-




Pericytes were cultured in 12 well plates in SGM and allowed to reach 
approximately 25% confluence before induction of osteogenesis. When 
placed in osteogenic media pericytes proliferated rapidly forming a dense 
monolayer of cells within 1 week (Fig 4.14 A). Pericytes then began to form 
small nodules of mineralization that demonstrated strong staining. The 
number and size of nodules increased throughout the duration of 
osteogenesis (Figure 4.14 B&C). After 4 weeks there was mineralization 
throughout the wells in both nodules and the cells forming the monolayer 




Figure 4.14. Osteogenesis of adipose derived pericytes. Pericytes (passage 6) grown 
in 12 well plates in SGM until 25% confluent and then changed to osteogenic media 
(StemPro® Osteogenesis differentiation kit, Gibco™), staning with Alizarin Red to 
demonstrate mineralization A.) After 1 week small nodules of mineralization began to form. 
B.) Staining after 2 weeks showing denser and larger nodueles C.) After 3 weeks, multiple 
nodules demonstrating mineralization with mineralization also developing in the monolayer 
of cells.  D.) Multiple nodules that coallesece with mineralization throughout the monolayer of 




Pericytes were cultured in 12 well plates in SGM and allowed to reach 
approximately 40% confluence before induction of adipogenesis. Higher 
confluency would result in the cell monolayer becoming over confluent and 
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detaching before adipogenic induction was complete. Small lipid vacuoles 
began to appear after 5 days and continued to increase in number for the 
duration of adipogenic induction. After 2 weeks most cells contained lipid 
vacuoles and the smaller vacuoles began to coalesce into larger vacuoles. 
Adipogenesis seemed to be enhanced in areas of high cell density.  
 
Figure 4.15. Adipogenesis of adipose derived pericytes. Pericytes (passage 6) grown in 
12 well plates in SGM until 40% confluent and then changed to adipogenic media 
(StemPro® Adipogenesis differentiation kit, Gibco™). A.) Lipid filled vacuoles began to 
appear after 5 days and were present in approximately 20% of cells at 1 week. B.) 50% of 
cells containing vacuoles at 2 weeks. C.) Over 80% of cell containing vacuoles at 3 weeks 
with appearance of larger vacuoles. D.) Adipogenesis occurred earlier and to greater degree 






Pericytes were cultured in T75 flasks in SGM until sufficient numbers of cells 
were obtained. 300,000 cells were required for each pellet and 
chondrogenesis was induced according to the protocols described in Chapter 
2.6. 
 
After centrifugation, the cells formed a small pellet in the base of the 15ml 
centrifugue tube. Pellets in chondrogenic media grew in size over the period 
of chondrogenic induction and produced ECM that caused them to stick to 
the sides of the tubes requiring gentle agitation to free them when media was 
changed. On histological examination of pellets, concentric rings of ECM 
could be seen on the outer surface of pellets. Control pellets grown in SGM 
did not grow or produce ECM. Many of the pellets involuted and disintegrated 




Figure 4.16 Chondrogenesis of adipose derived pericytes. Pericytes (Passage 6) were 
formed in to pellets by centrifuging for 3 minutes at 300g (300,000 cells/pellet). Pellets (n=6) 
were grown in chondrogenic media (StemPro® Chondrogenesis differentiation kit, Gibco™), 
changed 3 times per week for a total of 4 weeks. Controls (n=6) were grown in SGM. A.) 24 
hours after centrifugation, pellets can been seen in the bottom of 15ml tubes. B.) Alcian Blue 
staining of pellets after 4 weeks of chondrogenic induction showing positive staining of 
proteoglycans and ECM production. New tissue can be seen as concentric rings on the outer 
surface of the pellet. C.) Pellets cultured in chondrogenic media (n=6) were significantly 







4.5 Prospective isolation of pericytes by FACS 
 
Given the frequency of these cells within adipose tissue, and the large 
quantities of adipose tissue that can be safely harvested, adipose tissue was 
analysed to determine the potential yield of pericytes to determine if sufficient 
numbers could be isolated to eliminate the need for expansion. Adipose 
tissue from 22 patients was processed using the protocol described in 
Chapter 4.3. Details of the patients and their samples and the yield of cells is 
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plete data set of n=22 adipose tissue donors. 
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Age  (Years) 
 









SVF  (Cells x 106) 
 
Viability  (%) 
 
Pericytes  (%) 
 
Yield  (Cells x 106) 
 
Female = 20 
Male = 2 
 
Mean = 40.3  (Range 29 - 64) 
 
Mean = 28.1  (Range 22 - 32) 
 
Whole fat = 12 
Liposuction = 10 
 
Abdomen = 18 
Thigh = 3 
Torso = 2 
 
Mean = 40.7  (Range 8 - 68) 
 
Mean = 85.8  (Range 70.1 - 95.7) 
 
Mean = 11.1  (Range 4.2 - 26.9) 
 
Mean = 3.85  (Range 0.54 – 8.86) 
Table 4.4: Summary of the demographic data from Edinburgh donors and samples. 
 
4.5.1 Accumulation of data from Edinburgh and Los Angeles 
!
 
All adipose tissue samples processed by the 2 Péault Group Laboratories  
(Edinburgh and Los Angeles) between 2011 and 2014 were examined to 
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establish the SVF and stem cell content of adipose tissue and to compare 
this to the recorded patient and processing variables. All samples processed 
in Edinburgh were done so by a single operator  (myself), there was a total of 
5 different operators involved in the processing of tissue in LA, however all 
flow cytometry data was independently reviewed by myself and colleagues in 
Edinburgh and LA to ensure consistency. In addition to pericytes, the 
frequency of a second population of MSC like cells – namely adventitial cells 
– was recorded. Following on from the initial observations that pericytes 
represent the in-vivo precursor of the MSC (Crisan et al. 2008), a second 
population of cells within the adventitial layer of blood vessels was identified 
which had the same properties (Corselli et al. 2012). These cells are 
distinguishable from pericytes by their unique surface marker profile  
(Pericytes: CD146+, CD34-, CD45-, CD31- versus Adventitial: CD146-, 
CD34+, CD45-, CD31-). Collectively these 2 populations are referred to as 
perivascular stem cells  (PSC). 
 
A total of 131 individual samples were analysed (Edinburgh n=22, Los 
Angeles n = 109) following the protocols described in section 4.3. A summary 
of the demographic data is found in Table 4.5.  
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Age  (Years) 
 
BMI  (Kg/M2) 
 
SVF  (Cells x 106) 
 
Viability  (%) 
 
Pericytes  (%) 
 
Adventitial cells  (%) 
 
PSC total  (%) 
 
PSC Yield  (Cells x 106) 
 
Female = 104 
Male = 18 
 
Mean = 41  (Range 22 - 64 ) 
 
Mean =  26.4  (Range 19 – 36 ) 
 
Mean = 34.7  (Range 4.7 - 120 ) 
 
Mean = 83%  (Range 36 – 99) 
 
Mean = 8%  (Range 0 - 55) 
 
Mean = 32.6%  (Range 3 – 72) 
 
Mean = 40.9%  (Range 6 – 78) 
 
Mean = 11.6  (Range 1.1 – 47.1) 
Table 4.5: Combined donor and sample data from Edinburgh and UCLA. 
 
 
The mean yield of SVF from 100cc of lipoaspirate was 34.7 x 106 nucleated 
cells  (Range = 4.7 - 120). Within this population, the mean viability was 83%  
(Range = 36 - 99). Haematopietic cells  (CD45+) represented a mean of 
31.6% of the total viable SVF. Pericytes represented a mean of 8%  (Range 
0 - 55), and adventitial cells a mean of 32.6%  (Range 3 – 72) of the viable 
SVF. Therefore collectively PSC represented 40.9%  (Range 6 – 78) of the 
viable SVF. There were no significant differences observed in the yield of 
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SVF or PSC procured per 100cc of adipose tissue between Edinburgh and 
Los Angeles  (Figure 4.15). 
 
 
Figure 4.15. Comparison of SVF yield  (A) and PSC Yield  (B) as a percentage of live cells 
per 100mls of lipoaspirate between UCLA and Edinburgh demonstrating no significant 
differences between centres. 
 
4.5.2 Age, sex, BMI and cold storage time do not affect yield  of SVF or 
PSC. 
!
The mean age was 41 years  (range: 22 to 64, n=129). There were no 
differences observed in either the total number of viable SVF cells, or the 
proportion of PSC as a percentage of live cells with age with linear 
correlation coefficients  (R) of 0.116 and 0.125, respectively  (Figure 4.16 
a&b). No statistical difference  (p > 0.05) was observed in the yield of viable 
SVF cells or PSC between genders  (Figure 4.16c & 4.16d, respectively). 
Body mass index  (BMI) had no significant effect on either the total yield of 
SVF cells, or the proportion of PSC as a percentage of live cells  (R = -0.05 




Figure 4.16. Linear fit of SVF yield & PSC yield  (x106) per 100mls of lipoaspirate with 
respect to donor age  (n=124, R = 0.07 and 0.09 respectively)  (A & B).  One way ANOVA 
analysis of SVF and PSC yield  (x106) versus donor gender  (n=131, male = 19, female = 
112) with green diamonds reflecting the mean yield  (center line) and 95% confidence 
interval  (vertical span) for each gender and the grand mean in gray  (C & D).  Linear fit of 
SVF yield  (E) and proportion of PSC comprising the SVF  (F) with respect to donor BMI  
(n=97, R = 0.05 and 0.01 respectively). 
 
 
After surgical removal, adipose tissue was stored at 4°C until processed. The 
majority of samples were processed within 24 hours following the surgery; 
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however some samples were stored for up to 7 days.  A general decline in 
the yield and viability of SVF cells was observed with increased cold storage 
time with linear correlation coefficients  (R) of -0.05 and -0.20, respectively  
(Figure 4.17 A&B), however this reduction was primarily observed in the 
CD45+ haematopoietic cells  (R = -0.26; Figure 4.17C). The proportion of 
viable PSC comprising the SVF remained relatively constant for up to 48 
hours with no significant effect upon PSC yield per 100ml of lipoaspirate with 
respect to time by linear regression analysis  (R = 0.07; Figure 4.17D). 
 
 
Figure 4.17. Linear fit of various cell isolation parameters from 100cc of adipose 
tissue with respect to storage time at 4⁰C.  Total SVF yield  (A), cell viability  (B), CD45+ 





4.5.3  Optimisation and process control 
 
Work in this chapter has demonstrated the ability to deliver populations of 
pericytes that were subsequently expanded in vitro for further 
characterisation, analysis and experimental work. As interest in these cells 
has developed and their potential for immediate clinical use was explored,  it 
was observed that large numbers of the cells recovered immediately from 
FACS were of poor quality, and were in the process of dying. This had been 
previously overlooked in in vitro populations as only the healthy cells would 
adhere and expand. For PSC to be used immediately after FACS, it is 
imperative to demonstrate that it is possible to recover pure, viable and 
consistent yields of cells. Our protocols were therefore refined to maximise 
not only total cell yield, but maximum viable cell yield, purity and consistency 
leading to the development of an optimized protocol that is described in 
Chapters 2 and 4. Using this protocol it has been demonstrated not only the 
recovery of healthy and pure populations of cells, but that results are under 
statistical control which is fundamental if the immediate use of these cells is 
to be considered a viable option for clinical therapies  (Figure 4.18). 
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Figure 4.18:  Statistical control chart demonstrating that optimization improved the 
reproducibility of PSC isolation and confirming that both the UCLA and UK isolation 
processes are under statistical control.  A Levey-Jennings chart depicting individual data 
points for PSC Yield  (x106) obtained from 100mls of lipoaspirate using the UCLA isolation 
process, before and after optimization, as compared to the UK process  (n=131).  The 
central green line represents the general mean and is delimited by upper and lower control 




Adipose tissue is a unique donor source as it is rich in stem and progenitor 
cells, and can be harvested in large quantities even from individuals of 
normal BMI with minimal morbidity. By developing an understanding of the 
exact identity and location of MSC precursors in vivo, the ability to purify to 
homogeneity two distinct populations of multipotent cells – pericytes and 
adventitial has been demonstrated.  Furthermore, the ability to isolate 
significant numbers of cells from moderate amounts of lipoaspirate has been 
Post-optimisation
Mean = 9.3 million PSC
SD = +/- 5.5 x 10^6
Mean = 13.8 x 10^6 (SD = +/- 10.3x10^6)
Mean = 9.2 x 10^6
(SD = +/- 6.2x10^6) Mean = 9.6 x 10^6
(SD = +/- 4.9 x 10^6
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demonstrated, which in theory should be sufficient to address many clinical 
applications. 
 
In the retrospective analysis of 131 adipose tissue donor samples, a 
theoretical yield of 11.6 million PSC per 100ml of lipoaspirate was 
demonstrated; however, an average of 9.3 million PSC per 100ml is a more 
realistic and consistent estimate of PSC based upon process optimisation 
and data compiled from two different laboratories. Typical cosmetic 
liposuction procedures frequently exceed 1 litre, and therefore it can be 
predicted that sufficient cells can be prospectively isolated to satisfy a range 
of regenerative applications. Table 4.2 summarises in vivo data from our own 
group and also clinical trials registered at www.clinicaltrials.gov, and 
estimates the amount of PSC and hence adipose tissue required for a variety 
of therapeutic uses.  Moderate amounts of adipose tissue would be sufficient 
to provide cells for many of these applications that include tissue engineering 
and the localised stimulation of regeneration. For those applications where 
the application is systemic, or when multiple doses are required, such as 
graft versus host disease, prospective isolation may not be a viable option, 
and ex vivo culture would still be necessary. Estimates made suggest that for 
total ear reconstruction 50 million cells would be required. Based on the data 
provided in this chapter this could be delivered from 400cc of adipose tissue. 
This is not a significant amount of lipoaspirate and could be removed safely 
from adults even in those with a BMI within normal limits. However 400cc is 
less likely to be achievable in children, and therefore the use of PSC without 
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prior ex vivo expansion is unlikely to yield sufficient cells for use in paediatric 
ear reconstruction.  
 
Whilst this data represents the largest published analysis of SVF and 
stem/progenitor cell content, the demographics of this cohort reflect the 
unique type of patient undergoing cosmetic plastic surgery, and might not 
reflect the demographics of people requiring stem cell therapies. Generally 
patients undergoing cosmetic surgery are young to middle age women and 
free from any significant co-morbidities. Whilst these results suggest that age 
is not a factor in PSC yield, the oldest patient in our study was 69. Therefore 
further studies are required on patients at the extremes of age. Furthermore, 
this study was limited to looking only at the number and viability of cells and 
did not examine their function or potency for particular regenerative 
purposes. By selecting a purified population of stem/progenitor cells, it is 
more likely to increase the efficacy of these cells by eliminating 
contaminating cells, however the effects of patient lifestyle, genetic 
background, and other variables on the function of the resulting populations 
should be examined as both age and disease have been implicated in 
reduced function (El-ftesi et al. 2009). This is particularly relevant if an 
allogeneic source of MSC is to be proposed and defended as a viable 
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With respect to the function and application of PSC, at present experimental 
data are limited to in vitro and small animal studies focusing on 
haematopoiesis support (Corselli, Chin, et al. 2013), bone (James, Zara, 
Corselli, Askarinam, et al. 2012; James, Zara, Zhang, et al. 2012), muscle 
(Park et al. 2011), pulmonary (Pierro et al. 2012), peripheral nerve (Lavasani 
et al. 2014) and cardiovascular regeneration (Campagnolo et al. 2010; Chen 
et al. 2012; Katare & Madeddu 2013; Dar et al. 2012; He et al. 2010). In 
these models, the function of PSC has been shown to be equivalent or 
superior to conventional MSC or other progenitor populations. A broader 
assessment of function/potency in a range of assays, and large animal and 
clinical trials, is required before PSC can be deemed to be equivalent or 
perhaps superior to conventional MSC in multiple indications. Evidence from 
other studies demonstrates that pericytes are able to undergo 
chondrogenesis and produce ECM proteins required to generate mature 
cartilage (Farrington-Rock 2004). Furthermore, highly chondrogenic subsets 
of MSC were identified and expressed pericyte markers (W. S. Khan et al. 
2008). This data supports the potential application of adipose derived 
pericytes for auricular tissue engineering.  
 
Technically, the process of purification of PSC in this work relies on 
sophisticated and costly FACS flow cytometers, a device that is not common 
in clinical settings; and there are significant costs associated with the 
acquisition and maintenance of these instruments.  Additionally, clinical-
grade cell sorters have not been approved by regulatory bodies that govern 
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clinical procedures although many companies are now actively involved in 
the development of instruments that address the regulatory requirements 






5 High-throughput microarray screening of a polymer library 
to identify substrates that support the attachment, 






As discussed in chapter 1, there are many different types of biomaterials 
used in regenerative medicine, each with potential advantages and 
disadvantages. A major hurdle in the identification of novel materials has 
been the slow and laborious traditional methods of screening and testing. 
This has led to the development of high-throughput strategies that allow rapid 
and automated screening of multiple materials simultaneously and in parallel.   
 
These techniques were pioneered by 2 main research groups, namely the 
Langer Group  (Massachusetts Institute of Technology) and the Bradley 
Group  (University of Edinburgh). Both groups generated extensive libraries 
of polymers that were printed onto standard microscope slides. Langer 
originally developed a polymer microarray of 576 polymers made from 25 
different acrylate monomers. Using slides coated with poly (HEMA) to 
prevent non-specific cell binding they incubated hESC for 6 days on the 
microarrays in the presence of retinoic acid – a known differentiation factor 
for ectodermal lineages. Through this they were rapidly able to identify 
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substrates that demonstrated enhanced cytokeratin 7  (epithelial marker) 
expression (D. G. Anderson et al. 2004). Whilst this study demonstrated the 
potential of microarrays for cell selection, it did not evaluate the long term or 
large-scale potential of these substrates. 
 
In contrast, the Bradley Group developed and validated two distinct 
approaches in the production of microarrays. The first technique uses contact 
printing of preformed polymers onto the surface of agarose coated slides  
(Figure 5.1). The agarose coating prevents non-specific adhesion of cells to 
the slide, and is optimal for this application as it can be easily UV sterilised, 
and does not dissolve in most organic solvents which would cause leaching 
into the other polymers during fabrication (Tourniaire et al. 2006). The group 
invested significant effort in ensuring all stages of the process were fully 
optimised and characterised to facilitate rapid and efficient identification of 
substrates followed by immediate scale-up. Variables including the type of 
solvent, type of substrate, inking time, stamping time, number of stamps per 
spot and washing conditions were all investigated and shown to have 
significant effects on the shape, uniformity and reproducibility of the printed 
spots. Using this approach the group examined multiple different cell types 
and lines including ESC, iPSC, ADSC and endothelial progenitor cells 
resulting in the development of in vivo scaffolds for tissue engineering (F. 
Khan et al. 2010), coatings for biomedical implants (Pernagallo et al. 2012), 
and pre-clinical tools for drug identification and screening (Hay et al. 2011). 
Significantly, this approach confirmed the ability to rapidly scale up the 
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identified polymers and demonstrate large scale and longterm functional 
benefits. 
 
Figure: 5.1. Microarray printing of polymer libraries on to agarose coated microscope 
slide as developed by the Bradley Group. A Q-arrayermini  (Genetix, UK) machine, using 
aQu solid tipped pins  (K2785, Genetix, UK) inked from a 384 well plate containing 1%  (w/v) 
polymer solutions in N-methylpyrrolidone  (NMP) was used. The central image shows the 
pins inking from a 384 well plate before transferring to the microscope slide. 
 
The second approach was to develop inkjet fabrication of microarrays in 
which the polymerisation occurred in situ on the microscope slide, as 
opposed to the printing of preformed polymers as previously described. 
Monomers, crosslinkers, and initiators can all be printed onto the slide. 
Traditionally this was achieved using water compatible polymers, but with the 
use of organic solvents the repetoire of monomer and reagents that can be 
printed has expanded creating new polymers. The main advantage of this 
system was that the non-contact approach allowed a greater degree of 
control over the size and morphology of the printed dots. Using inkjet 
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fabrication, Hansen et al developed a high density microarray in which over 
7000 polymers were printed on a single microscope slide  (standard 
microarrays developed by the Bradley group contain approximately 380 
polymers). This was used to identify synthetic substrates for the stable long 
term culture of hESC (Hansen et al. 2014). In addition to the printing of dots 
on microarrays, Hansen et al demonstrated the ability to print combinations 
of 2 or more monomers in gradients. In this experiment 84 polymer gradients 
were created and screened with 2 different cell lines. The gradients allowed 
for optimal polymer compositions to be identified from a theoretically infinite 
number of combinations (Hansen et al. 2012). 
 
To allow rapid analysis of the polymer microarrays, high-resolution high 
content  (HCS) systems have been developed that allow detailed imaging of 
structures down to 0.2µm. The systems are based on a standard 
fluorescence microscope attached to a motorised stage. This allows the 
microarrays to be automatically scanned and multiple images of each spot 
can be captured in different channels. When used in conjunction with 
automated image analysis software  (such as the Pathfinder™ software 
package used in this chapter) multiple parameters including cell number, 
shape, size and fluorescence levels can be ascertained from thousands of 
images allowing accurate assessment of multiple assays  (Figure 5.2). 
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Figure 5.2. Workflow of the Bradley Group’s high-throughput screening and analysis. 
Polymer microarrays printed onto the surface of microscope slides in a variety of methods. 
Rapid automated screening and analysis to allow early selction of ‘hit’ polmyers for scale up 
and further biomechanical, in vitro and in vivo assessment. 
 
Biomaterials have been used in ear reconstruction in a variety of 
applications. The first work describing the routine use of a synthetic 
framework to act as a permanent implant was by Cronin in 1966 (Cronin 
1966). Cronin used a soft silastic framework, however he acknowledged the 
principle problem of extrusion associated with this type of implant due to a 
lack of biocompatibility, subsequently abandoning the technique in favour of 
autologous methods.  
 
The most common permanent synthetic framework in current use is 
Medpor® which is a porous polyethylene scaffold. In the largest published 
series comparing autologous and Medpor® based reconstructions, 1864 
patients were studied and significantly higher extrusion rates were seen in 
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also greater overall satisfaction in the autologous group versus the Medpor® 
group  (98% versus 84% respectively) (Yanyong Zhao et al. 2009).  
 
The commonest group of synthetic polymers used for auricular tissue 
engineering are aliphatic polyesters such as poly(glycolic acid) (PGA), 
poly(lactic acid) (PLA) and poly(caprolactone) (PCL), which are 
biodegradable through hydrolysis of the ester linkages. These groups have 
been shown to be biocompatible and support the growth and differentiation of 
both chondrocytes and stem cell populations (Cao et al. 1997). Problems 
arising with these polymers come from acidic degradation products that can 
cause resorbtion of the engineering structure. Immunogenictiy of the 
degradation products (Nayyer et al. 2012), and insufficient biomechanical 
strength to maintain the shape of the engineered structure long term in vivo 
(Shieh et al. 2004) (Cao et al. 1997). Blending of different polymers allows for 
alterations in their degradation rates and has demonstrated improved 
biomechanical function in longer terms studies of 20 weeks in vivo 




The aim of this section is to identify potential synthetic polymers that can be 
used as scaffolds in auricular tissue engineering. In Chapter 4, the ability of 
adipose derived pericytes to function as multipotent mesenchymal stem cells 
was demonstrated. By identifying the unique phenotype of these cells they 
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could be isolated using FACS in sufficient numbers for many clinical 
applications. However, the numbers of cells required for auricular 
reconstruction (approx. 50 million) would require an estimated 400cc of 
lipoaspirate if both PSC populations are used (pericytes and adventitial 
cells), and 1600cc of lipoaspirate if only pericytes are to be used, which is not 
feasible in children. Therefore, in addition to demonstrating the ability to bind 
adipose derived pericytes, the ability of the polymers to support both the long 
term, stable proliferation of cells and their subsequent differentiation is also 
necessary.  
 
Polymer microarrays will be used as a high throughput method to screen a 
library of polyacrylates/acrylamides synthesized from acrylate, acrylamide 
and vinyl monomers as candidates with high binding affinity for human 
adipose derived pericytes. In addition, the ability of these substrates to 
support the stable proliferation of PSC whilst maintaining their phenotype in 
vitro will assessed by performing IHC and flow cytometry on cells grown on 
glass coverslips coated with the specific polymers. Furthermore, polymers 
that are capable of supporting the subsequent differentiation of cells in vitro 
that may be able to act as substrates for the delivery of these cells in vivo will 
be identified using quantitative assessment of functional staining for 
adipogenesis, osteogenesis, and chondrogenesis.  
 
Therefore the specific aims of this chapter are: 
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1. Use a high throughput approach to screen a library of polyurethanes 
and polyacrylates to identify substrates with high binding affinity for 
human adipose derived pericytes 
 
2. Assess the ability of selected polymers to support the stable growth of 
pericytes in extended periods of in vitro culture. 
 
3. Quantitatively analyse the ability of substrates to support and promote 





5.2 Screening of microarrays 
!
!
Microarrays were created from the polymer library as described in Chapter 2. 
Cells were seen to adhere to polymer spots (Figure 5.3C), and also 
consistently adhere to the replicated spots of individual polymers (Figure 
5.3A). Figure 5.3 B shows a polymer with no cells attached. A general 
observation was that the majority of polymers had no, or very few cells 
attached, however those polymers that did bind cells did so in large numbers. 
This was reflected in the mean, median and mode number of cells per 
polymer spot being 3, 2 and 0 respectively, however the range was 0 – 563. 
Figure 5.3D demonstrates nuclear staining using DAPI which was used to 
perform automated cell counts. Figure 5.3E demontrates the retained 




Figure 5.3. Polymer and pericyte binding after 24 hours. Polymer microarrays of 382 
distinct polymers printed onto a single agarose coated glass slide seeded with 500,000 
adipose derived pericytes (Passage 3). A.) Pericytes binding to two replicate polymer spots  
(Brightfield). B.) Polymer demonstrating no cell attachment  (Brightfield). C.) Higher 
magnification of cells bound to polymer spot  (Brightfield). D.) Nuclear staining of cells bound 
to polymer seen through the DAPI channel. E.) ICC staining of cells with CD146  (Abcam 
Inc) demonstrating retained expression whilst bound to polymer. Scale bar 300µm. 
 
Statistically significant differences were observed between the mean values 
of all the groups observed  (p<0.0001), demonstrating significant differences 
in the overall binding ability between polymers. Analysis of each individual 
polymer versus control  (no polymer), demonstrated specific polymers with a 




first analysis can be seen in Table 5.1  (NS = Not significant, * = p<0.05, ** = 
p<0.01, *** = p<0.001).  
PA-27 NS PA-18 NS PA-59 NS PA-132 * PA185 NS PA-329 * PA-3 NS PA-387 NS 
PU-29 NS PU-46 NS PU-102 NS PU-28 NS PU-92 * PU-14 NS PU-73 NS PU-3 NS 
PU-210 NS PU-153 NS PU-105 NS PU-143 NS PU-185 NS PU-134 ** PU-173 NS PU-115 NS 
PA-426 NS PU-254 NS PA-416 NS PU-256 NS PU-259 NS PU-250 NS PU-178 NS PU-162 NS 
PA-141 NS PA-496 NS PA-326 NS PA-470 NS PA-522 ** PA-453 NS PA-513 ** PA-475 NS 
PA-142 NS PA-497 NS PA-327 NS PA-474 NS PA-523 NS PA-458 NS PA-512 NS PA-499 NS 
PA-401 NS PA-215 NS PA-222 NS PA-190 NS PA-358 NS PA-181 NS PA-155 NS PA-137 NS 
PA-43 NS PA-106 NS PA-131 NS PA-210 *** PA-17 NS PA-186 NS PA-58 NS PA-223 NS 
PU-71 NS PU-99 NS PU-104 NS PU-33 NS PU-94 NS PU-19 ** PU-81 NS PU-5 NS 
PU-122 NS PU-156 NS PU-197 NS PU-145 NS PU-187 NS PU-137 NS PU-175 NS PU-128 NS 
PA-429 NS PU-212 NS PA-418 NS PU-244 ** PU-264 NS PU-208 NS PU-203 NS PU-218 NS 
PA-143 NS PA-500 NS PA-323 NS PA-437 NS PA-531 ** PA-459 NS PA-514 * PA-442 NS 
PA-411 * PA-216 NS PA-207 NS PA-199 NS PA-363 NS PA-182 NS PA-154 NS PA-307 NS 
PA-55 NS PA-14 NS PA-138 NS PA-179 NS PA-13 NS PA-204 NS PA-105 NS PA-375 NS 
PU-116 NS PU-69 NS PU-108 NS PU-35 NS PU-96 NS PU-20 NS PU-83 NS PU-7 NS 
PU-257 NS PU-159 NS PU-199 NS PU-148 NS PU-161 NS PU-138 NS EMPTY NS PU-129 NS 
PA-430 NS PU-246 NS PA-419 *** PU-233 NS PA-435 NS PU-242 NS PU-25 NS PU-205 NS 
PA-162 NS PA-504 NS PA-330 NS PA-476 ** PA-528 ** PA-460 NS PA-515 NS PA-443 NS 
PA-397 NS PA-178 NS PA-390 NS PA-357 ** PA336 ** PA-183 NS PA-364 NS PA-306 NS 
PA-100 NS PA-21 NS PA-117 NS PA-113 *** PA-12 NS PA-316 *** PA-20 NS PA-191 NS 
PU-117 NS PU-53 NS PU-110 NS PU-27 ** PU-97 NS PU-22 NS PU-85 NS PU-8 NS 
PU-247 NS PU-164 NS PU-121 NS PU-149 NS PU-189 ** PU-139 ** PU-179 NS PU-130 NS 
PA-431 NS PU-235 NS PA-420 NS PU-223 * PU-205 NS PU-220 NS PU-278 NS PU-239 NS 
PA-163 NS PA-507 ** PA-331 NS PA-477 NS PA-434 NS PA-465 NS PA-517 * PA-444 NS 
PA-393 NS PA-194 NS PA-395 *** PA-201 NS PA337 *** PA-184 NS PA-167 NS PA-309 NS 
EMPTY NS PA-60 NS PA-44 NS PA-19 NS PA-22 NS PA-315 NS PA-56 NS PA-136 * 
PU-118 ** PU-119 * PU-112 NS PU-39 NS PU-98 ** PU-23 NS PU-87 NS PU-10 NS 
PU-236 NS PU-166 NS PU-201 NS PU-151 ** PU-191 ** PU-140 NS PU-181 NS PU-131 NS 
PA-432 NS PU-225 NS PA-421 ** PU-230 NS PU-269 NS PU-222 NS PU-226 NS PU-229 NS 
PA-153 NS PA-508 NS PA-332 ** PA-481 ** PA-360 NS PA-467 NS PA-518 NS PA-446 NS 
PA-394 NS PA-192 NS PA-396 NS PA-187 * PA338 ** PA-185 NS PA-168 NS PA-171 NS 
PA-140 NS PA-218 ** PA-56 NS PA-104 NS PA-23 NS PA-318 * PA-57 NS PA-133 * 
Table 5.1: Results of the first polymer screen after pericytes had been incubated on the 
polymer coated glass microscope slide for 24 hours. Total number of cells bound to polymer 
spots was compared to control areas of no polymer coating. Polymers displaying 
significantly greater binding affinity  (compared to control) highlighted in yellow using 
Dunnett’s Multiple Comparisons Test.  (NS = Not significant, * = p<0.05, ** = p<0.01, *** = 
p<0.001). 
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5.2.1 Development of ‘hit’ array 
!
Analysis of the results from the microarray data identified 5 polymers that 
showed significantly higher binding affinity when compared to control on all 4 








PA133! *! *! *! **!
PA187! *! *! **! **!
PA210! ***! **! *! ***!
PA337! ***! **! **! ***!
PA338! **! ***! ***! **!
Table 5.2: A summary of the ‘hit’ polymers demonstrating 5 polymers with significantly 
enhanced binding efficacy compared to control in each of the 4 screens performed using 
different donor cells  (* = p<0.05, ** = p<0.01, *** = p<0.001). 
 
Based on these results from the initial screens, a “hit” array was developed 
using the same microarray printing techniques described in Chapter 2. The 5 
polymers identified in Chapter 5.2.1 were cross-referenced with a library of 
over 2000 other polymers to identify similar, yet distinct polymers to include 
in this array  (Table 5.3). The “hit” array thus contained 19 polymers each 























PA!132! MEMA! VPF4! ! 90! 10!
PA133! MEMA! VPF4! ! 70! 30!
PA134! MEMA! VPF4! ! 50! 50!
PA135! MEMA! VPF2! ! 90! 10!
PA136! MEMA! VPF2! ! 70! 30!
PA137! MEMA! VPF2! ! 50! 50!
!
PA186! HEMA! VPF4! ! 90! 10!
PA187! HEMA! VPF4! ! 70! 30!
PA188! HEMA! VPF4! ! 50! 50!
PA189! HEMA! VPF2! ! 90! 10!
PA190! HEMA! VPF2! ! 70! 30!
PA191! HEMA! VPF2! ! 50! 50!
!
PA210! MMA! EGMPFH! ! 90! 10!
PA225! MEMA! EGMPFH! ! 90! 10!
PA226! MEMA! EGMPFH! ! 70! 30!
PA227! MEMA! EGMPFH! ! 50! 50!
!
PA336! MMA! GMA! MAn! 90! 10!
PA337! MMA! GMA! MAn! 70! 30!
PA338! MMA! GMA! MAn! 50! 50!
 
Table 5.3: Generation of a ‘hit’ array. The 5 candidate polymers identified in the initial screen  
(yellow) were cross-referenced with the extended polymer library to identify similar polymers 
for further analysis and evaluation. 
 
‘Hit’ polymer screens were performed with 2 separate patient samples  (n=2), 
which were different to the samples used in the initial screen, and each array 
was performed in duplicate. Slides were fixed and analysed as described in 
Chapter 2. Analysis of the all the groups demonstrated significant differences  
(p<0.001) between the groups. As the hit array had been developed from 
polymers known to have a high binding affinity for pericytes, it was decided to 
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use the mean value of all the groups tested instead of no polymer as the 
standard control when analysing specific polymers. Using this method 5 
polymers demonstrated significantly greater binding ability compared to the 
mean of all groups; PA133  (P<0.05), PA136  (P<0.05), PA210  (P<0.05), 




Figure 5.4: Analysis of hit polymers showing the total number of cells bound to each 
polymer after 24hours incubation. Results represented as box and whisker plots showing 
mean, range and upper and lower quartiles, with results grouped according to the family of 
polymers they are from. Mean of all polymers is seen in pink, those polymers demonstrating 




5.2.2 Intra sample correlation 
!
!
To determine the reproducibility of the individual polymers ability to bind 
pericytes, the screening process was repeated with the same patient cell 
sample on 2 separate occasions. The cells for each experiment were from 
different stocks and at different passage (Passage 3 and passage 8) in an 
effort to maximise the heterogeneity between the 2 samples and minimise 
the chance that the cells were derived from an identical population or clone. 
Results were calculated as the mean number of cells bound to each 
replicated polymer spot  (n=8). These data were plotted to demonstrate those 
polymers that displayed the best intra sample correlation. Data was analysed 
using nonparametric Spearman correlation, and 2 tailed t-test. Results of this 
experiment demonstrate that there was excellent reproducibility when the 
same sample was screened at different passages  (r = 0.82, 95%CI = 0.69 – 
0.9, p<0.0001). Polymers identified from the hit array are highlighted in 








Figure 5.5: Assessment of intra-sample correlation represented by comparing the numbers 
of cells bound to each polymer spot when the screen was repeated with cells from the same 
donor after 24 hours of incubation. Screen 1 = passage 3 cells, screen 2 = passage 8 cells. 
Spearman correlation demonstrated strong correlation  (r=0.82, 95%CI = 0.69 – 0.9, 
p<0.0001) and hence strong reproducibility of the polymers tested. Polymers identified from 
the hit array are highlighted in the upper right quadrant demonstrating both high binding and 
excellent intra-sample reproducibility. Data plots grouped according to family of polymers 
(Blue circle = PA132 – 137, orange diamond = PA186 – 191, green triangle = PA210 – 227, 
red square = PA336 – 338). 
!
5.2.3 Inter sample correlation 
!
!
To determine the reproducibility of the individual polymers ability to bind 
pericytes from different donors, the screening process was performed with 
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pericytes from 2 separate donors  (n=2) and repeated. This information was 
important to ensure the candidate polymers we selected would bind pericytes 
from multiple, and not specific donors. Results were calculated as the mean 
number of cells bound to each replicated polymer spot  (n=8). These data 
were plotted to demonstrate those polymers that displayed the best inter 
sample correlation. Data was analysed using nonparametric Spearman 
correlation, and 2 tailed t-test. Results of this experiment demonstrated good 
reproducibility when the experiment was repeated with different donor 
samples  (r=0.51, 95%CI = 0.12 – 0.76, p = 0.01). Polymers identified from 
the hit array are highlighted in figure 5.6 demonstrating both high binding and 




Figure 5.6: Assessment of inter-sample variation represented by comparing the numbers of 
cells bound to each polymer spot when the screen was repeated with cells from different 
donors. Spearman correlation demonstrated good correlation  (r=0.51, 95%CI = 0.12 – 0.76, 
p = 0.01) and hence good reproducibility of the polymers tested. Polymers identified from the 
hit array are highlighted in the upper right quadrant demonstrating both high binding and 
good inter-sample reproducibility. Samples were analysed after 24 hours of incubation. Data 
plots grouped according to family of polymers (Blue circle = PA132 – 137, orange diamond = 
PA186 – 191, green triangle = PA210 – 227, red square = PA336 – 338). 
 
5.3 In vitro effects of polymers on PSC 
!
 
The 5 candidate polymers were dissolved in solvent  (PA133, 136, 337, 338 
in THF, and PA210 in NMP) to make a final solution of 2%  (w/v). Individual 
polymers were then spin coated onto the surface of standard glass coverslips 
using a Spincoater Model P6700 Series  (Specialty Coating Systems, Inc). 
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Slides were dried overnight at 40°C in a vacuum oven  (Full details described 
in Chapter 2). All subsequent experiments were performed with the glass 
coverslips placed in the bottom of a low adherence 12 well plate  (Corning 
Supplies) unless otherwise specified. A glass coverslip with no polymer 
coating used as control. Low adherence plates were used to prevent the 





5000 pericytes in 2ml of SGM were placed onto the surface of polymer 
coated glass coverslips and differences in morphology were observed.  In the 
control wells with uncoated glass cover slips, pericytes formed an evenly 
spaced monolayer of cells with typical fibroblast like appearance  (Figure 5.7 
F). A similar morphology was seen in the cells plated on PA210 coated glass 
coverslips  (Figure 5.7 C). Cells grown on coverslips coated with PA337 and 
PA338 initially formed a monolayer but subsequently continued to rapidly 
proliferate and continued to grow past confluency. The resulting cultures 
demonstrated densely packed layers of overlying cells that apparently lacked 
the normal cell to cell inhibition  (Figure 5.7 D & E). Cells grown on coverslips 
coated with PA133 developed thin spindle like projections that communicated 
with other cells, at higher confluency these formed into ridges of cells  (Fig 
5.7 A). Cells grown on PA136 had similar morphological characteristics to 
those plated on PA133  (Fig 5.7 B), however in addition they also formed 
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Figure 5.7: Morphology of pericytes grown on polymer coated glass cover slips. A.) 
Cells placed on polymer PA133 with spindle shapes at low density. B.) Cells placed on 
PA136 showing formation of ‘perispheres’  (Yellow box). C.) Cells placed on polymer PA210 
displaying normal morphology. D) & E) Cells placed on PA337 and PA338 respectively 
rapidly grew to overconfluency with lack of cell to cell inhibition. F.) No polymer  (control). 




Perispheres are a feature that have been previously observed in pericytes 
grown in standard conditions, however they only appeared after cells had 
been cultured for long periods in vitro, and were left to grow beyond 
confluence. The appearance of perispheres in cells plated on PA136 
occurred immediately and at low density, which has not been previously 
observed. Other than their early appearance at low density, the perispheres 
seen on the PA136 coated glass coverslips were indistinguishable from 
those previously seen. They range in size from 100 - 400µm  (Figure 5.8 
A&B), are able to detach from the base of the well and become freely mobile 
and merge with other spheres  (Figure 5.8 C), and can repopulate a 





Figure 5.8: Perispheres formed from cultures of pericytes grown on glass cover slips 
coated with polymer PA136. A & B Formation of perispheres. C. 2 mobile perispheres 
merging together. D. A perisphere transferred to an empty uncoated well and regenerating a 
monolayer of cells  (x20). 
 
PA136 coated coverslips with perispheres were placed in 2ml of adipogenic 
medium  (StemPro® Adipogenesis differentiation kit, Gibco™) and media 
was changed every 48 hours for 1 week. It was observed that the cells 
migrating out from the periphery of the perisphere were highly adipogenic, 
however the cells in the centre did not differentiate and appeared to continue 




Fig 5.9: Perisphere placed in adipogenic medium for 1 week showing cells emerging from 
the periphery of the sphere rapidly differentiating into adipocytes  (x40). Scale bar = 100µm 
 
To further assess the characteristics of the perispheres, ICC was performed 
to determine the phenotype of cells in the centre of the perisphere and those 
emerging from the periphery. ICC was performed using the protocol 
described in Chapter 2. Perispheres were stained for pericyte markers and 
also markers associated with pluripotency (Oct-4). Cells at the periphery of 
the sphere, and those growing out from it demonstrated the normal pericyte 
phenotype with positive expression of pericyte markers. Interestingly, the 
cells in the centre of the sphere demonstrated much weaker expression of 
pericyte markers  (Fig 5.10 A & B). When stained with markers associated 
with pluripotency, cells in the centre of the sphere showed positive 
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expression of Oct-4, however this expression was absent in cells at the 
periphery and those growing out from the perispheres  (Fig 5.10 C). 
 
 
Figure 5.10: Staining of perispheres demonstrating week expression of pericyte markers on 
cells in the centre of the sphere with strong expression in cells emerging from the periphery  
(A & B). Oct-4, a marker associated with pluripotency that is not normally expressed by 
pericytes was also expressed in cells found in the centre of the speheres but absent in those 
emerging from the periphery  (C)  (x40). 
 
To further analyse the perispheres, FACS was performed on cells from the 
perispheres  (nodules) and those from the monolayer of cells outside of the 
nodules. FACS analysis supported the ICC data and demonstrated 89% of 
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cells in the centre of nodules showing positive Oct-4 expression, but no 
expression seen in the cells from outside the nodule  (Figure 5.11).  
 
To further examine and confirm these observations, the mRNA expression of 
pluripotency genes Oct4 and Nanog was assessed in cells from perispheres  
(nodules) compared to the total population.  Higher levels of both genes were 
detected in cells from nodules when compared to cells from the monolayer. 
Relative expression of Oct-4 was 447 versus 17, and Nanog was 249 versus 





Figure 5.11: A. FACS analysis of cells contained within nodules  (perispheres) 
demonstrating 89% of cells with positive expression of Oct4. B. Analysis of cells outside of 
nodules demonstrating 0% of cells with positive Oct4 expression. C. RT/qPCR of total cell 
population  (purple) versus cells from nodules  (crimson) demonstrating higher mRNA 
expression of Oct4 and Nanog in cells from within nodules.  (Data and figures provided by 
M. Crisan) 
 
5.3.2 Long term culture 
!
!
The ability of the polymer-coated coverslips to maintain stable pericyte 
phenotype through extended periods of in vitro culture was assessed using 
flow cytometry to examine the proportion of cells expressing pericyte specific 
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and MSC associated surface markers. Pericytes from different donors  (n=2) 
were seeded onto the surface of polymer coated glass coverslips and 
cultured in SGM at 37°C until the cells became confluent. At this point cells 
were removed from the polymer coated coverslips with 0.25% trypsin. 20% of 
recovered cells were replated on new polymer coated coverslips, the 
remaining 80% were analysed at passage 3, 6 and 9 for their surface marker 
phenotype by flow cytometry using the protocols described in Chapter 2. 
Data is represented as the average value from all donors. 
 
Expression of pericytes markers CD146 and PDGFR-β was retained at high 
levels  (>95%) on polymers PA210, 337, 338 and control. A gradual 
decrease in CD146 positive cells was seen on polymer 133  (92% at 
passage 9), with a marked decrease seen on polymer 136  (76% at passage 
9)  (Figure 5.12). This decrease was seen in association with an increase in 
the formation of perispheres  (see previous section). 
 
 
Figure 5.12. Expression of pericyte markers by cells cultured on polymer coated cover slips. 
A. Expression of CD146. B. Expression of PDGFR-β. 
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Expression of MSC marker CD105 followed a similar pattern to pericyte 
markers with high levels of expression  (>95%) on polymers PA210, 337, 338 
and control. A slight decrease observed on polymer PA133  (91% at passage 




Figure 5.13. Expression of CD105 by cells cultured on polymer coated glass coverslips. 
 
Expression of other markers  (CD31, CD34, and CD45) was negative 





The ability of the individual polymers to support, and potentially enhance the 
differentiation of pericytes into mesodermal lineages in vitro was assessed. 
Polymer coated glass cover slips were created as detailed in Chapter 2, prior 
to subsequent experiments. Passage 4 and 5 pericytes from n=3 different 
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donors were seeded on to the polymer-coated glass coverslips at an initial 
density of 10,000 cells per well for osteogenesis, and 20,000 cells per well for 
adipo and chondrogenesis in SGM and allowed to attach for 48hours. Slides 
were then washed 3 times in PBS to remove dead or non-adherent cells and 
the media changed to either osteogenic or adipogenic media  (StemPro® 
Adipogenesis / Osteogenesis / Chondrogenesis differentiation kit, Gibco™). 
Thereafter, media was changed three times each week for a total of 3 weeks 
for adipo and osteogenesis and 4 weeks for chondrogenesis. At the end of 





Osteogenesis was quantified using an alizarin red elution assay as described 
in Chapter 2 (Gregory et al. 2004). Briefly, slides were fixed and stained with 
alizarin red to demonstrate the presence of mineralization as seen by red 
staining. Alizarin red was then eluted using acetic acid, neutralized with 
ammonium hydroxide and then quantified using colourimetric detection at 
405nm. 
 
Osteogenic differentiation was observed in all wells tested however there 
were clear variations between patient samples where there was a general 
trend for ADP31 to show the most evidence of mineralization and ADP37 to 
show the least  (Figure 5.14 A). 
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General trends were observed in the ability of the polymers to support 
osteogenesis with PA133, PA337 and PA338 performing better then control, 
and PA136, PA210 worse than control. There were no significant differences 
observed between the means of the groups when analysed using the 
Kruskall-Wallis test. Furthermore, no significant differences were observed 
when the individual groups were compared with each other using Dunn’s 
multiple comparisons test. 
 
 
Figure 5.14. Osteogenesis on polymer coated glass coverslips. A.) Appearance of cells 
following 3 weeks of osteogenic differentiation on polymer coated glass coverslips (Stained 
with Alizarin Red). B.) Elution of staining prior to assessment. C.) Quantitative assessment of 
osteogenesis using colourimetric assessment of mineralization using Alizarin Red staining. 




Adipogenesis was quantified using an Oil Red O elution assay  (Chemicon® 
International – ECM950). Following 3 weeks of differentiation in Adipogenic 
growth media cells were fixed and stained with Oil Red O to demonstrate the 
presence of intracellular lipids. Cells were stained following the protocol 
described in chapter 2. Following this, 0.5ml of Dye Extraction Solution was 
added to each well and transferred to an orbital shaker for 15 minutes. 150µl 
of the solution was then transferred in triplicate to the wells of a 96 well plate 
and quantified using colourimetric detection at 520nm. 
 
Clear differences in the degree of differentiation were observed between the 
cells grown on different polymer coatings. This was confirmed on quantitative 
assessment of adipogenesis. ANOVA  (Kruskall-Wallis test) demonstrated 
significant differences in the means of the groups analysed  (P = 0.01), and 
when Dunn’s multiple comparisons test was applied to compare all groups, 
significant differences was observed between PA133  (worst performing) and 
PA338  (best performing) (P < 0.01).  
 
PA337 and PA338 both showed greater amounts of lipid production 





Figure 5.15. Adipogenesis on polymer coated glass coverslips. A.) Apperance of cells 
before staining following 3 weeks of adipogenic differentiation on polymer coated glass 
coverslips. Intracellular lipid droplets can be seen. Scale bar 200µm B.) Quantitative 
assessment of adipogenesis using colorimetric assessment of Oil Red O staining of lipid 
production. Significant differences in lipid production were observed between PA133 and 





Chondrogenesis was quantified using an alcian blue elution assay as 
described in Chapter 2. Briefly, slides were fixed and stained with alcian blue 
to demonstrate the presence of GAGs. Alcian blue was then eluted using 
0.5ml of 1M HCl, and then quantified using colourimetric detection at 620nm. 
 
Chondrogenesis of pericytes (n=3) was demonstrated in all samples cultured 
in chondrogenic media on polymer coated coverslips and also control wells 
with no coating as evidenced by the presence of GAGs and positive blue 
staining with alcian blue (Figure 5.16 A). 
 
Genral trends were observed with PA133 and PA337 coated coverslips 
showed greater amounts of GAG production when compared to other 
polymers and controls. There were no significant differences observed 
between the means of the groups when analysed using the Kruskall-Wallis 
test. Furthermore, no significant differences were observed when the 






Figure 5.16. Chondrogenesis of adipose derived passage 4 and 5 pericytes (n=3) on 
polymer coated glass coverslips. A.) Apperance of cells following 4 weeks of 
chondrogenic differentiation on polymer coated glass coverslips (Staining with alcian blue). 
B.) Quantitative assessment of chondrogensis using colorimetric assessment of alcian blue 
staining. No significant difference were observed using Dunn’s multiple comparisons test. 
 
5.4 Polymer analysis 
 
 
The 5 lead polymers identified through the initial screens were all from a 
library of co-polymers synthesised from acrylate, acrylamide and vinyl 
monomers. A summary of the composition of these monomers can be seen 
in table 5.4.  
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PA133 MEMA VP-4  70 30 
PA136 MEMA VP-2  70 30 
PA210 MMA EGMP-H  90 10 
PA337 MMA GMA MAn 70 30 
PA338 MMA GMA MAn 50 50 
Table 5.4. The composition and ratio of monomers in the selected polymers. 
 
It can be seen from this table methyl methacrylate  (MMA) is present in 3/5 
polymers, 2-Methoxyethylmethacrylate  (MEMA) and N-methylaniline 
functionalized glycidyl methacrylate  (GMA) are each present in 2/5 polymers 
with 2-vinylpyridine  (VP-2), 4-vinylpyridine  (VP-4) and ethylene glycol 
methacrylate phosphate  (EGMP-H) each being present in 1/5 polymers. 
 
Four of the 5 polymers contained monomers with amine groups. VP-2, and 
VP-4 both contain tertiary amines, whilst MAn which was used to 
functionalise GMA in PA337 and PA338, contains a secondary amine. These 
nitrogen containing moieties can form bonds with hydrogen presenting 
molecules such as water and proteins including integrins which are important 
in cellular attachment. Amines and the phosphate group contained in EGMP-
H are commonly found in the body and therefore these moieties are thought 
to demonstrate desirable biocompatibility (Table 5.5). Methyl Methacrylate  
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(MMA) was present in 3/5 polymers. Previous work has demonstrated the 
methyl  (-CH3) functional group to play a critical role in the maintainence of 
stem cell state in MSC (Curran et al. 2006; Benoit et al. 2008). 
 
 





























































Within this chapter a high throughput approach has been utilised which has 
successfully identified candidate polymers that can be used to support the 
long term, and stable growth of pericytes, whilst maintaining their phenotype. 
Polymers were also shown to support osteo-, adipo- and chondro-genesis of 
pericytes .  
 
Initial screen rapidly identified a small number of distinct polymers that 
preferentially bound populations of human adipose derived pericytes on 
repeated testing. The results shown within this chapter suggest that polymer-
cell interactions are specific due to the small number of polymers that bound 
cells compared to the large numbers of polymers that showed little or no 
binding. This effect may be enhanced by the fact that homogenous 
populations of purified pericytes were used for the screening thus minimizing 
the effects of any heterogeneity or contamination within the cell samples. In a 
similar experiment using heterogenous adipose derived MSC, the number of 
candidate polymers was significantly larger (Duffy et al. 2014). Further 
evidence that the polymers identified within this experiment are specific to 
pericyte binding and function are that they are entirely distinct from the 
polymers identified when the microarray was used with other distinct cell 
populations (Hay et al. 2011; Pernagallo et al. 2012). 
 
The effects of polymers on the behavior and function of pericytes was 
assessed and quantified. All polymers tested were able to support the long 
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term and stable proliferation of pericytes when assessed using flow 
cytometry. Growth rates on polymers PA337 and PA338 were greatest and 
cells appeared to lack the normal cell-cell contact inhibition seen in standard 
culture. Osteogenic, adipogenic and chondrogenic differentiation was 
quantified, and although differences were observed between polymers they 
were not siginificant. Whilst general trends were observed, differences in the 
ability of cells to differentiate between different patient samples produced 
large variation in the results making statistical significance difficult to 
demonstrate with this relatively small sample size. This has potential clinical 
implications if that variation limits the ability of individual donors cells to 
adequately differentiate to the require purpose. 
 
Assessment of the ability of polymers to support chondrogenesis was 
performed in monolayer cultures. Staining using alcian blue demonstrated 
the production of GAGs and therefore showed that pericytes are capable of 
producing cartilage specific ECM. Monolayer culture and quantification of 
GAG production is not sensitive enough to assess whether enough ECM is 
produced to engineer biomechanically stable cartilage able to withstand the 
forces associated with ear reconstruction. Assays that will allow this to be 
ascertained using 3-dimensional tissue engineering are currently being 





The basic principle of plastic and reconstructive surgery is to restore form 
and function. In doing this, surgeons have to balance the potential benefits 
against the risks and morbidity associated with the procedure. Auricular 
reconstruction is an example where the morbidity associated with the harvest 
of costal cartilage has prompted surgeons to seek for alternatives to the 
current practice.  
 
Studies using a variety of cells types, biomaterials and fabrication techniques 
have aimed to generate cartilage de novo for the purposes of auricular 
reconstruction. Depsite much effort, the results have been variable and no 
techniques are currently being used in routine clinical practice. However, the 
combination of appropriate stem cells seeded onto a suitable scaffold 
appears to be the most likely to deliver the solution. Thus the aims of this 
project were to identify cells and substrates for the purposes of auricular 
reconstruction. 
 
Mesenchymal stem cells have been studied extensively for their ability to 
differentiate into mesodermal lineages in vitro (Caplan 2007), and their ability 
to generate chondrocytes is well established (A. H. Huang et al. 2005). 
Traditional sources of MSC such as bone marrow are limited in the amount 
of tissue that can be harvested, and also the morbidity associated with that 
harvest. Adipose tissue has been shown to be a source of MSC, and in 
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contrast to bone marrow can be harvested in large quantities with minimal 
morbidity. Therefore the first section of this thesis sought to establish a tissue 
bank to collect, store and utilise adipose derived MSC for research. 
 
Prior to establishing the tissue bank we sought to gain an understanding of 
the attitudes of potential donors toward tissue donation and the use of stem 
cells in research. Whilst 82% of patients had heard of stem cells, only 4% 
were aware that adipose tissue was a useful source of stem cells for 
regenerative medicine. Despite this lack of knowledge, after a simple 
explantion all patients stated they would be happy to donate tissue. 
Therefore, despite a prior lack of knowledge, patients undergoing cosmetic 
lipectomy procedures present as excellent potential donors. Tissue collected 
through the tissue bank has been used to facilitate the research contained 
within this thesis and numerous other projects and successful grant 
applications.  
 
Data from our group and others has demonstrated the ability of pericytes to 
function as MSC in vitro, and that these cells may represent the in vivo 
counterpart of the MSC previously observed (Crisan et al. 2008; Covas et al. 
2008). These findings were confirmed specifically with pericytes from 
adipose tissue. Using IHC it is demonstrated that pericytes reside in vivo on 
the abluminal surface of endothelial cells and can be identified by a unique 
surface marker profile. They express markers associated with conventional 
MSC both in vivo and when cultured ex vivo. In addition they can differentiate 
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into multiple mesodermal lineages when cultured in the appropriate 
conditions, including chondrogenesis as assessed by staining with Alcian 
Blue.!
 
This unique surface marker profile can be used to prospectively isolate 
purified populations of cells using FACS. In addition, adipose tissue contains 
a second anatomically and phenotypically discrete population of MSC 
precursor – adventitial cells– together with pericytes they are referred to as 
perivascular stem cells  (PSC). These cells can be purified to homogeneity 
using flow cytometry in clinically relevant numbers from modest amounts of 
lipoaspirate thus potentially eliminating the need for purification and 
expansion by in vitro culture prior to clinical application. The number and 
frequency of cells are minimally affected by factors such as age, sex, BMI 
and storage time in this cohort, however further studies are required to 
examine the effects of extreme age and pathology on the number and 
efficacy of these cells.  
 
With specific reference to the use of these cells in auricular reconstruction, it 
is estimated that 50 million cells would be required to generate sufficient cells 
for clinical use. Based on the data presented within this chapter that would 
require on average 400cc of lipoaspirate if both PSC populations were to be 
used, and 1600cc if only pericytes were to be used. Therefore, prospective 
use of PSC is not a viable option in children where 400cc of lipoaspirate is 
unlikely to be achievable, and cells expanded in vitro will be required.  
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Through the use of the high-throughput microarray platform, distinct 
polymers that support the long term phenotype of pericytes in vitro have 
been identified. Assays that can sensitively quantify the abilty of the polymers 
to support chondrogenesis are actively being developed. In particular assays 
that allow the quantification of cartilage specific ECM are required to show 
that the cells are capable of generating cartilage capable of the requirement 
of in vivo implantation and long term survival. 
 
Work that has contributed toward this thesis has led to the establishment of a 
biobank that has provided cells for this project and numerous collaborations. 
In addition it has highlighted the need for clinicians and researchers to 
understand patients attitudes towards research and tissue donation in order 
to maximise access to tissue. The patients encountered in this study were 
very willing to donate tissue when provided with the appropriate information.  
 
The ability to purify pericytes from adipose tissue using FACS has been 
demonstrated, and they have been shown to be a candidate cell source of 
mesenchymal tissue engineering. The ability to demonstrate their purity and 
identity has significant advantages over conventional MSC in terms of clinical 
translation. However, robust evidence that they are able to produce cartilage 
of the quality required for tissue engineering is lacking.  
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This thesis provides a detailed analysis of the identitiy of stem cells within 
adipose tissue and confirms their niche to be perivascular. It is the largest 
analysis of the stem cell content of adipose tissue within the published 
literature, and details the patient and procedure based factors that may 
influence this yield. This is fundamental information for the clinical translation 
of these cells. 
 
Distinct synthetic polymers that are able to support the attachment, long term 
stable proliferation and subsequent differentiation of pericytes have been 
identified. These polymers have been shown to support this action in vitro, 
and thus provide the basis for the design of scaffolds for in vivo implantation. 
 
Collectively this body of work provides the platform on which further studies 
can be based with the aim of delivering a tissue engineered auricle for 





7 Future directions and preliminary studies 
 
7.1 Assays of chondrogenesis and cartilage tissue engineering 
 
Professor Anthony Hollander  (Currently The University of Liverpool, 
previously The University of Bristol) 
 
The most widely used in vitro assay of chondrogenesis is the ‘pellet’ in which 
300,000 – 500,000 cells are centrifuged to form a pellet which is then placed 
in chondrogenic differentiation media for a period of 4-6 weeks, as 
demonstrated in Chapter 4.  This assay is believed to replicate the early 
condensation of mesenchymal precursors in the developing limb buds that 
subsequently differentiate into cartilage. The pellet assay has been used to 
demonstrate the ability of stem cells, including MSC and PSC, to differentiate 
in to chondrocytes. Despite this, it is not itself clinically translatable as the 
conditions in which the assay are performed can not be scaled up to clinically 
relevant models.  
 
Whilst this assay has been used and replicated in many publications, it has 
significant limitations and drawbacks. Each pellet requires 300,000 – 500,000 
cells, and can only be used for a single type of analysis eg Histology or 
PCR/qPCR or quantification of protein/ECM production. Furthermore, due to 
the small amounts of RNA and protein recovered from a single pellet, 
multiple pellets are required for each assay performed. Experience from this 
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work found that an average of 8 pellets were required to recover enough 
RNA to perform basic qPCR experiments. Therefore once replicates are 
included the number of cells required for a single experiment is very large 
and makes assessing different factors prohibitively difficult. Therefore, I have 
sought to learn and develop alternative assays that required fewer cells, 
were relevant to the ultimate aim of generating tissue engineered cartilage, 











Figure 7.2 Discs of neo-cartilage generated from MSC using the protocol described in 
Figure 7.1. 
 
I had initially planned to combine this technique with the polymers identified 
in chapter 5 and coat the PGA discs with the polymers and quantify their 
effects on chondrogenesis. However, the polymers are dissolved in solvents  
(THF and NMP) and when the PGA discs were placed in the polymer 
solutions, they dissolved and lost their structure making further assessment 
impossible. To avoid this issue I aim to develop scaffolds from the polymers 





7.2 Identification of chondrogenic subsets of MSC / PSC 
 
In collaboration with Professor Anthony Hollander – University of Liverpool. 
The manuscript generated from this work is currently under review with 
Science; Translational Medicine. 
 
Cultured MSC are recognized as heterogenous populations of cells. This was 
clearly demonstrated by Guilak et al who showed that there was marked 
variation in the ability of different clonal populations of ADSC to differentiate 
into multiple lineages. Only 52% of clonal populations were able to 
differentiate into 2 or more lineages, with only 43% demonstrating 
chondrogenic ability (Guilak et al. 2005). 
 
Surface markers that have been used to define MSC (Dominici et al. 2006) 
are neither inclusive nor exclusive of the ability to differentiate into 
mesodermal lineages and therefore are not reliable markers for MSC 
function. For example, CD105 expression has been shown to be inversely 
related to osteogenic potential of MSC (Levi et al. 2011). It is therefore 
recognized that MSC are likely to harbor subsets of cells with specific 
functions, and the need to identify functional markers of subsets is required. 
A method of identifying and isolating MSC with an enhanced capacity for 
cartilage formation would be a useful tool in regenerative medicine.  
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In an experiment designed to identify markers for highly chondrogenic 
subsets of MSC, Professor Anthony Hollander and his team produced 
multiple MSC clones from human bone marrow and quantitatively assessed 
their ability to differentiate into chondrocytes, produce proteoglycans and 
type II collagen. mRNA was extracted from the 4 clones that demonstrated 
the highest and lowest chondrogenic ability and analysed using a gene 
microarray to identify surface markers that were exclusively expressed by the 
highly chondrogenic clones. Using this platform, ROR2 - a Wnt5a receptor - 
was identified as a marker predictive of highly chondrogenic subsets of MSC. 
Using ROR2 positive cells, Professor Hollander and colleagues have 
demonstrated enhanced chondrogenesis in vitro, and also in large animal 
models with 30% more tissue engineered cartilage produced compared to 
control. They also observed a 70% increase in the production of 
proteoglycans, and a high type II versus type I and X collagen ratio, which 
indicates high quality cartilage.   
 
All of the observations so far had been made using cells cultured and 
expanded in vitro. Professor Hollander asked our group to help determine if 
ROR2 expression was an artifact of the in-vitro process, or if ROR2 was also 
expressed natively by MSC. Using techniques identical to those described in 
Chapter 4 to demonstrate the location and identity of pericytes,  I was able to 
demonstrate the native expression of ROR2. Using immunohistochemistry, 
ROR2 expression was observed in the developing limb bud and co-localised 
with MSC markers CD90 and CD105, and pericyte marker CD146. Smaller 
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numbers of ROR2 positive cells were also seen in perivascular locations in 
adult bone marrow sections. Using flow cytometry on freshly isolated adipose 
tissue and bone marrow, ROR2 positive cells were observed. 67% of the 
CD146+ pericytes in bone marrow were ROR2 positive compared to 19% of 
the pericytes in adipose tissue. This data confirmed that ROR2 positive MSC 
precursors are a native cell, and that they are present in more than one 
tissue type. Whilst the bulk of the work in this thesis used standard pericytes, 
future work will aim to evaluate the potiential of adipose derived ROR2 





7.3 Purification and culture of clinical grade cells 
 
In collaboration with Professor John Campbell, Scottish National Blood 
Transfusion Service  (SNBTS). £12,000 of funding already secured from 
William Rooney Plastic and Burns Surgery Research Trust. 
 
MSC have been the focus of much attention due to their ability to differentiate 
into mesodermal tissue, to modulate the immune system and to stimulate 
regeneration through the secretion of cytokines and trophic support. Through 
this research 2 anatomically and phenotypically distinct populations of MSC 
precursors that reside in the walls of blood vessels – namely perivascular 
stem cells  (PSC) have been identified. As detailed in chapter 4, methods for 
the purification and isolation of these cells using fluorescence activated cell 
sorting  (FACS) have been developed. Using cells isolated by this method 
our group has demonstrated in a range of in vitro and in vivo assays a 
function that is equal to, and on occasions superior to standard MSC. The 
ultimate aim is to translate this pre-clinical research to novel therapies for a 
range of different treatments including auricular reconstruction. 
 
Whilst FACS allows purification of cells for use in research, there are very 
few FACS machines that are licensed for use in humans and their cost at 
present make their use prohibitively expensive. Therefore, to allow 
translation of pre-clinical research to human therapies, an alternative method 
of prospective purification needs to be considered. Magnetic cell sorting  
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(MACS) is similar to FACS and allows specific cells to be purified based on 
surface marker profile. Magnetic Cell Sorting  (MACS) also uses antibodies 
against specific cell surface markers but the particles are conjugated to 
paramagnetic particles and not fluorescent particles. Significantly, this 
technique is licensed for human use with clinical grade antibody conjugates 
and the CliniMACS separator readily available. This method has been used 
to purify a variety of different cells used in clinical trials. MACS reagents are 
available at lab and clinical scale. Therefore, small scale experiments can be 
directly scaled up to clinical scale. A current collaboration with SNBTS to 
modify the current FACS based protocols to utilise MACS to derive PSC at 
clinical grade. If successful, this fundamental step would allow us to translate 
our research findings to use PSC in clinical trials.  
 
Translation of FACS protocols where populations are excluded by electronic 
gating, and the selection of specific cells by collection of the desired fraction 
can be reproduced by magnetic selection by first magnetically depleting the 
start population of unwanted cells, and then positive enrichment of the 
desired cells. Our existing FACS protocol excludes CD45+  (haematopioetic) 
and CD31+  (endothelial) cells, these can be depleted from primary adipose 
mononuclear cell preparations using biotinylated antibodies to these markers 
and anti-biotin MACS beads. We will compare the efficiency of depletion 
using 3.5um MACSi beads and 50nm Microbeads and columns – reagents 
for both methods are available at clinical grade. PSC will then be isolated 
using CD146 and CD34 microbeads and the appropriate selection column.   
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